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Abstract
The mitochondria of malaria have big potential to be explored as a drug targeting site. 
This is due to the differences in the composition of the Plasmodium respiratory complex 
compared with the human host. The Plasmodium respiratory chain consists of 2 unique 
dehydrogenases PfNDH2 and MQO which are only encoded in prokaryotic cells. Apart from 
these two, the Plasmodium bc\ complex has low amino acid similarity when compared to the 
bc\ complex of other eukaryotes. Currently the only approved antimalarial drug targeting 
Plasmodium mitochondria is atovaquone. This drug is used in combination with proguanil 
(Malarone™) and is widely used for the curative and prophylactic treatment of malaria. 
Atovaquone, a 2-hydroxynaphthoquinone, is a competitive inhibitor of the quinol oxidation 
(Qo) site of themitochondrial cytochrome bcj complex. Inhibition of this enzyme results in the
collapse of the mitochondrial membrane potential and subsequent parasite death. However, 
atovaquone resistance developed very soon after its implementation as malaria chemotherapy. 
Previous studies have established that the resistance of the parasite is the result of mutations 
in the bc\ Q0. To date we are the first group to elucidate the genotype and biochemical 
characterisation of the atovaquone resistant P. falciparum TM90C2B. The GeXP multiplex 
quantitative PCR (qPCR) revealed that a number of genes encoding energy metabolism 
proteins and genes associated with redox control are upregulated in the resistant parasite 
compared to the atovaquone sensitive strain 3D7. This has been supported by automated 
sequencing results which indicate the presence of a single point mutation in the DNA 
sequence of TM90C2B cytochrome b which resulted in the substitution of tyrosine by serine 
at position 268. The drug sensitivity assays and kinetic studies were conducted in order to 
understand the phenotypic consequences of this mutation. As expected, TM90C2B strain was 
resistant to almost all electron transport chain inhibitors. The enzymological characterisation 
of TM90-C2B bcj complex (steady-state decylubiquinol:cytochrome oxidoreductase assay) 
showed that enzyme turnover was approximately 50% of the atovaquone-sensitive strain with 
a threefold increase in Km for decylubiquinol (3D7 : Pmax = 97.4 ± 5.1 nmol cyt c 
reduced/min/mg protein, Km = 5.5+ 1.1 mM dQH2, IC50 6 nM, Kt = 0.6 nM; TM90C2B : Kmax 
- 60.2 ± 3.2 nmol cyt c reduced/min/mg protein, Km - 18.5+ 2.6 mM dQH2, IC50 600 nM, K\ 
= 162 nM). The other mitochondrial respiratory complexes’ specific activities were also 
measured using samples prepared from Percol® fractionation. Apart from Complex II, we 
also managed to demonstrate the specific activities of the other complexes’. The PfNDH2 and 
bc\ complex proteins of TM90C2B strain had 50% less activity than the 3D7 strain.This was 
supported by data from western blot analysis showing a decrease in PfNDH2 and ISP proteins 
content of the TM90C2B compared to the 3D7 strain. In addition to this study, we also 
characterised the Plasmodium falciparum mitochondrial malate quinone oxidoreductase 
(MQO). MQO is involved in the electron transport chain, oxidising malate to oxaloacetate in 
the oxidative arm of Plasmodium tricarboxylic acid cycle (TCA cycle). This enzyme contains 
a flavin cofactor which donates electrons to cytochrome bc\ complexvia reduction 
ofubiquinone to ubiquinol. The bioinformatic analysis data indicates that PfMQO is a
1
membrane-bound mitochondrial protein with only one transmembrane domain. The PfMQO 
gene was successfully amplified from genomic DNA of 3D7 P. falciparum and cloned into 2 
expression vectors pET-15b and pUC19. The presence and orientation of the gene in the 
respective vector were confirmed by restriction enzyme analysis and automated sequencing. 
The putative PfMQO gene (1566 bp) was successfully amplified and predicted to produce an 
approximately 60-kDa protein. Only when the PfMQO gene was cloned into pET15b was 
overexpression of the recombinant protein achieved. The recombinant PfMQO was purifiable 
under denaturing conditions due to its insolubility and formation of inclusion bodies. This 
protein is inactive and appears to be improperly folded thus producing the inconsistent results 
of the kinetic analyses. In conclusion, our study provides new insights into the understanding 
of the molecular and biochemical regulation of atovaquone resistant parasites through a 
mutation in the bc\ complex. The partial characterisation of PfMQO is a starting point for the 
development of a new drug target in Plasmodium mitochondria by taking into account the 
uniqueness of this enzyme which is not found in the human host.
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Chapter 1.0: Introduction
1.1 History of Malaria: Key Discoveries
The word malaria comes from the latin word ‘mal aria \ which means ‘bad air1. This 
is due to the close relationship between the disease and the swamp area (261). Malaria 
parasites were for the first time ever reported in 1880 by a French physician and military 
surgeon Charles Alphonse Laveran (1845-1922) in the Roman Campagna. He found the 
cresent-shaped bodies in the blood of patients who had become infected under the light 
microscope. He gave the name of the organism as Oscillaria malariae. He also described 
swamps and low humid plains were the most favourable environments for malaria. However, 
swamp itself is not a main cause of the disease. In 1886, Camillo Golgi (1843-1926) 
discovered the parasite produced asexually by multiple fission and the symptoms of the fever 
were due to the release of the parasite from infected RBC.
Diagnosis of malaria began with the invention of methylene blue and eosin stain by 
Dimitri Romanowsky. He demonstrated the nucleus and the cytoplasm of the organism are 
differently stained. However, the result was not reproducible after being repeated by other 
investigators. The problem was resolved with the invention of a similar stain by Gustav 
Giemsa (1867-1948). This Giemsa stain, is still the gold standard stain for diagnosis of human 
malaria parasites.
The sexual stages of the parasite were revealed by two medical students from Johns 
Hopkins University of Baltimore, Maryland USA in 1897. They demonstrated the sexual
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stages of the parasite are formed from two sex cells, micro and macrogametocytes. The 
concept of exflagellation was firstly described in the formation of male gametocyte from 
microgamete.
The mode of transmission of malaria parasites was first discovered by Sir Ronald 
Ross. Sir Ronald Ross, a British physician in the Indian Medical Service, demonstrated the 
presence of the parasite in dissected mosquitoes, which were fed with infected blood from the 
malaria patient. His work was published in British Medical Journal in December 1897. In the 
subsequent year, he proved that female mosquitoes are the vector in malaria transmission. 
This study was continued by Professor Giovanni Batistta Grassi who successfully 
demonstrated that only the Anopheleine genus can act as the vector for malaria transmission. 
Historical accounts of malaria are described by Irwin B. Sherman entitled “A Brief History of 
Malaria and Discovery of the Parasite’s Life Cycle” (238).
1.2 Malaria Epidemiology
In the year 2010, the World Health Organisation (WHO) World Malaria Report 
estimated 240 million cases and about 781,000 deaths globally in 2009 (278). 40% of the 
World’s population are at risk of contracting malaria mainly in tropical and subtropical 
countries (Figure 1.1); mainly in Sub-Saharan Africa, South East Asia, China, Central and 
South America. The climatic conditions in these areas provided the favourable environments 
to support the Anopheline mosquito breeding sites. Malaria has caused a negative impact on 
the economic status of these countries. In Africa only, it is estimated to cost $12 billion US 
per annum in lost productivity and 25% of all deaths recorded in children under the age of
2
Figure 1.1: Geographical Distribution of Malaria
World map showing malaria endemic countries areas at risk of transmission in 2008. Dark blue colour 
indicates areas where high transmission occurs mainly in tropical areas of Asia, the Americas and Sub- 
Saharan Africa. Light blue indicates areas with limited risk and white areas representing malaria free 
countries (279).
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five (244).
Human malaria is caused by one or a combination of four species of Plasmodium 
parasites namely P. falciparum, P. vivax, P. ovale and P. malariae. Recently, P. knowlesi the 
primate malaria has also been reported to be responsible for human malaria cases in South 
East Asia (39). These species can be distinguished via morphological structure, 
clinicopathology and their geographical distribution (although P. knowlesi and P, malariae 
can only be distinguished using molecular-based methods). P. falciparum, pre-dominantly 
found in sub-Saharan Africa causes 90% of fatality mainly in young children. P. vivax is the 
second most widespread species but rarely causes fatality. P. ovale is restricted to West Africa 
regions, while P. malariae is found worldwide with low frequency (278).
Malaria is transmitted through biting of female Anopheles mosquitoes. 400 species of 
Anopheles mosquitoes have been recorded worldwide. 60 species are served as malaria 
vectors and 30 species are the major species for malaria transmission (261).
1.3 Malaria Life Cycle
The malaria parasite has a complex and multistage life cycle. All malaria parasites 
undergo almost similar life cycles (5). Figure 1.2 describes the life cycle of malarial parasites. 
It begins with injection of sporozoites by an infective female Anopheles mosquito during a 
blood meal. The sporozoites then travel actively through the bloodstream to the liver and 
invade the hepatocytes. The sporozoites invade the Kupffer cells within which they are 
enclosed in a parasitophorous vacuole then invade the hepatocytes. As the sporozoites enter
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Figure 1. 2: The Life Cycle of Malarial Parasites
(A) Plasmodium life cycle in the human host (asexual stage), showing the inoculation of 
sporozoites into the circulation thus end up in the liver cells. In the liver cells, the sporozoites 
develop into merozoites which are released from the hepatocytes into blood circulation and 
eventually infect the red blood cells. A merozoite then develops into a trophozoite, multiply 
into a schizont and finally new merozoites are released when RBC ruptures. A fraction of the 
merozoites develop into gametocytes.
(B) The life cycle of malaria parasites in the mosquito host (sexual stage). The sexual 
reproduction starts when the female Anopheles mosquito takes a blood meal from an infected 
person. In the process it ingests male and female gametocytes. The gametocytes develop into 
male and female gametes which fertilise within the mosquito midgut to form a zygote which 
develops into a motile ookinete. The ookinete penetrates the mosquito midgut and forms the 
oocyst on the outer surface of the epithelium. The matured oocyst filled with sporozoites 
eventually burst to release sporozoites which travel to the mosquito salivary glands. Adapted 
from Wirth (2002).
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the hepatocytes, they undergo morphological changes leading to the formation of 
mononucleated forms. The nucleus start to divide and the cytoplasm grows substantially to 
form schizonts. After completion of the nucleus division, the cytoplasm segments and 
individual merozoites are formed. The mature schizonts can produce up to thousands of 
merozoites per hepatocyte occupying the entire cytoplasm. This phase is known as the 
exoerythrocytic cycle (119). The number of merozoites produced at this cycle varies between 
species. Approximately, 2000 merozoites produced for P. malariae, 10,000 for P. ovale and 
P- vivax, and up to 30,000 merozoites for P. falciparum (83). Some species, including P. 
vivax and P. ovale undergo dormant periods in the liver in the form of hypnozoites in the liver 
in the form of hypnozoites. Instead of immediate asexual proliferation, the hypnozoites will 
only be reactive from several weeks to several years after the primary infection. This dormant 
period is responsible for the relapse of the disease (138).
Upon the rupture of mature schizonts, the merozoites are released into the sinusoids of 
the liver and invade RBCs. The invasion of RBCs by merozoite is coordinated by the apical 
organelles and result in the invagination of the RBCs plasma membrane to form 
parasitophorous vacuole (PV), which surrounds the parasite and separates it from the RBC 
cytosol (38, 85). The pathological manifestation is started during the intraerythrocytic stage. 
Within the PV, the parasite matures through serial developmental stages. In those particular 
cells, the parasites undergo a tropic period and develop into ring forms (young trophozoites). 
The parasites mature into trophozoite stages about 18-28 hours after RBC invasion. Within 
the digestive vauole (DV) in the RBCs, the trophozoites obtain nutrients from digested 
haemoglobin. The degraded haemoglobin is used as an amino acid source for the parasite and 
the remaining haem is converted into hemozoin , also known as malaria pigment (12). At this 
stage, the parasite RNA and protein synthesis occur at the highest level and DNA synthesis is
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initiated (8). The parasite nucleus continuously multiplies to produce two or more nuclei and 
subsequently matures into schizonts. Finally, the schizont undergoes cytokinesis and abundant 
merozoites are released from ruptured schizonts, which infect the other RBCs and iniate 
another intraerythrocytic developmental stage.
Apart from the asexual multiplication, some merozoites differentiate into female and 
male gametocytes. During a blood meal from an infected person, the female Anopheles 
mosquito ingests the gametocytes. In the mosquito gut, the gametocytes shed the erythrocyte 
membrane and transform into female and male gametes (macro and microgametes). The 
macrogamete does not undergo much morphological changes where as the nucleus of the 
microgamete actively divides forming a thread-like microgamete which tears free from the 
original structure. This process is referred to as exflagellation. The female and male gametes 
then fuse to form a zygote which undergoes elongation and in about 18 hours forms the motile 
ookinates, which later penetrates the gut wall of the mosquito, establishes itself beneath the 
basal lamina and form oocysts. The oocysts eventually undergo multiple rounds of asexual 
replication to form sporozoites. The numbers of sporozoites produced vary between species; 
for example, 4,000 to 10,000 for P. falciparum. Duration of sporogony also varies between 
species for instance; 10 to 12 days for P. falciparum, 5 days for P. vivax and P. ovale and 5 to 
23 days for P. malariae. the These sporozoites are released and travel to the salivary gland of 
the mosquito which finally invaded the mosquito salivary gland cells (166). This mosquito is 
highly infective and will injected the sporozoites into the human body allowing the cycle of 
infection to be continue between human and mosquito hosts.
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1.4 Malaria Pathogenesis
P. falciparum causes the most severe form of malaria infection. The clinical 
manifestations of malarial symptoms are associated with the rupture of infected RBCs during 
the blood stage of the parasites's life cycle. The common complications related to malaria 
infection include fever, metabolic acidosis, hypoglycaemia, respiratory distress and severe 
anaemia, cerebral malaria and in pregnant women can cause abortions, still births which may 
result in hospitalisation and death (275).
In severe malaria, tissue hypoxia largely contributes to organ failure. The mechanis of 
hypoxia due to malaria was proposed by sequestration of parasitized RBCs which involve 
cytoadherence, rosette formation and deformation of the RBCs. Miller et al. (2002) described 
sequestration and rossetting as two factors which attribute to complicated disease outcomes. 
Within the infected RJBCs, the Plasmodium parasites adjust the erythrocyte surface causing 
the infected RBCs to adhere to the vascular endothelium (143). Cytoadherence is mediated by 
the antigenically variant P. falciparum erythrocyte membrane protein 1 (PfEMP-1) on the 
surface of the infected RBCs (143). Kyes et al. (2001) postulated that PfEMPl is anchored on 
the surface of parasitized RBCs in electron dense knobs through interactions with RBC 
cytoskeleton proteins and parasite encoded proteins, including knob-associated histidine rich 
protein (KAHRP) (132). The roles of other surface antigens (RIFIN and STEVOR) in the 
pathogenesis of malaria are still not well ellucidated. However, based on the size, structure 
and expression patterns between RIFIN and STEVOR, these proteins are speculated to be 
involved in antigenic variation (148,149).
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PfEMP-1 acts together with CD36, intracellular adhesion molecule 1 (ICAM-1) and 
chondroitin sulphate A (CSA) to promote infected RBCs adherence to the endothelial cells. 
Previous studies show that the PfEMP-1 mediated adhesion to ICAM-1 plays an important 
role in the pathogenesis of cerebral malaria (273). Meanwhile, the adhesion of PfEMP-1 to 
CSA contributes to pregnancy-related malaria (104). Sequestration to the endothelium is also 
detected in other organs including the heart, liver and kidneys resulting in the blockage of 
microvascular blood flow in the affected organs (175). The sequestration of the parasites to 
the deep microvascular tissues thus prevents the infected RBCs to be cleared by the spleen 
and helps the parasite to evade the host immune system (175). Resetting is the second 
phenomenon of P. falciparum infected RBCs that spontaneously bind to uninfected RBCs. 
Rosetting enhances microvascular obstruction in the targeted organs which exacerbates the 
patholophysiology of severe malaria. These processes are mediated by the interaction between 
PfEMP-1 adhesion molecule, CR1 and other several receptors that are expressed on the
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1.4.1 Anaemia
Anaemia remains the most common and serious complication associated with malaria 
infection. Severe anaemia occurs when the concentration of haemoglobin is less than 5 g/dL 
(60). Excessive burden of the plasmodial parasite leads to the invasion and rupture of the 
infected RBCs, resulting in severe haemolytic anaemia in the infected hosts (231). There are a 
few mechanisms attributable to the destruction and production of the RBCs including lysis of 
the infected and uninfected RBCs (214), splenic sequestration of RBCs (214, 216), 
dyserythropoiesis and bone marrow suppression (1) and also co-infections with bacteria (15).
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Due to the invasion of plasmodial parasites, infected RBCs undergo several changes on 
their surface thereby reducing their membrane deformability, leading to rapid sequestration in 
the spleen (95). Apart from that, the uninfected RBCs are also destroyed via phagocytosis and 
cleared by the reticuloendhothelial system (RES) (144). The high level of P. falciparum 
erythrocyte-membrane proteins (PfEMP-1) in the plasma during the infection may adhere to 
the uninfected RBCs and remove them from the circulation via initiation of the antibody 
response or complement cascade (95). In humans, severe anaemia is caused by the high ratio 
of uninfected to infected RBC clearance in the ratio 12 to 1 (174). The anaemia may resolve 
with antimalarial therapy and blood transfusion (60, 249).
Dyserythropoiesis occurs when the bone marrow is unable to function accordingly due to 
immune response triggered by the host, resulting in low levels of reticulocytes, as seen during 
P. falciparum infection (211). The Thl cytokines such as IL-6, IFN-y and TNF-a, other 
inflammatory mediators and parasite-derived hemozoin potentially suppress haematopoiesis, a 
biological process of producing the RBCs in the bone marrow. This exacerbates anaemia in 
the infected hosts (95). Recent findings show that IL-4, a Ti,2 cytokine may also be 
responsible for the dyserythropoiesis (95). Co-infections with helminth or bacteria may 
extend the severity of malarial anaemia as well due to their activation of the immune system 
(98, 173).
1.4.2 Cerebral malaria (CM)
The cytoadhering mechanical blockage caused by the infected RBCs through
sequestration in microvessels is reported to be involved in the pathogenesis of CM .The
obstruction pertubs blood flow, causing hypoxia of the neurons and glial cells as well as
haemorrhages. The accumulation of infected RBCs in the brain is shown to promote
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chemotactic, inflammatory and toxic mediators that can further accelerate the microvascular 
obstruction through positive-feedback mechanism (113).
Monocytes potentially secrete coagulation factors that may contribute towards brain 
sequestration in CM patients (92), whereas neutrophils are found to trigger the release of pro- 
inflammatory cytokines such as TNF-a, IL-12, IL-18 and IFN-y that are implicated in CM. As 
the neuthrophils deplete, downregulation of Thl cytokines is accompanied by reduction of the 
monocytes sequestration and microhaemorrhages in the brain, thus limiting the damage 
caused by CM as demonstrated in in vivo studies in mice infected with P. berghei (183) 
Excessive production of inflammatory cytokines aggravate the inflammation process giving 
rise to coma and seizures in CM (161). CD8+T cells are involved as well by increasing the 
permeability of the blood-brain barrier through perforin-dependent mechanisms (212).
The malaria parasites also release soluble malarial toxin known as 
glycosylphosphatidylinositol (GPI) that triggers the production of TNF-a and IL-1 cytokines 
by macrophages (232). GPI alone or in combination with IFN-y is capable of generating the 
inducible form of nitric oxide synthase (iNOS) and amplify the production of nitric oxide 
(NO) in the host tissues which is usually in low levels (190). Up-regulation of intracellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in the host 
cells is also implied the pathogenesis of CM (116).
1.4.3 Fever
Fever is the most common symptom observed during malaria infection. It is associated 
with vomiting, malaise, joint pain and to some extent convulsions which is common among 
children (198). The innate immune response has been recognised as the host’s first-line of
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defence against the parasite during the early stage of infection by inducing inflammation and 
fever (233). RBC rupture activates the macrophage system through antibody-dependant and 
independent phagocytosis (161). Upon invasion by the parasites, the infected host immune 
system recognises the parasitic deoxyribonucleic acid (DNA) via Toll-like receptor-9 (TLR-9) 
and subsequently induces fever. Engagement of TLRs is more likely to trigger the 
transcription of nuclear factor kappa-light-chain enhancer of activated B cells (NF-kB) in the 
nucleus to produce pro-inflammatory cytokines (205). The activation of inducible 
cyclooxygenase-2 (COX-2) may also increase the synthesis of prostaglandin, changing the set 
point of the host thermaregulatory centre and ultimately leading to fever (125).
Furthermore, the pathogenesis of malarial fever has been thought to arise from various 
pro-inflammatory cytokines released by parasite-induced host immune cells (207). As 
mentioned earlier, the release of GPI upon the rupture of RBCs is capable of inducing the 
production of TNF-a and IL-1 by the macrophages. The release of IL-1, a pyrexia-related 
cytokine may cause paroxysmal fever and chills (207). Several groups of researchers have 
acknowledged the importance of TNF-a in the pathogenesis of fever in malaria as they found 
a positive correlation between serum concentration of TNF-a and the degree of pyrexia during 
malaria (123). Apart from that, IFN-y also possesses a pyrogenic property that mediates 
through the induction of IL-1 and TNF-a during the clinical paroxysms (7).
1.5 Malaria Chemotherapy and Drug 
Resistance
At present there is no effective malaria vaccine, and therefore chemotherapy remains 
the mainstay of malaria control by clearing the parasites from the infected host. To date
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antimalarial drugs can be classified according to their chemical structures or biological 
activities i.e targeting specific stages in the life cycle or interruption of the specific cellular 
metabolic pathways in the malaria parasite. Summaries of the classification of the antimalarial 
drugs are shown in Table 1.1 and Table 1.2. The action of antimalarial drugs targeted on the 
specific subcellular organelles are illustrated in Figure 1.3.
The emergence of antimalarial drug resistance is arises from a combination of several 
factors such as host population, overuse of drugs for prophylaxis and incomplete therapeutic 
treatments of infected patients. This is might due to related to lack of the compliance of the 
drugs or usage of counterfeit drugs which are defective their stated doses. Resistance is also 
being associated with genetic alteration in the parasites therefore affected the drugs metabolic 
pathways in the parasite (187). The summary of the molecular basis of drug resistance in 
human malaria parasite P. falciparum is illustrated in appendix 1.
1.5.1 Quinine and its Derivatives
Quinine is the oldest antimalarial drug, used by the native population of Peru for 
centuries to treat fevers and chills. In 1944 the active alkaloid compound of quinine was 
successfully isolated from pulverised bark of the cinchona tree (115). The structure of the 
quinoline ring system is used to synthesise other quinoline derivatives such as 4- 
aminoquinolines as the example of chloroquine, the most used antimalarial in malaria 
endemic areas. Other drugs in this category include amodiaquine, primaquine, piperaquine 
and mefloquine. Halofantrine and lumefantrine (benflumetol) are two drugs which were 
chemically synthesised by manipulation of the quinoline portion of the 4-quinoline methanols 
and replacement with a different aromatic ring system to form ary amino alcohols (Figure 1.4) 
(187).
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The mechanism of action of these antimaiarial drugs is through the inhibition of the 
formation of crystallised hemozoin (malaria pigment) in the parasite digestive vacuole (DV). 
The development of malaria parasites in infected erythrocytes depends on the degradation of 
haemoglobin of the host ceils as a source of nutrients. The degradation of 
haemoglobinproduced a large amount of free haem or ferriprotoporphyrin IX (FPPIX) in the 
parasite DV which is toxic to the parasites (76). In malaria parasites the FPPIX is oxidised 
and dimerised to beta hematin followed by crystalisation into hemozoin which is non-toxic to 
the parasite and accumulates in the DV (202). 4-Aminoquinolines and their derivatives bind 
to FPPIX in DV thus interfering with the detoxification of FPPIX (an eythrocytic 
haemoglobin by-product into hemozoin (59, 71). The toxic form of haem monomer is 
believed to generate oxidative radicals that in turn permeabilise the parasite membrane, 
ultimately leading to parasite killing (295).
Chloroquine was introduced as an antimaiarial drug in 1943 and has been the main­
stay for falciparum malaria treatment for many years before resistance being reported (6). 
Resistance emerged approximately 10 years after its introduction, along the Thai-Cambodian 
border in 1957, at the Colombia-Venezuela border in the 1959 and all sub-Saharan Africa 
1980s (177). From genetic epidemiology the resistance to chloroquine spread from Southeast 
Asia to Africa in the late 1970s (177). The chloroquine resistance is associated with mutations 
in the transporter proteins which are located on the DV or the plasma membrane of the 
parasite (187). The major transporter proteins in the malaria parasite are PfCRT, PfMDRl 
(PfPGHl), PfNHEl and PfMRPl. The underlying mechanism(s) underpinning chloroquine 
resistance are not completely understood and several hypotheses have been presented. One 
hypothesis that has received support is the “Charge drug leak” model. This model states that
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Table 1.1: Classification of the Major Antimalarial Drugs According to their Chemical 
structures
Drugs compound Drugs
4-aminoquinolines amodiaquine, naphthoquine, , piperaquine,
chloroquine, Tert-butyl isoquine,
hydroxchloroquine
8-aminoquinolines primaquine, diethylprimaquine, bulaquine,
tafenoquine
sulfonamides sulfadoxine, sulfadiazine, sulfamethoxazole
Amino alcohols lumefantrine, halofantrine,
mefloquine,quinine
Antifolates pyrimethamine, proguanil, dapsone,
cycloguanil, chlorproguanil
Hydroxynapthaquinones atovaquone
Antibiotics trimethoprim, azithromycin, tetracycline,
fosmidomycin, mirincamycin, doxycyclin,
thiostrepton
Endeperoxide artemisinin, artemether, artesunate,
artemisone, dihdroartemisinin
others riboflavin, pentamidine, cycloheximide, N-
acetyl-D-penicillamine, deferoxamine,
pyroaridine
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Table 1.2: Classification of the Antimalarial Drugs According to the Different Stages in 
the Life Cycle of the Parasite
Developmental Stages Drugs
Intraerythrocytic schizontocidal drugs quinine, chloroquine, amodiaquine,
mefloquine, halofantrine, pyronaridine,
atovaquone, pyrimethamine, sulphadoxine,
artimisinins, tetracycline, clindamycin
tafenoquine, amodiaquine
Tissue schizontocidal drugs primaquine, tafenoquine, proguanil,
tetracycline, pyrimethamine
Gametocytocidal drugs primaquine, tafenoquine, proguanil,
tyetracycline, pyrimethamine.
Hypnozoitocidal drugs primaquine
Sporonticidal drugs proguanil, chloroguanidine, pyrimethamine,
atovaquone
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Apicoplast
Drugs: Antibiotics: 
azithromycin,
Doxycycline,
Clindamycin, fosmidomycin
Mitochondrion 
Drugs: Atovaquone, 
Tafenoquine, Pyridones, 
New DHODH inhibitors
Cytosol 
Drugs: antifolates 
Pyrimethamine-sulphadoxine 
Chlorproguanil-dapsone 
New DHFR inhibitors
Hemozoin Digestive vacuole
Drugs:4-aminoquinolines: Drugs: Falcipains Plasma membrane 
chloroquine,Amodiaquine; inhibitors 
Quinolinemethanols: quinine, 
mefloquine
Intraerythrocytic 
Plasmodium parasite
Cytostome
Exocytic vesicle
Nucleus
Free ribosome
Rough ER Golgi complex
Figure 1.3: Illustrated Picture of Antimalarial Drugs Targeted at the Specific 
Subcellular Organelles
The 4-aminoquinolines (e.g chloroquine and amodiaquine), and the quinolinemethanols (e.g 
quinine and mefloquine) act inside the DV of the parasite. The falcipain inhibitors targeted to 
the cycteine proteases. Antibiotics e.g azithromycin, doxycycline and clindamycin act inside 
the apicoplast (plastid like organell) by inhibit protein translation. Atovaquone and selected 
compounds inhibit electron transport in Plasmodium mitochondrion. The antifolate drugs act 
by disrupting de novo biosynthesis of folate in cytosol. The action of artemisinin and its 
derivatives is still actively investigated. Adapted from Greenwood et al. (2008).
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Figure 1.4: The Chemical Structures of Some Antimalarial Drugs
Chloroquine, quinine, and mefloquine are 4-substituted quinolines that interfere with haeme 
polymerization; sulfadoxine, pyrimethamine, and cycloguanil are substrate analogs that interfere with 
folate metabolism. In humans, proguanil is converted by CYP2C19 and CYP3A4 to form cycloguanil. 
Atovaquone acts through destabilisation of the malaria parasite cytochrome be, complex, thus causing 
proton leakage at to occur at this site. Artemisinin is newer antimalarial with a novel molecular 
structure. Several mechanisms have been proposed e.g the activation of endoperoxides which bind to
Fe (haem) therefore generating oxygen radicals and inhibiting the sarco/endoplasmic reticulum Ca 
2+-ATPase (SERCA).
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mutations in PfCRT (principally the K76T) enables protonated chloroquine (CQ+4) to 
tranverse the DV membrane thereby reducing the DV chloroquine concentration (17, 187).
Mutations in pfmdrl are commonly associated with those in pfcrt. However the 
pattern of the mutation of pfmdrl is different based on geographical locality, for example 
South American mutant strains have mutations in amino acids S1034C, N1042D and D1246Y 
while the Southeast Asia and Africa counterpart is often associated with N86Y amino acid. 
(209). The relationship between pfmdr and pfcrt is not well understood, but is it hypothesised 
that pfmdr mutations are responsible for increasing chloroquine resistance (in K76T pfcrt 
parasites) to levels which result in clinical failure. This hypothesis is supported by evidence 
that shows that although the K76T pfcrt mutation is found in all chloroquine clinical failures, 
this mutation alone is not predictive of clinical failure.
1.5.2 Antifolate Drugs
Antifolate drugs can be classified into 2 groups: Class 1 and Class II. The Class I or
sulfa group consists of sulfadoxine and dapsone. Sulfa drugs inhibit the dihydropteroate
synthase enzyme (PfDHPS) activity of the bifunctional hydroxymethylpterin
pyrophosphokinase (HPPK)-DHPS protein. DHPS is responsible for the de novo synthesis of
folate coenzymes (187). Class II antifolate drugs are pyrimethamine and proguanil. Class II
antifolate inhibit the dihydrofolate reductase (PfDHFR) activity of the bifunctional
DHFR/thymidylate synthase enzyme (187), DHFR present in both parasite and human host is
an essential enzyme for synthesis of the reduced form of folate (tetrahydrofolate).
Tetrahydrofolate is involved in several metabolic pathways including one carbon transfer
reactions and synthesis of DNA. Sulfadoxine-pyrimethamine (SDX-PYR) (SP;Fansidar™)
was introduced as a combination therapy in 1970s to overcome the CQ resistance problem in
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Africa (115). Antifolate combination therapy is currently used as intermittent preventive 
malaria treatment in pregnant women and infants in malaria endemic areas. SP is used as the 
drug of choice whenever the ACT (artemisinin combination therapy) supply is not available 
or in the poor countries where the cost of ACT is prohibitively expensive (181).
The rapid emergence of antifolate resistance is due to point mutations in both targeted 
enzymes (PfDHPS and PfDHFR). Partial pyrimethamine resistance is identified due to a point 
mutation at codon 108 ofpfdhfr gene that changes serine to asparagines (101). The severity of 
the resistance is increased with further mutation at codons 51 (asparagines to isoleucine, 
N51I) and/or 59 (cysteine to arginine, C59R) (164). Another mutation at codon 161 
(isoleucine to leucine, I164L) was detected among isolates from South America and Asian 
countries that cause triple mutation of the pfdhfr gene. Five mutations of the pfdhps gene at 
codons 436 (serine to alanine/phenylalanine, S436A/F; alanine to glycine, A437G; lysine to 
glutamic acid, K540E; alanine to glycine, A581G; alanine to serine or threonine, A613S/T) 
were identified to be associated with sulphadoxine drug resistance (259). Mutation at the 437 
codon of pfdhps gene has been identified as a causative factor in the emergence of mutation at 
codons 581 and 613 for the SP resistance in P. falciparum isolated from patients in the 
African continent. Mutations at these codons are widely spread in South America and South 
East Asia, and are associated with high-level SP resistance (168), Another factor that 
contributes to the SP treatment failure is associated with pfdhps double mutant 
(A437G/K540E) and the pfdhfr triple mutant (S108N/N51I/C59R) from the pfdhfr/pfdhps 
quintuple mutant haplotype (141).
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1.5.3 Artemisinins
Artemisinin (Qinghaosu; active compound) is an extract from the Artemisia annua 
(Chinese wormwood) and has been used as a herbal remedies for many centuries for many 
illnesses including malaria in China (277). The first clinical trial of artemisinin was conducted 
in China in 1975 and subsequently it was introduced as an antimalarial drug in 1979. This 
drug has low toxicity and high efficacy against all types of human malaria parasites including 
those resistant to conventional antimalarial treatment (154).
The chemical structure of the active qinhaosu is ilustartes in Figure 1.3. The 
artemisinin has a unique trioxane structure (C15H22O5) with an endoperoxide bridge (C-O-O- 
C), lacking the nitrogen containing ring system which is found in most antimalarial drugs 
(172). However the setback of this compound is low solubility (57) as well as elimination 
half-life its short 0.5-1.4 h (22).
To improve the solubility of artemisinin, semi-synthetic artemisinin derivatives have 
been developed. These include: artemether, artesunate, dihydroartemisinin (DHA), artenimol, 
artemotil. These artemisinin derivaties are used widely and given in combination therapy 
(ACT) with other antimalarial drugs (17). Currently ACT is used mainly in the treatment of 
uncomplicated malaria (193). The combinations of artemisinin derivatives which are currently 
used as ACT include: artemether-Iumefantrine (Coartem®) (most commonly applied 
worldwide), artesunate-sulfadoxine-pyrimethamine, dihydroartemisinin-piperaquine and 
artesunate-pyronaridine (278).
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The mechanism of action of artemisinin and artemisinin derivatives is not fully 
elucidated and still debatable (65). It has been hypothesised that artemisinin activity is due to 
cleavage of the endoperoxide bridge and haem-iron degradation leading to a formation of 
reactive carbon radicals that alkylate essential biomolecules in the food vacuole of the parasite 
(209). The detail of the biochemical reaction of artemisinin was described by O'Neill et al., 
(2010). They concluded that the interaction of the drug is not only on heme degradation but 
also with free intracellular reduced iron species. This interaction thus activates the artemisin 
activitity to bind to macromolecules throughout the whole parasite(195). At the cellular level 
artemisinin was reported to interact with phospholipids and to cause oxidative membrane 
damage (99,187).
Eckstein-Ludwig et al. (2003) reported that artemisinin inhibits PfATP6 
(sarco/endoplasmic reticulum calcium-dependent ATPase SERCA). The inhibition of PfATP6 
is said to lead to the disruption of Ca2+ homeostasis in the parasite. This has been supported 
by in vitro study inX. laevis oocytes that showed the activity of PfATP6 is inhibited by ART 
but is not affected by other antimalarial drugs (58). The exact location of PfATP6 is still not 
fully elucidated, however recent study showed the effect of artemisisnin is through the 
disruption of DV and not on the endoplasmic reticulum. Based on this finding they speculate 
that PfATP6 is located in the DV of the parasite (45).
Artemisinin resistance has not been documented until 2010 on the Thai-Cambodian
border (52). However the direct evidence of the resistant mechanisms were not well
understood. Results from the sequencing data did not show any correlation between
artemisinin resistance and pfcrt.pfmdrl or pfatp6 genes. Further studies have to be carried out
to determine the genetic and biochemical bases of the artemisinin resistance mechanisms.
22
Nevertheless the worrying signs are that ACT clinical failures are on the increase in South 
East Asia.
1.5.4 Hydroxynaphthoquinones (Atovaquone) 
and the P. falciparum bcx Complex
Hydroxynaphthoquinone compounds have been identified to act as competitive 
inhibitors of ubiquinone (CoQ) since then 1940s. However, these compounds showed poor 
bioavailability, lack of metabolic stability and high plasma protein binding (14). Exploration 
of this class of compound was carried out by Wellcome Laboratories UK in the 1980’s. The 
study conducted by Fry and Pudney developed a hydroxynaphthoquinoe recognised as (2- 
[^ram-4-(4’-chlorophenyl)cyclohexyl]-3-hydroxy-l,4-napthoquinone), known commonly as 
atovaquone, which targets the mitochondrial cytochrome bc\ complex in Plasmodium 
parasites (79).
To minimise atovaquone resistance/clinical failure, this drug is given in combination 
with proguanil (antifolate drug). An in vitro study showed proguanil as having a synergistic 
effect when given with atovaquone (130). Combination of atovaquone-proguanil was 
introduced in Europe in the mid 1990s and in 2000 it was recognised as antimalarial drug by 
the U.S Food and Drug Administration (FDA). The combination atovaquone-proguanil when 
given in a fixed dose tablet drug combination (Malarone®) produced a 97% curative rate 
compare to 67% when atovaquone was given as monotherapy (158). However, due to the high 
cost of production this drug is used mainly as chemoprophylaxis for travellers visiting malaria 
endemic areas (130).
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Atovaquone is a lipophilic hydroxynaphthoquinoe and can be regarded as a structural 
analogue to coenzyme ubiquinone (CoQ). Atovaquone has been used in the treatment of 
infections by apicomplexan parasites Plasmodium spp.. Toxoplasma gondii, Thieleria spp. 
and Babesia spp. (246). It is suitable for the treatment of multidrug resistant parasites (245, 
264). However when used as a monotherapy it has been shown to give rise to an unacceptable 
high recrudescence rate of ~30% (157).
1.5.4.1 Mechanism of Action
Studies on atovaquone have shown that this compound binds to cytochrome b in the 
bc\ complex of the inner mitochondrial membrane of the malaria parasite. The cytochrome 
be i complex (also known as Complex III) is responsible for the electron transfer from 
ubiquinol to cytochrome c. The electron transport is linked to the translocation of protons 
across the inner mitochondrial membrane, resulting in the generation of a membrane 
potential, a key feature of an active mitochondrion (14).
Atovaquone acts by selectively inhibiting the mitochondrial electron transport in 
parasite mitochondria without affecting human mitochondrial functions. Atovaquone binds to 
the quinol oxidation site of cytochrome b known as the Q0, at a site, close to the conserved 
PEWY region, which itself is located close to the iron-sulphur binding region of the hinge 
protein. Binding at this site inhibits catalytic turnover of the enzyme, resulting in the 
depolarisation of the mitochondria and a loss of mitochondrial function, which includes 
disruption of pyrimidine biosynthesis, specifically by the loss of activity of dihydroorate 
dehydrogenase (DHODH) (130, 203, 208).
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Various studies have been conducted to determine the molecular mechanism of 
atovaquone on the cytochrome bc\ complex. The most extensive studies have been carried out 
using the yeast model Saccharomyces cerevisiae (reviewed in (14, 130). Studies using 
Electron Paramagnetic Resonance (EPR) spectroscopy show that yeast cytochrome bc\ 
complex demonstrate the formation of a hydrogen bond between the hydroxyl group on 
napthoquinone ring of atovaquone and HislBl of the mobile Rieske iron sulphur protein 
located proximal to cytochrome b (14, 130). The hydroxyl group of the
hydroxydioxobenzothiazole is ionised when the inhibitor is bound to the Q0 site. The second 
hydrogen bond is formed at the carbonyl group at the position 4 on the quinone ring via a 
water molecule with Glu-272 of cyt b to stabilise the structure. As a result of these 
interactions, atovaquone binding to the Rieske protein near cytochrome b has the effect of 
lowering the midpoint potential of the Rieske protein cluster (130). The molecular model of 
atovaquone interaction with S. cerevisae bc\ complex is illustrated in Figure 1.5.
As described earlier, atovaquone is given in combination with proguanil, an antifolate, 
to curb the rapid acquisition of resistance to atovaquone. Proguanil inhibits dihydrofolate 
reductase (DHFR) via its metabolite cycloguanil. However the combination of 
cycloguanilwith atovaquone fails to produce a synergistic effect (203). It is suggested that 
proguanil acts by inhibiting the mitochondrial phosphate transporter and thereby synergises 
with the inhibitory activity of atovaquone (Painter et al., 2007). However there is no data at 
present to support this hypothesis and it should be added that no in vivo synergy between 
proguanil and atovaquone has been reported and this may therefore be a red herring as in most 
people proguanil is rapidly metabolised to cycloguanil.
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Figure 1.5: Diagram of the Interactions of Atovaquone with the Yeast bc\ Q0 Site
Molecular model of atovaquone (Atv) docked into the Q0 site of yeast cytochrome bcl complex 
(3CX5.PDB), showing hydrogen bonding to Rieske protein residue HislSl and cytochrome b residue 
Glu272 (via bridging water molecule). Yeast residues are labelled in white, with the corresponding P. 
falciparum residues labelled in orange. The cytochrome b polypeptide backbone is represented in 
green, with the Rieske protein backbone in brown. The [2Fe2S] cluster of the Rieske protein is 
represented in CPK form (sulphur: yellow, iron: pink). Hydrogen bonds are indicated by yellow dotted 
lines. A 1.4 A-radius CPK dotted surface has been added around the docked atovaquone molecule to 
aid visual clarity. The side chain of HI81 is shown in the imidazolate conformation, although it has 
not been established which group contributes the hydrogen atom in the putative hydrogen bond 
between this residue and the (ionisable) naphthoquinone hydroxyl of atovaquone. Adapted from Fisher 
et al. (2012).
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1.5.4.2 Atovaquone Resistance Mechanisms in 
Plasmodium falciparum
As mentioned, atovaquone is extremely potent against P. falciprarum malaria, 
however when use as a monotherapy it causes an unacceptable level of drug failure due to 
parasite resistance (14, 35, 130). The sequencing data obtain from resistant parasites shows 
the presence of point mutations spanning the codons 271-284 at the site of ubiquinol 
oxidation site (Q0) of the bc\ complegene (235). This region consists of 13 ammo acids within 
the e-f helix to transmembrane helix FI of the cytochrome b which contains a universal 
PEWY sequence (245). The most common mutation is detected at amino acid position 268 
where tyrosine is replaced with serine (Y268S). The Y268 amino acid is highly conserved 
across the apicomplexa phylum (14). Polymorphisms also detected at the 268 codon are 
Y268N or Y268C, however both mutations are rarely reported (3).
In the malaria parasite, cytochrome b is encoded by the mitochondrial DN A (mtDNA) 
(3, 84). The polymorphism of the gene encoded by mtDNA is reported in mammals to exhibit 
10 x higher mutation rate than nuclear DNA (3, 36). The mechanisms of the polymorphisms 
might due to due to spontaneous base substitution or insertions which accumulated the time 
and also due to the multi-copy nature of the mitochondrial cytochrome b gene (62). 
Cytochrome b is highly exposed to ROS which are produced in Complex III mitochondna and 
also possibly due to poor proof reading by the mitochondrial DNA polymerase (186, 217). 
Study in malaria parasites showed a rapid mutation rate (105) of Pfcytb (84), but the recent 
study showed the rate was lowered by 100-1000 times (3,135).
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1.5.4.3 Mechanisms of Atovaquone Binding in the Yeast 
Model
The S. cerevisae yeast model has been used to elucidate the resistance mechanisms in 
P. falciparum bc\ complex. S. cerevisae is easily grown and the crystal structure of the bcj 
complex is available thus facilitating the study of P. falciparum mutations (68, 114). 
Mutations in yeast bci complex can be directly introduced through transformation therefore 
the expressed mutated protein can be purified and crystallised to get the structure of the 
protein.
The mutation of Y268S in P. falciarum was introduced into yeast bc\ genome resulted 
a mutation at amino acid residues Y279S of S. cerevisae. This mutation of Y279S is also 
located in e-f helix component of the Q0 site (269-295) which consists of PEWY (68, 130). 
The atovaquone inhibition study was conducted and showed that the mutation is responsible 
for alteration of atovaquone binding to bc\ complex of mutated yeast (68, 130). The IC50 
value of the mutated yeast was 4000 nM compared to the sensitive strain. The study on the 
steady state turnover of the bc\ complex showed the mutant yeast has a slower rate (decreased 
30%) compared to the wild type strain (14,68,130).
1.6 Vaccines for Malaria
For a long time development of malaria vaccines has been dependent on the study of
parasite surface antigens and on the discovery of potential target antigens recognised by the
sera of immune adults. The target of malaria vaccines generally followed three strategies of
immunisation, namely pre-erythrocytic liver stage, the blood stage or the sexual stage
(transmission-blocking vaccines). Pre-erythrocytic stage vaccine consists of antigens or
antigen subunits produced on the surface of sporozoites and/or the stage of the parasite. This
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vaccine targets the Plasmodium sporozoite thus preventing invasion of the host hepatocytes 
and finally eliminates the parasites from the infected individuals. The blood stage or asexual 
vaccine is targets the merozoite preventing their invasion of RBCs and eventually prevent the 
clinical manifestations of malaria infections. Transmission blocking vaccines are specifically 
designed to break transmission target molecules that are unique to gametocytes or to 
subsequent mosquito stages(257).
1.6.1 Pre-erythrocytic Vaccines
The circumsporozoite protein (CSP) contains a central repeat region containing 37 
repeats of the amino acids sequence asparagines-alanine-asparagine-proline (NANP) and 
flanked on each side by non-repetitive regions containing T cell epitopes. The central repeat 
region is encoded by the immunodominant surface antigen on the sporozoite of the human 
malaria parasite P. falciparum (46, 257). It has been demonstrated that the antibody response 
in malaria infected humans is elicited against the central region of CSP. The mechanism of 
action of the CSP antibody against this region is by sloughing off the protein coat, therefore 
blocking the invasion into the hepatocytes (10). Several clinical trials have been conducted 
using either a synthetic peptide or a recombinant protein containing multiple copies of P. 
falciparum CSP B-cell epitopes. Results from these trials showed that the vaccines only 
conferred partial immunity, with low antibody titres against sporozoites in the vaccinated 
groups (10). At the later stage, more advanced adjuvants and carrier protein systems are 
introduced and incorporated into the vaccine formulation. Use of the adjuvant system 
improves the immunogenicity of CSP based vaccine. With the advent of molecular biology 
technique, the recombinant CSP based vaccine was created and recognised as RTS,S vaccine. 
RTS,S vaccine is a recombinant protein composed of amino acids 207 to 395 of the central 
repeat region (R) and T cell epitopes (T) of P. falciparum CSP fused with a 226-amino acid
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polypeptide chain of the hepatitis B surface antigen (S) as a carrier matrix (225). The 
recombinant constructs then was co-expressed in S. cerevisiae (S) which assembles it into 
antigenic particles. The RTS,S vaccine formulation consists of the liposomal based Adjuvant 
System AS01 or AS02 which contains the immunostimulants monophosphoryl lipid A and 
QS21 (saponin derivative extracted from the bark of the Quillaja saponica tree). 
Subsequently, the efficacy of RTS/S recombinant vaccine had shown progressive 
improvements resulting in improved efficacy in vaccinated and challenge groups (26, 91). To 
date, in November 2011, London-based GlaxoSmithKline (GSK) released the recent clinical 
data from phase 3 clinical trials of RTS,S (Mosquirix) vaccine. The clinical Phase 3 results 
showed that RTS,S caused 54% reduction in clinical malaria cases and 47% reduction in 
severe malaria (4). The Phase 3 clinical study showed that the RTS,S vaccine is highly safe 
with tolerability profiles. The protective immunity conferred by RTS,S vaccine lasts up to 4 
years and interestingly no evidence of a post-immunisation “rebound” has been detected 
among the vaccinated group (257).
1.6.2 Blood Stage Vaccines (Asexual Erythrocytic 
Stage)
The asexual erythrocytic stage of the malaria parasite’s life cycle begins with the
release of merozoites from infected hepatocytes. This is followed by rapid invasion of RBCs 
and further intraerythrocytic development stages leading to the rupture of merozoites from the 
parasitized RBCs. The released merozoites then re-infect new RBCs or differentiate into the 
sexual stages of the parasite. Clinical outcomes caused by Plasmodium occur mainly during 
the erythrocytic stage of the parasite’s life cycle. Most erythrocytic stage vaccine candidates 
are developed based on antigens that coat the surface of the invasive parasites. The immune
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response generated against the erythrocytic stages is primarily antibody mediated with the 
added support of CD4+ T-cell activity and cytokine production (86).
The first merozoite surface protein rigourously studied is PfMSPl. This antigen is 
believed as the best candidate of many proteins expressed on the merozoite surface and being 
targeted for vaccine development. The vaccine formulation is similar to the RTS,S vaccine 
using the hepatitis B surface antigen as a carrier matrix. Several clinical trials were done to 
evaluate the efficacy of the vaccine in immunised people in the malaria endemic areas. 
Results from the clinical trial data show that MSP1 vaccine enables to produce antibodies in 
adult exposed to P. falciparum but it had no protective efficacy against clinical malaria in 
children (197). The drawback of the MSP1 antigen is the extensive genetic diversity that may 
contribute to the lack of efficacy of the vaccine (257).
The apical membrane antigen 1 (AMA-1) is another candidate for the development of
erythrocytic stage vaccine. The AMA-1 resides in the apical complex of the merozoite (210)
and plays a vital role in the success of RBC invasion by merozoites (178). The AMA-1
antigens are among the most higly conserved proteins in apicomplexan groups (21). The
AMA-1 has 62 polymorpic amino acids, representing more than 15% of the amino acid sites
and distributed over three domains of AMA-1 protein (253). The greatest polymorphism is
detected in domain I amino acids cluster that plays a vital role in RBC invasion.and is located
near to a hydrophobic pocket of the AMA-1 protein (9). An in vitro study showed that
antibodies against AMA-1 antigen are naturally acquired and confer protection of RBCs from
the invasion by merozoites (106). Two AMA-1 based vaccines are already at the stage of
efficacy trials in humans. The first one is the bivalent AMA-1 recombinant vaccine that is
based on 3D7 and FVO P. falciparum strains. This vaccine was expressed in Pichia pastoris
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and adjuvanated with aluminium hydroxide developed by the Malaria Vaccine Development 
Branch of the National Institute for Allergy and Infectious Disease of the U.S National 
Institute of Health. A phase II clinical trial of this vaccine was carried out in adults and 
children in Mali although the results were unsatisfactory (226). The second one is a 
monovalent AMA-1 formulated vaccine using RTS,S adjuvant systems (AS01 and AS02). 
This vaccine showed highly immunogenic responses when tested in a similar population 
(256). However, higher degrees of polymorphism in coding regions were observed (253) 
therefore may limits its success as a vaccine candidate.
The PfEMPl is another candidate for erythrocyte stage vaccines. PfEMPl is encoded 
by the var multigene family (243) and transported to the surface of infected RBC. An in vivo 
study using severe model of malaria showed that the PfEMPl recombinant vaccine 
constructed in Semliki forest virus (SFV) prevents the sequestration of Plasmodium parasite 
infected RBCs in mouse (33). Another study in E.coli host system using PfEMPl variant 
(ITvar9/R29varl) also produced antibodies against the recombinant antigen of PfEMPl(87). 
Even though this vaccine had shown promising results, the designing of this vaccine is not 
straight forward due to a large genetic variation of the var gene. Designing vaccine using 
PfEMPl conserved epitopes that are highly immunogenic is perhaps a better approach to 
address this problem.
One of the latest development in malaria erythrocyte vaccine is published by a group 
of scientists from Oxford’s Jenner Institute, UK and the Kenyan Medical Research Institute 
using the P. falciparum reticulocyte binding protein homologue 5 (PfRH5). PfRH5 is 
expressed as a 63 kDa protein and localised at the apical end of the merozoite. The PfRH
family consisting of six genes (PfRHl, PfRH2a, PfRH2b, PfRH3, PfRH4 and PfRH5) play an
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important role in ligand-receptor interaction (55) except PfRH3 (255). Doughlas et al. (2011) 
are using the full-lenght of P. falciparum PfRHS gene and cloned into replication-deficient 
adenovirus human serotype 5 (AdHU5) which is one of the most promising result in malaria 
vaccine develpoment. The vaccination trial was carried out in animal models and showed that 
the PfRH5 was able to induce IgG antibodies, which are recognised by native malaria 
parasites. The enzyme-linked immunosorbent assay (ELISA) also demonstrated that the 
recombinant PfRH5 vaccine produced a high level of antibody titres (10, 000 units/ml serum). 
The authors also indicate that the anti-PfRH5 IgG antibodies were more effective than 
antibodies produced by PfAMAl and PfMSPl antigens when tested against P. falciparum 
3D7 parasites (53).
1.6.3 Transmission-Blocking (TB) Vaccines
TBV are designed to induce an immune response in the human host that are capable of 
blocking the parasite’s growth in the mosquito host. This is a novel and promising approach 
in malaria vaccine development for avoiding selection pressure within the host that favours 
“vaccine resistant” parasite (51). Pfs25 and Pvs25 are two leading TB vaccine candidates. 
Both proteins are expressed on the surface of ookinetes in the mosquito stages of P. 
falciparum and P. vivax respectively. Data from animal studies showed that both antigens are 
able to induce strong transmission blocking activity (179). However, an early clinical trial 
showed that the anti-Pfs25 antibodies were detected but had marginal activity in blocking the 
transmission (124). Meanwhile, other human trials using recombinant Pvs25 were able to 
inhibit parasite development in mosquitoes but the levels of protection were too low for an 
effective vaccine (162).
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1.6.4 Multi-stage, Multi Antigens Vaccines
Malaria parasites have a complex life cycle and bigger genome size than bacteria or 
viruses. Ideally, a multiantigenic approach is the best approach to stimulate immune responses 
thus conferring protection from malaria. The NYVAC-Pf7 and SPf66 are the two Plasmodium 
vaccine candidates in the development of multi-stage vaccine for malaria.
The NYVAC-Pf? vaccine is a genetically engineered, multistage, multiantigenic and 
highly attenuated vaccinia virus consisting of seven P. falciparum genes (43). Clinical phase I 
and II trials showed that the NYVAC-Pf7 was safe and well tolerated in all vaccinated 
volunteers; however, the immune responses observed were variable.
The SPf66 vaccine was the first multiangtigen vaccine to undergo extensive field 
studies. This vaccine comprises a synthetic “hybrid construct” containing amino acid 
sequences of MSP 1 antigen linked by the central repeat of the pre-erythrocytic antigen (206). 
The results from various clinical trials conducted in Asia and Africa showed that the vaccine 
did not produce significant protective efficacy (254). Attempts to develop DNA based vaccine 
(142) and recombinant vaccinia viruses (196) were also unsuccessful.
1.6.5 Attenuated Whole-Organism Vaccines
A purified, radiation-attenuated, metabolically active and non-replicating sporozoite 
vaccine (PfSPZ) was manufactured from aseptically raised mosquitoes (108). This vaccine 
conferred 90% protective efficacy when delivered by bites of at least 1,000 irradiated 
mosquitoes. Nevertheless, this vaccine did not have significant protective efficacy when 
administered by intradermal or subcutaneous routes (61). A study in monkeys showed that the
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vaccine produced highly protective efficacy when administered intravenously (61). To date, 
the attenuated whole parasite vaccines have received significant attention by a number of 
research groups around the globe due to the promising vaccination results shown in monkeys 
(167). On the other hand, development of attenuated whole organism vaccines is hampered by 
inadequate quantities of sterile, metabolically active and non-replicating sporozoites that are 
safe, well tolerated and immunogenic in human. The next obstacle is the method of delivery 
as the size of the PFZ measures 0.5-1.0 pm x 7-10 pm, in order to confer more than 85% 
protection.
1.7 The Apicoplast of Malaria Parasite
The apicoplast is a plastid-related organelle that present in almost all parasites of the 
apicomplexan group i.e Plasmodium, Toxoplasma, Crytosporidium, Eimireia, Babesia and 
Thileria spps. This is a single non-photosynthetic plastid eukaryotic cell that was acquired by 
the secondary endosymbiosis of plastid containing red alga (170). Therefore, this organelle is 
surrounded by three or four membranes. Except for Cryptosporidium which loses the 
apicoplast over time, this plastid organelle is maintained in the rest of the apicomplexan 
parasites although it is no longer involved in photosynthesis (111, 192). During the 
intraeythrocytic stages, the apicoplast closely resembles the Plasmodium mitochondrion (248, 
269). Like the Plasmodium mitochondrion, the apicoplast is structurally elongated and 
branches out during schizogony. This has been supported by the electron micrographs that 
revealed a ‘spherical body’ of apicoplast closely associated with the single mitochondrion of 
Plasmodium parasites (192). At the later stage of schizogony, the branched apicoplast 
continuously divides, so that each newly formed merozoite carries a new apicoplast in their 
cytoplasm (268).
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The P. falciparum apicoplast posseses a circular ~35-kb genome, high number of A+T 
content and completely lacks any genes related to photosynthesis. As a result of the 
establishment of the endosymbiont, majority of the apicoplast genes are transferred into the 
parasite nucleus (165). Therefore, majority of the genes are encoded by nuclear genes and 
only less than 50 proteins are encoded by the apicoplast genome both of which produce gene 
products targeted into the organelles (169). The P, falciparum genome revealed 
approximately 10% of the nucleus encoded proteins likely to be targeted to the apicoplast 
(82). Data from pharmacological and genetic studies in Toxoplasma and Plasmodium have 
consistently demonstrated that the apicoplast is essential for parasite growth (191).
Studies by (Ralph et al., 2004, Seeber and Soldadi-Favre, 2010) showed that the 
apicoplast is involved in the biosynthetic pathways for fatty acids, isoprenoids, iron sulphur 
cluster assembly and segment of the haem pathways. In the photosynthetic algae these 
metabolites are generated by chloroplast through the photosynthesis pathway. Since the 
photosynthesis is abandoned in apicomplexans group, the energy for metabolites generation is 
carried out in the parasite cytoplasm (155, 236). Several studies have shown that several 
antibiotics can inhibit the apicoplast DNA replication, transcription and translation therefore 
leading to death of the parasites (44, 90). Some antibiotics namely ciprofloxacin, rifampicin 
and thiostrepton can cause an immediate effect whereas tetracycline and clindamycin result in 
the delayed death of the parasites (44, 90). To date, some of these antibiotics are currently 
used in combination therapies for malaria.
The biosynthetic pathways for fatty acids and isoprenoid precursors appears to be the
only de novo synthesis machine for malaria parasites and differs from the other mammalian
cells (82, 251). Like in bacteria and plants, fatty acid biosynthesis in Plasmodium parasites is
36
via type II fatty acid synthesis (FAS II) pathway, which consists of single enzymes acting in 
concert to catalyse the condensation, dehydration and reduction reactions (219).
Type I fatty acid biosynthesis pathway in eukaryotic cells consists of fatty acid 
synthase which contains all enzymatic reactions sites important for fatty acid synthesis. 
However, not all apicomplexan parasites have retained the type II FAS synthesis pathway. For 
example in Crytosporidium spp.the fatty acid synthesis is performed via type I FAS pathway. 
Meanwhile in the apicomplexan parasites T. gondii and Eimeria tenella have both types (FAS 
I and II) of fatty acid synthesis pathways (271, 296).
In FAS II pathway, acetyl-CoA is required in the first step of the pathway, and is 
provided by the pyruvate dehydrogenase complex (PDH) within the apicoplast (75, 171). 
Acetyl-CoA is carboxylated by acetyl-CoA carboxylase to form manoyl-CoA which is the 
committing step in the fatty acid biosynthesis. In malaria parasite, type II fatty acid synthesis 
is only essential for malaria parasite at late liver cell development. An in vitro study showed 
that the Plasmodium FAS was inhibited by antimicrobial drugs thiolactomycin and triclosan. 
Thiolactomycin is an inhibitor of the condensing enzymes FaB (p-ketoacyl-ACP synthase I), 
FabF (P-ketoacyl-ACP synthase II) and FabH (p-ketoacyl-ACP synthase III) (274) and 
triclosan acts on FabI (enoyl-ACP reductase) activity in FAS II pathway (251). Triclosan also 
produced positive results in parasitic clearance of mice infected with the rodent malaria 
parasites P. berghei (251).
Another important biosynthetic pathway in apicoplast of the Plasmodium parasites is
the non-mevalonate dependent isoprenoid biosynthesis. Isoprenoids is derived from a simple
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five-carbon precursor isopentenyl pyrophosphate (IPP) and its isomeric form dimethylallyl 
pyrophosphate (DMAPP). The IPP is synthesised in 2 different pathways: L using
intermediate mevalonate e.g in animals and fungi, ii. 1 -deoxy-D-xylulose-5-phosphate 
(DOXP) pathway e.g in apicomplexan parasites, bacteria and plants. In vitro and in vivo 
studies showed that the antibiotic fosmidomycin inhibits the DOXP reductoisomerase thus 
killing the parasites (189, 281).
The Plasmodium apicoplast is also involved in haem synthesis. Haem is an essential 
prosthetic group of cytochromes and is involved in oxygen and electron transport in the 
Plasmodium mitochondria. Plasmodium parasites generate haem through DOXP pathway and 
also from digested haemoglobin of host cells (250). Haem synthesis in Plasmodium parasites 
involves a number of enzymatic reactions which take place in different cellular compartments 
i.e in the apicoplast, mitochondrion and possibly the cytosol (219). The first step in the 
reaction is the synthesis of 5-aminolevulinate from glycine and succinyl-CoA. This process is 
catalysed by 8-aminolevulinate synthase which is located in the mitochondrion (228, 270). 
The subsequent reactions are carried out by enzymes located in the apicoplast (228,269). This 
haem synthesis is completed using three enzymes namely HemF (coproporphyrinogen 
oxidase), HemG (protoporhyrinogen oxidase) and HemH (ferrochelatase). The HemH 
contains N-terminal targeting peptides thus suggesting these enzymes are located in the 
Plasmodium mitochondria (219). On the contrary, HemG does not possess an obvious N- 
terminal targeting peptide, suggesting that this protein is located in the Plasmodium cytosol. 
However, the prediction of Plasmodium HemF location is difficult because it contains several 
introns at the N-terminus (219).
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1.8 Mitochondria: Background
In eukaryotic organisms mitochondria are involved in cellular respiration via 5 major 
complexes namely Complex I, Complex II, Complex III, Complex IV and Complex V (Figure 
1.6) embedded in the inner mitochondrial membrane which lead the generation of ATP as an 
energy source (54, 221). This bioenergetic process starts after glucose is broken down through 
the glycolytic pathway in the cytosol. The breakdown of glucose produces pyruvate which is 
the end product of the glycolysis. Glucose is then converted into acetyl CoA by 
decarboxylation and enters the TCA cycle in the mitochondrial matrix producing CO2 as a bi­
product as well as many intermediates required for amino acid and fatty acid biosynthesis. 
During the TCA cycle, electrons are released from NADH or FADH2 to ubiquinone to supply 
the mitochondrial respiratory chain. The movement of electrons in the respiratory chain thus 
initiates the membrane electrochemical gradient where protons are translocated in and out 
from the mitochondrial matrix and finally ATP is generated via ATP hydrolysis by plasma 
membrane ATPase (Complex V).
1.8.1 The Mitochondrial Genome
The linerised form of the 6-kb malaria parasite mitochondrial DNA (mtDNA) is the 
smallest genome among the eukaryotic cells. The parasite mtDNA contains 30-100 copies of 
the genome which encode only three subunits belonging to the mitochondrial electron 
transport chain (mtETC): subunits 1 and III of cytochrome c oxidase (cox I and cox IV of 
Complex IV), a cytochrome b subunit of ubiquinol-cytochrome c reductase (Complex III) and 
fragmented ribosomal RNA genes (62,139,263).
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MtDNA is T-rich and highly conserved among apicomplexan phytogeny (63, 121). 
The transcription of the mtDNA is highly active during the late trophozoite and early schizont 
compare to the ring stage (139). To date, there is not so much information related to the 
mtDNA during gametogenesis and in the life cycle of the parasites in the mosquito host.
1.8.2 Malaria Parasite Bioenergertics: Glycolysis,
the TCA cycle and Mitochondrial Electron 
Transport
1.8.2.1 Glycolysis
Blood-stage malaria parasites rely mainly on glycolysis for energy generation. 
Glucose from the plasma enters into the Plasmodium cytoplasm and is subsequently degraded 
to lactate via the anaerobic Embden-Meyerhoff-Pamas (EMP) pathway. Studies by Roth Jr et 
ah (1988) showed that infected RBC use 100 fold more glucose (mainly during trophozoite 
and schizont stages) than non-infected erythrocytes. Glucose is used in Plasmodium metabolic 
pathways for nucleic acid biosynthesis, amino acid biosynthesis the TCA cycle and lipid 
biogenesis. 60-70% of the glucose consumed by P. falciparum is incompletely oxidised to 
lactic acid and only a small amount of glucose is oxidised to form CO2 and ATP (199). A 
number of studies have shown that the twelve glycolytic enzymes in Plasmodium are highly 
conserved and tightly co-regulated throughout the intraerythrocytic life cycle (25, 82). The 
glycolytic pathway in Plasmodium is illustrated in Figure 1.7. Plasma glucose is amed into 
the parasite by the hexose transporter located on the surface of infected RBC. The level of 
hexokinase expression is reported higher during active infection (133, 240) therefore also 
increases substrate entry into the parasite penthose phosphate pathway.
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Figure 1.6: The Mammalian Mitochondrial Respiratory Complex
The respiratory complex of the mammalian mitochondrial dehydrogenases consists of Complex I 
(NADH dehydrogenase). Complex II (succinate dehydrogenase). Complex III (bc\ complex) Complex 
IV (cytochrome oxidase) and Complex V (ATPase). The ubiquinone and cytochrome c are 2 mobile 
electron carriers in the inner mitochondrial membrane. The electrons pass via complex 1 and II and are 
accepted by ubiquinone resulting in the generation of ubiquinol. Ubiquinol is net oxidised by the bc\ 
complex (III) which in turn reduces cytochrome c. Finally cytochrome c is oxidised by 02, the 
terminal electron acceptor. Electron flow through these complexes is coupled with translocation of 
protons from the matrix into the intermembrane space thereby generating an electrochemical gradient 
which in turn is used to generate ATP via complex V (ATP synthase).
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Glucose-6-phosphate isomerase (GPI) catalyses the conversion of glucose-6- 
phosphate to fmctose-6-phosphate. Phosphofructokinase (PFK) catalyses the formation 
fructose-1,6-bisphosphate from fructose-6-phosphate. Fructose-1,6-biphosphate is cleaved to 
form two different triose phosphates glyceraldehyde-3-phosphate (G-3-P) and 
dihydroxyacetone phosphate (DHAP) using the aldolase enzyme. Only glyceraldehyde-3- 
phosphate is oxidised to form 1,3-bisphosphoglycerate (1,3-DPG) by glyceraldehyde-3- 
phosphate dehydrogenase (GAPDH). DHAP is converted to form G-3-P using triose 
phosphate isomerase (TPI) thus re-entering the glycolytic pathway.
The following steps in the glycolytic pathway are recognised as a source of ATP 
production in malaria parasite. These enzymes’ subunits are described in the Plasmodium 
genome database (82). The phosphoryl group of 1,3-DPG is phosphorylated to form 3- 
phosphoglycerate (3-P-glycerate) by phosphoglycerate kinase (PGK) and 2 molecules of ATP 
are generated at this stage. 3-P-glycerate is converted to 2-phosphoglycerate (2-P-glycerate) 
by phosphoglycerate mutase. This is followed by the conversion of 3-P-glycerate to 
phosphoenolpyruvate (PEP) catalysed by enolase enzyme. Eventually, PEP transfers its 
phosphoryl group to ADP thus generating 2 molecule of ATP. This reaction is catalysed by 
pyruvate kinase (PK).
In eukaryotic cells pyruvate is oxidised by mitochondrial pyruvate dehydrogenase 
(PDH). PDH has been recognised as an essential enzyme responsible for connecting the 
glycolytic pathway and TCA cycle and catalyses the conversion of pyruvate to acetyl-CoA in 
the mitochondrial matrix. However in malaria parasites the PDH enzyme is not expressed as
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Figure 1.7: Malaria Parasite Glycolytic Metabolite Pathway
The component enzymes of the glycolysis pathways are encoded in the Plasmodium genome. Glucose 
from host plasma protein is transported into the parasite via the hexose transporter which located on 
the surface of infected RBC. Glucose was degraded by Plasmodium glycolytic enzymes thus 
producing lactate as an end product. The Plasmodium glycolytic pathway produces 2 molecules ATP 
as a carbon source for their cellular activities. The oxidation of phophoenolpyruvate (PEP) produces 2 
molecules of pyruvate for the production of lactate (fermentation) and for lipid biogenesis in the 
apicoplast. Oxidation of pyruvate also produced OAA to enter the Plasmodium TCA cycle. Adapted 
from Daily et al. (2007).
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originally predicted by Sherman (1998). Instead, Foth et al. (2005) demonstrated that the PDH 
enzyme complex is detected in the parasite apicoplast and used for generation of acetyl-CoA 
for lipid biogenesis. The formation of large quantities of lactic acid by the parasite would 
have implications for cytosolic pH. To mitigate this, the parasite removes lactic acid via a 
monocarboxylate transporter on the parasite surface membrane (40).
In most eukaryotic cells despite using glycolytic pathways, glucose can be generated 
via gluconeogenesis, the reverse mechanism of glucose synthesis from pyruvate. However, in 
the P. falciparum this mechanism is not available due to the unavailability of fructose 
bisphosphatase an enzyme which is essential for gluconeogenesis. This has been proved by 
the unavailability of this gene in the Plasmodium genome(82) On the other hand the parasite 
genome encodes phosphoenolpyruvate carboxykinase (PEPCK; PF13_0234) which is an 
important enzyme for gluconeogenesis which converts oxaloacetate (OAA) and ATP back to 
phosphoenolpyruvate (PEP) and CO2. However, a study by Olszewski et al (2010) failed to 
detect the present of PEPCK activity in vitro. However, a study by Hayward (2000) 
demonstrated the upregulation of this enzyme during the sexual life cycle in mosquito host. 
PEP is then converted into pyruvate by pyruvate kinase. The P. falciparum genome has 2 
genes encoded for pyruvate kinase (PF10_0363 and PFF1300w). Pyruvate kinase is already 
characterised and demonstrated to be involved in lipid biosynthesis in the apicoplast of the 
parasite whereas the activity of PFF1300w is still not understood (160).
The parasite genome also encodes phosphoenolpyruvate carboxylase (PEPC; 
PF14_0246) which is an essential enzyme in plant photosynthesis (82). The PEPC enzyme 
was successfully been purified from P. berghei (199). In P. falciparum, PEPC is
demonstrated involved in the process of reconversion of PEP from OAA. Later, with the
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presence of inorganic phosphate (Pi), NADH efficiently reduces OAA to malate by 
cytoplasmic malate dehydrogenase (MDH) (102).
The OAA generated by PEPC is also converted to aspartate by aspartate transaminase 
(PFB0200c) when the cellular aspartate level is low. Bulusu et al (2011) demonstrated the 
role of aspartate in the Plasmodium asexual life cycle. Aspartate is used for protein, purine 
and pyrimidine biosynthesis. However this phenomenon does not exist in in vitro culture 
since aspartate is supplied in the growth medium. Instead of converting into aspartate, OAA is 
reduced to malate by cytoplasmic MDH (199). This is supported by their previous study on 
radiolabbeled glucose showing the active involvement of PEPC catalysing the conversion of 
OAA to malate (200).
1.8.2.2. The Malaria Parasite TCA Cycle
The P. falciparum genome encodes all the necessary enzymes for TCA cycle (82). 
These enzymes are actively synthesised during the asexual blood life stages (25).
The first step in the Plasmodium TCA cycle is the production of citrate by citrate 
synthase using OAA and acetyl-CoA as substrates. Plasmodium has a citrate synthase 
homologue (PF10_0218) which has an N-terminal presequence to transport this protein into 
the Plasmodium mitochondrion (257). However in a recent study by Olszewski et al. (2010)
demonstrated that the entry point for the TCA cycle in the malaria parasite is a-ketoglutarate
(2-oxoglutarate) instead of citrate. From their study it was demonstrated that the TCA cycle in
the malaria parasite is branched and not cyclic as in the canonical TCA cycle present in most
higher eukaryotic cells (Figure 1.8). The two Frances of the Plasmodium TCA architecture
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are: the oxidative branch (following the canonical TCA cycle) and the reductive branch which 
is run in the reverse of the standard direction. However, only the reductive branch is 
responsible for the Plasmodium TCA cycle (200).
Two amino acids glutamine and glutamate have been identified as the major carbon 
sources which feed the cycle. The degradation of host haemoglobin produces glutamine and 
glutamine is then is converted to glutamate by Plasmodium glutamate synthase (PF14 0334) 
and finally converted to 2-oxoglutarate by glutamate dehydrogenase (GDH). The P. 
falciparum genome encodes 3 different genes for GDH: an NADP-dependent enzyme 
(PF14_0286), cytosolic NADP-GDH (PF14_0164) and fungal type NAD-dependent GDH 
(PF08_0132). An NADP -dependent enzyme is hypothesise targeted to the apicoplast which 
supply NADPH for biosynthetic reactions within the Plasmodium apicoplast (199).
The cytosolic NADP-GDH enzyme is speculated to be involved in redox homeostasis 
producing cytosolic 2-oxoglutarate (223). The cytoplasmic 2-oxoglutarate enters the 
mitochondrion through the malate:oxoglutarate antiporter (200) and eventually provides a 
carbon source to the TCA cycle.
1,8.2.2,1 The Reducing Branch of the Plasmodium TCA Cycle
The reducing arm of the Plasmodium TCA cycle is started by the reduction of 2- 
oxoglutarate to isocitrate by isocitrate dehydrogenase enzyme 2 (IDH2). In higher eukaryotic 
cells the isocitrate dehydrogenase (IDH) enzyme is available in 3 isoforms: mitochondrial 
NADP-dependent (IDH1), mitochondrial NAD-dependent (IDH2) and cytosolic NAD- 
dependent (IDH3).
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Figure 1.8: The Branched Tricarboxylic Acid Cycle in P. falciparum
The TCA cycle in Plasmodium mitochondria is structurally divided into reductive and oxidative 
pathways. Red arrows present the reductive pathway and blue arrows depict the oxidative pathway. 
Only reductive pathway is responsible for the Plasmodium TCA cycle. The reduction of citrate to 
OAA produced acetyl CoA, but the cellular function and the catalytic enzyme in this process are still 
unclear. The apicoplast acetyl-CoA is responsible for lipid biogenesis. Glutamate and glutamine are 2 
amino acids that feed the cycle which converted to alpha ketoglutarate /2-oxoglutarate and enter the 
Plasmodium mitochondrial matrix. Asterisk (*) indicates the specific enzyme responsible for the 
citrate cleavage step but its location are unclear. Double asterisk (**) represents enzymes malate 
quinone oxidoreductase (MQO) or malate dehydrogenase (MDH) catalysing the conversion of OAA to 
malate. Abbreviations: Gin, glutamine; Glu, glutamate; OG, 2-oxoglutarate; ICT, isocitrate; Cit, 
citrate; Ac-R, acetate/acetyl-CoA; Ac-CoA, acetyl-CoA; OA, Oxaloacetate; Mai, malate; Sue, 
succinyl; Suc-CoA, succinyl-CoA; Fum, fumarate; Glc, glucose; Asp, aspartate; PEP, 
phosphoenolpyruvate; Pyr, pyruvate; Lac, lactate. Both oxidative and reductive branches of the 
Plasmodium TCA cycle produced malate which is transported out from Plasmodium mitochondria. 
Adapted from Olszewski et al. (2010).
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. In the oxidative mode, isocitrate is oxidised to 2-oxoglutarate using IDH3 producing 
02 and reducing NAD+ and NADP+. However in P. falciparum the mitochondrial genome 
encodes only mitochondrial NADP+ dependent isocitrate dehydrogenase IDH2 (PF13_0242) 
(288) which uses NADP+ as a cofactor. The parasite’s mitochondrial NADP(H) specific 
glutamate dehydrogenase (PF14__0164) and glutamate oxidation provide the cofactor for the 
p, falciparum IDH2. Therefore, due to the absence of the IDH3, it is suggested that the P. 
falciparum TCA cycle uses the branched architecture (200).
The PfIDH2 amino acid sequence has been identified, containing a mitochondrial 
presequence signal (leader sequence) and shown to be highly upregulated during oxidative 
stress (288). As mentioned earlier this enzyme uses oxidative NADP+ instead of NAD+ as a 
cofactor. The Plasmodium mitochondria require NADPH for anti-oxidant protection from 
ROS which are highly synthesised in the mitochondria (186, 288).
The next step in the reductive TCA branch is the isomeration of isocitrate to citrate 
catalysed by mitochondrial aconitase (PF13_0229). Aconitase is a reversible enzyme which 
can oxidised citrate to isocitrate or vice versa.
The Plasmodium genome encodes two citrate synthase homologues (PF10 0218) and 
PFF0455w (25, 82) occupied with an N-terminal presequence signal to transport this protein 
into the Plasmodium mitochondrial matrix (258). From metabolomic data, citrate is shown to 
be cleaved (deacetylation) into OAA followed by the reduction of OAA to malate (200). The 
reduction of citrate is catalysed by reversible citrate synthase enzyme. This is different from 
the canonical TCA cycle where the action of citrate synthase is irreversible. However a study
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in fatty acid oxidation shows that citrate synthase can be reversed to catalyse the reduction of 
citrate to OAA (105). The reduction of OAA to malate generates acetyl-CoA which is 
transported from mitochondria into the cytoplasm and thereafter transported into the parasite 
nucleus to produce nucleic acids (DNA and RNA). The OAA is reduced to malate in the final 
step of the Plasmodium TCA cycle. The reduction of OAA to malate is catalysed by 
mitochondrial malate enzyme (either MDH or MQO) (200),
1.8.2.2.2 The Role of the Oxidative Branch of Plasmodium TCA 
Cycle
Due to the TCA cycle in Plasmodium being performed only by the reductive arm, the 
role of the oxidative arm of Plasmodium TCA has drawn new interest in the metabolic study 
of the P. falciparum. As mentioned earlier the Plasmodium genome encodes all the enzymes 
which are involved in the canonical TCA cycle (25, 82)
The oxidative arm is started by the conversion of 2-oxoglutarate to succinyl-CoA by 
alpha ketoglutarate dehydrogenase complex (PF08_0045). Succinyl CoA has been identified 
as a precursor enzyme for the cellular de novo haem biosynthesis pathway in Plasmodium 
falciparum (265, 269). According to the normal canonical TCA cycle, succinyl Co-A is 
converted to succinate by succinyl-CoA synthase (PF11_0097) and GTP is generated. The 
Plasmodium genome indicates the presence of alpha and beta subunits of succinyl-CoA 
synthase (PF11_0097 and PF14 0295) (82,269).
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Succinate then is oxidised to fumarate by succinate dehydrogenase which is the 
Complex II of the Plasmodium electron transport system. Oxidation of succinate supplies 
electrons to the mitochondrial respiratory chain via the reduction of FAD to FADH2.
A study on the fate of fumarate in the oxidative branch was carried out by Bulusu et 
al, (2011). From the NMR study of the free parasite preparation, fumarate is incorporated into 
nucleic acids and proteins by biosynthesis (aspartate, alanine and glutamate). They reported 
that cytosolic Plasmodium fumarate is formed via the purine salvage pathway in the parasite 
cytoplasm. The Plasmodium fumarate pool in the parasite cytoplasm is transported into the 
mitochondria via the malate oxoglutarate transporter. The presence of this transporter in the 
Plasmodium genome was demonstrated using real time PCR (RT-PCR) analysis (Bulusu et 
al., 2011).
The role of fumarate in pyrimidine biosynthesis was demonstrated by Painter et al. 
(2007) using transgenic parasites bearing the S. cerevisae DHODH (SCDHODH) gene. 
Unlike PfDHODH, the ScDHODH gene product is localised in the cytoplasm and uses 
fumarate as electron acceptor which is produced from the purine salvage pathway in 
Plasmodium (27,203).
Fumarate is then converted into aspartate and malate by the reversible fumarate
hydratase (PFI1340w). The oxidation of fumarate to malate is catalysed by the fumarate
hydratase Type 1. Pf fumarate hydratase/fumarase is unique and different from Type II
fumarate hydratase which is found in yeast or mammalian cells. Pf fumarate hydratase has a
resemblance to bacterial fumarate hydratase (73, 287). From the Kyoto Encylopedia of Genes
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and Genomes (KEGG) database it is demonstrated that fumarate can be converted into three 
amino acids, glutamate, aspartate and alanine (27, 122). Glutamate is also derived from the 
degradation of host haemoglobin thus used as a precursor to initiate the TCA cycle in the 
Plasmodium parasite. Aspartate provides the carbon skeleton for the backbone of the 
pyrimidine ring in de novo pyrimidine synthesis in P. falciparum. In the parasite mitochondria 
fumarate is converted to malate by fumarate hydratase. Malate is then oxidised into OAA 
which is catalysed by the MQO enzyme. Bulusu et al., (2011) demonstrated that the oxidation 
of malate is mainly carried out by malate quinone oxidoreductase (MQO; PFF0815w) which 
is one of dehydrogenase enzymes in ftisPlasmodium electron transport system.
1.8.2.3 The Role of Malate in P. falciparum Metabolic 
Pathways
Malate is an essential substrate involved in central carbon metabolism of eukarytotic 
and prokaryotic cells. In the TCA cycle of the eukaryotic cells, malate is oxidised into OAA 
by mitochondrial malate dehydrogenase (MDH). Oxidation of malate to OAA thus reduces 
NAD+ to NADH therefore supplying the electrons tothe electron transport chain and finally 
ATP is generated.
Figure 1.9 depicts the malate aspartate shuttle in eukaryotic cells. This process is 
started when the OAA is converted into malate by cytosolic MDH thus re-oxidising the 
NADH (from glycolytic pathway) to NAD+. The malate passes the mitochondrial inner 
membrane via the malate-a-ketoglutarate transporter. Within the mitochondria, malate is 
oxidised to OAA by mitochondrial MDH and NAD+ is converted into NADH which passes 
electrons to the mitochondrial respiratory chain. The transamination of OAA to aspartate is
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Figure 1.9: The Malate Aspartate Shuttle of Mammalian Cells
(1) Glutamate aspartate transporter and (2) malate-a-ketoglutarate transporter. Cytosolic NADH from 
the glycolytic pathway provides equivalents to OAA. OAA is reduced to malate by cytosolic malate 
dehydrogenase. Malate is transported into the mitochondrial matrix via the malate-a-ketoglutarate 
transporter. Within the matrix, malate is oxidised into OAA by mitochondrial MDH and passes 2 
reducing equivalents to NAD+. OAA is transaminated to aspartate by aspartate aminotransferase and 
transported back into the cytosol via the glutamate-aspartate transporter. Aspartate is re-transaminated 
back to OAA to complete the cycle. During the transamination process, glutamate is converted into 2- 
oxaloacetate/alpha-ketoglutarate (in the mitochondrial matrix) and cytoplasmic 2-oxaloacetate re­
converted to glutamate using the same enzyme, aspartate aminotranferase. Abbreviations: Glu, 
glutamate; 20G, 2-oxaloacetate; OAA, oxaloacetate; MDH, malate dehydrogenase.
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catalysed by the aspartate aminotransferase enzyme. During the transamination of OAA to 
aspatate, glutamate is converted to a-ketoglutarate by glutamate dehydrogenase, a- 
ketoglutarate is then transported out from mitochondrial matrix via the malate-a-ketoglutarate 
transporter and aspartate is passed out via the glutamate aspartate transporter. The cytosolic 
OAA is then regenerated back through the transamination of aspartate by 
aspartateaminotransferase and a-ketoglutarate is re-converted to glutamate by reversible 
glutamate dehydrogenase in the intermembrane space (cytoplasm) (159).
Meanwhile the metabolic fate of malate in the Plasmodium mitochondria is slightly 
different from other eukaryotic cells. As mentioned in section 1.8.2.2 the metabolomic study 
conducted by Olszewski et al. (2010) showed that malate is produced as an end product in 
both oxidative and reducing branches of the Plasmodium TCA cycle. The excreted 
mitochondrial malate in the cytoplasm was demonstrated by the presence of radiolab elled 
malate, citrate and 2-oxoglutarate in the culture medium. They have proposed that the 
conversion of malate to OAA is catalysed by PfMDH and malate quinone oxidoreductase 
(PfMQO). However a recent study by Bulusu et al. (2011) shows that the oxidation of malate 
to OAA is mainly performed by MQO. The oxidised OAA is transported out from matrix 
mitochondria via the malate-oxoglutarate transporter. The oxidation of malate to OAA thus 
feeds electrons directly to the Plasmodium respiratory chain. Figure 1.10 shows the 
diagrammatic presentation of malate in the Plasmodium metabolic pathways.
The oxidation of fumarate to malate is catalysed by the fumarate hydratase in the
parasite mitochondria. Malate is then transported out from the mitochondrial matrix via the
malate-alpha-ketoglutarate transporter. This transporter is encoded in the Plasmodium
genome (PF 08_0031) and its expression validated by RT-PCR (27). However this
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Figure 1.10: The Malate Aspartate Shuttle in the Plasmodium Parasite
Malate has been recognised as the end product from both oxidative and reducing branches of the 
Plasmodium TCA cycle. Malate can also be synthesised through fumarate oxidation using fumarate 
hydratase (fumarase) within the Plasmodium mitochondrial matrix. The OAA in the reductive branch 
is converted to malate by mitochondrial MQO enzyme. Malate than is transported out from the 
mitochondrial matrix via the malate-oxoglutarate tranporter. Abbreviations: 200, 2-oxoglutarate; ICT, 
isocitrate; Cit, citrate; OAA, oxaloacetate; Fum, fumarate; Succ, succinate; Succ-CoA, Succinyl-CoA; 
MDH, malate dehydrogenase; MQO, malate quinone oxidoreductase; QH2, ubiquinone; Q, ubiquinol; 
DHODH, dihydroorotate dehydrogenase, bc\, cytochrome bc\ complex; PfNDH2, P. falciparum type 
II NADHiubiquinone oxidoreductase, Cplx IV, Complex IV.
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mechanism is not yet fully elucidated. In normal physiological condition only a small amount 
of OAA is transported out from mitochondria via malate-alpha-ketoglutarate transporter. The 
mitochondrial OAA is normally transported out via a glutamate-aspartate shuttle which is not 
encoded in the Plasmodium genome (269).01szewski and Llinas (2011) speculated that OAA 
could directly transport out from mitochondria without being transaminated to aspartate in the 
mitochondrial matrix. However transamination of the cytoplasmic OAA can be performed in 
the cytoplasm where OAA is converted to aspartate by the aspartate aminotransferase 
(PfAAT). PfAAT is encoded in the Plasmodium genome (PFIT_PFB0200c) and confocal 
microscope study depicts PfAAT in the Plasmodium cytoplasm and not in the mitochondria 
(27). The cytoplasmic aspartate is then integrated into Plasmodium purine salvage pathways 
and also into the synthesis of proteins and de novo pyrimidine biosynthesis.
At the same time the cytoplasmic OAA is converted to malate by cytosolic MDH, 
oxidising NADH to NAD+. Like in other eukaryotic cells malate is transported back to the 
mitochondria via a malate-oxoglutarate shuttle, and NAD+ is converted to NADH to supply 
electrons to the mitochondrial respiratory system in the parasite.
1.8.2.3 The Malaria Parasite Electron Transport
Chain
Plasmodium mitochondrial electron transport (mtETC) consist of 5 dehydrogenase 
enzymes namely NADH type 2 dehydrogenase (rotenone-insensitive complex 1), succinate 
dehydrogenase (complex II), ubiquinone-cytochrome c oxidoreductase, malate-quinone 
oxidoreductase (MQO), dihydroorotate dehydrogenase (DHODH) and glycerol-3-phosphate 
dehydrogenase (Figure 1.11). These dehydrogenase enzymes require their respective 
substrates to operate which are, NADH, succinate, malate, DHO and glycerol-3-phosphate.
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Figure 1.11: Schematic Drawing of the Organisation of the Mitochondrial Respiratory 
Complexes of P. falciparum
The chain consists of PfNDH-type II NADH: quinone oxidoreductase, DHODH (dihydroorotate 
dehydrogenase), G3PDH (glycerol-3-phosphate dehydrogenase), MQO (malate quinone 
oxidoreductase), SDH (succinate dehydrogenase), bc\ (cytochrome bc\ complex), Cyt c (cytochrome 
c), CIV (cytochrome oxidase), FiF0ATPase (Complex V) and UCP (putative uncoupling protein). 
Electrons are generated by mitochondrial dehydrogenases and passed to ubiquinone (QH). Re­
oxidation of QH2 releases 2 to mitochondrial intermembrane space and passes electrons to bc\ 
complex. The electrons are continuously passed to cytochrome c. Finally, the cytochrome c uses the 
electrons and H+ to reduce 02 to H20. The Plasmodium genome lacks F0 the subunit (subunits a and b) 
which is essential for ATP generation. Fisher et al.(2007) described the presence of a proton leak via 
the Plasmodium F|F0 respiratory chain to enable the maintenance of high transmembrane proton 
potential (ij/m). Another theory of re-entrance of protons into the mitochondrial matrix is through 
uncoupling protein (UCP). Adapted from Fisher, et al. (2009).
56
These dehydrogenase are involved in reduced ubiquinol and then reoxidised its to ubiquinone 
by the bc\ (Complex III). This redox reactions is proceeded with a reduction of ubiquinone 
cytochrome c. Finally, the reduced form of cytochrome c is oxidised by a cytochrome c 
oxidase (Complex IV) and molecular oxygen to yield water. A membrane potential is 
generated although this is not then used to generate ATP via Complex V. Probably, a small 
amount of ATP is generated in order to complete the proton circuit (66)
1.8.2.3.1 PfNDH2 (Alternative NADH dehydrogenase) 
(PF10735c)
Complex I, rotenone-sensitive NADH dehydrogenase, is an enzyme which oxidise 
NADH (generated in the TCA cycle) and finally feeds electrons into the respiratory chain of 
the mitochondrion. Oxidation of NADH is coupled to the reduction of ubiquinone and this 
process is coupled with proton translocation across the inner membrane, generating a trans­
membrane potential. The Plasmodium genome lacks a canonical Complex I and instead 
contains an alternative (rotenone insensitive) type II NADH:ubiquinone oxidoreductase 
(PfNDH2) (66, 82). PfNDH2 has a single subunit and has homologs in plants, bacteria and 
yeast but not in animals (139, 219, 269). Structurally PfNDH2 is a membrane bound protein 
located on the membrane external side of the inner mitochondrial membrane facing the 
cytosol (19,262).
PfNDH2 has a FAD prosthetic group in comparison to typical NADH dehydrogenase 
which have flavin mononucleotide (FMN) and multiple FeS centres. PfNDH2 does not couple 
a redox reaction to proton pumping. Fisher et al. (2007) demonstrated that PfNDH2 is a major 
contributor of electrons to the Plasmodium respiratory chain (e.g. 50% of total flux is derived 
from PfNDH2 compared to only 1% by DHODH).
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1.8.2.3.2 DHODH (Dihydroorotate dehydrogenase) (PFF0160c)
DHODH is a flavoenzyme located in the inner membrane of Plasmodium 
mitochondrion (140) and is a key enzyme in the biosynthetic pathway for the synthesis of 
pyrimidines. It also serves to regenerate ubiquinone in the Plasmodium respiratory chain.
There are two types of DHODH, known as DHODH type 1 and DHODH type II. Type 
II DHODH is an integral membrane protein, localised in the inner mitochondrial membrane 
with the active site facing the intermembrane space. It is found in most eukaryotic cells and 
also in some of Gram positive bacteria and S. cerevisae (49, 203). Unlike type II DHODH, 
type I DHODH is located in the cytosol and uses fumarate or NAD+ or NADP+ as an electron 
acceptor to re-oxidise the flavin (FMN) prosthetic group. A study in S. cerevisae showed that 
the oxidation of DHODH to oorate is responsible for the reduction of fumarate to succinate in 
the TCA cycle (294).
The synthesis of pyrimidine in Plasmodium species are unusual compared to the other 
eukaryotic organisms. In Plasmodium, de novo pathway is the only pathway supplies 
pyrimidines for cell growth using a the dihydroorotate enzyme (151, 203). Unlike eukaryotic 
cells, Plasmodium cannot scavenge pyrimidines and is totally depended on the de novo 
pyrimidine synthesis for generation of Plasmodium DNA and RNA, glycoproteins and 
phospholipids. Dihydroorotate interacts with DHODH which is located facing the 
intermembrane space. Dihydroorotate is oxidised to generate orotate which is transferred out 
from the Plasmodium mitochondrion to the cytosol. The activity of DHODH has been shown 
to be maximal at the trophozoite and schizont stages of Plasmodium asexual development 
(140).
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1.8.2.3.3 Succinate-ubiquinone Oxidoreductase (Succinate 
dehydrogenase; Complex II)
Mammalian mitochondrial Complex II consists of four subunits (Sdhl, Sdh2, Sdh3 
and Sdh4). Sdh3 and Sdh4 are two hydrophobic anchor b-type cytochromes bound to a 
soluble heterodimer of Sdhl and Sdh2. Electrons are transferred from Sdhl to a ubiquinone 
binding pocket within Sdh2 and subsequently transferred to Sdh3 and Sdh4 in the inner 
mitochondrial membrane (109, 290). Succinate dehydrogenase is the only enzyme in the 
mitochondria which is involved in electron transfer in the respiratory chain and also oxidises 
succinate to fumarate in the TCA cycle in the mitochondrial matrix.
Two subunits of the Complex II have been identified in the Plasmodium genome. 
These are Fp,Sdhl (flavoprotein; PF10_0334) and IP,SdhB (an iron-sulphur protein; 
PF0630w). Both are hydrophilic subunits bound to the matrix side of the inner mitochondrial 
membrane (31, 82). The existence of Sdh 3 and Sdh 4 is as yet unconfirmed.
In a bioinformatic study, Mogi and Kita (2009) reported the putative identification of 
the two ‘missing’ subunits using similarity searches. At this stage however, these data are not 
confirmed and other candidates have been put forward by other laboratories (Biagini, personal 
communication).
1.8.2.3.4 Glycerol-3-phosphate Dehydrogenase
P. falciparum has NAD+ linked (PFL0780w) and FAD linked (PFC0275w) glycerol-3-
phosphate dehydrogenases (G-3-PDH) (269). G-3-PDH is a part of the glycerol shuttle which 
provides an alternative way for transferring electrons to the mitochondrial ubiquinone. The
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cytosolic NAD+ linked glycerol-3-phosphate dehydrogenase catalyses the reduction of 
dihydroxyacetone phosphate (DHAP) to glycerol-3 phosphate with concurrent oxidation of 
cytosolic NADH.
The glycerol-3-phosphate then is transported to the mitochondrial intermembrane 
space and re-oxidised back to dihydroxyacetone phosphate using mitochondrial glycerol-3- 
phosphate dehydrogenase. The oxidation of glycerol-3-phosphate thus generates electrons 
which pass via the FAD cofactor to ubiquinone.
1.8.2.3.5 Malate Quinone Oxidoreductase (MQO; PFF0815w)
MQO is a lipid-dependent, peripheral membrane-bound flavoprotein which catalyses 
the oxidation of malate to oxaloacetate. This enzyme is a membrane associated protein 
containing a FAD prosthetic group (185). From biochemical studies MQOs can be divided 
into two major families which are MQO 1 and MQO 2. The actinobacterial MQO including 
Mycobacterium smegmatis and Corynebacterium glutamicum belong to one major bacterial 
MQO family (MQOl), while most £-proteobacterial Escherichia coli, Helicobacter pylori, 
Campylobacter jejuni, and apicomplexan {P. falciparum. Toxoplasma gondii, Babesia bovis) 
ones are members of the second group of MQO (MQ02) (182).
1.8.2.3.6 Complex III (Cytochrome bci or ubiquinol-cytochrome 
c oxidoreductase)
Cytochrome bci or ubiquinol-cytochrome c oxidoreductase is an essential enzyme of 
the cellular respiration in many eukaryotic cells including metazoa, fungi and protozoan 
parasites. Cytochrome bc\ is located in the inner mitochondrial membrane of eukaryotic cells.
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The functional complex is 480 kDa consisting of two monomeric units of 10 to 11 
polypeptides. The catalytic core of the cytochrome bc\ consists of cytochrome b (CYTb), 
cytochrome cl (PF14_0597) and the Rieske iron-sulphur protein (ISP) (PF14 0373) which 
are encoded by mtDNA whilst the other subunits are encoded by nuclear DNA.
Cytochrome bc\ catalyses the electron transfer from ubiquinol to cytochrome c, 
coupled with the vectorial translocation of protons, thus generates a transmembrane 
electrochemical gradient (proton motive force) used for ATP production by FqFi-ATP 
synthase (Complex V). The catalytic mechanism of the bc\ complex is known as the Q cycle 
which was first postulated by Mitchell in 1975 (68,130).
1.8.2.3.6.1 The Q cycle
The crystal structure of the cytochrome ba shows the presence of presence of redox 
prosthetic groups which are cytochrome cl and iron sulphur (ISP). This group consists of two 
membrane domains associated with large hydrophilic regions. While the cytochrome b is 
containing predominantly hydrophobic protein with 8 transmembrane helices connected with 
2 heme b (heme bn and heme bi) and 2 quinol binding sites. The Qi site is the core of the 
cytochrome b and is topographically proximal to the matrix side in the inner mitochondrial 
membrane. Qo is located at the interface of cytochrome b and the Rieske protein proximal to 
outer surface of inner mitochondrial membrane (68,130).
The mitochondrial Q cycle is illustrated in Figure 1.12. The mitochondrial redox 
system can be divided into two phases. The first phase starts by the diffusion of ubiquinol
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Figure 1.12: The Schematic Drawing to Illustrate the Q cycle in the Mitochondrial bcj 
complex
The bci Q cycle starts when ubiquinol (QH2) binds to the Q0 (quinol oxidation site) within the 
complex. The first electron is transferred to the Rieske protein (Fe-S) which is then transferred to 
cytochrome c. QH is then in a semiquinone anionic state, CoQ '. The second electron is transferred to 
the heme b 1 site and converts CoQH' to CoQ. CoQ diffuses out from the Qo site to the mitochondrial 
intermembrane space. An electron from bi is transferred to bH and thus passes the electron to Q] 
(quinone reduction site) thus generating stable CoQH ’. The second phase of Q cycle is similar to the 
first phase, in which 2 protons are translocated out into intennembrane space. 2 HT from the 
mitochondrial matrix oxidise CoQ.- to form ubiquinol which later diffuse from the Qj binding site.
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(QH2) generated from the mitochondrial dehydrogenase enzymes. Ubiquinol binds to Q0 site 
and is oxidised thus releasing 2 protons and 2 electrons. The 2 protons are released into the 
intermembrane space. Deprotonated ubiquionol in the form of a semiquinone anionic state 
(CoQ.-) transfers 1 electron through the iron-sulphur cluster of the Riske protein and 
cytochrome d and finally transfers the electron to cytochrome c to supply electrons to feed 
the mitochondrial electron transport chain. The second electron is transferred to the heme bi 
which oxidises the semi-quinone to ubiquinone (CoQH.- to CoQ). The electron at heme bi is 
transferred to the heme bH and is finally transferred to the quionone reduction site (QO thus 
generating a stable CoQ.- radical firmly bound to Qi binding site.
The second phase of the Q cycle is similar to the first half. The second molecule of 
ubiquinol (QH2) binds to the Q0 site and oxidised to CoQH.- at the Qi binding site. This 
process releases another 2 protons into the intermembrane space. The second electron is 
transferred to heme bi and transferred to the heme bn site. This electron is then transferred to 
CoQ.- which is firmly bound to Qi site. 2 protons from the mitochondrial matrix oxidise 
CoQ.- to form ubiquinol which later diffuse from the Qi binding site to form part of the 
ubiquionol pool.
In summary, during the mitochondrial Q cycle 2 molecules of ubiquinol are oxidised 
to quinone at Q0 site and 1 molecule of quinone is reduced at Qi site. 4 protons are 
translocated out to the intermembrane space (2 protons per 1 quinol oxidation). During this 
cycle electrons are translocated from ubiquinol to feed the mitochondrial respiratory chain 
and to regenerate ubiquiol to supply the ubiquinol pool in inner mitochondrial membrane.
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1.8.2.3.4 Complex IV (cytochrome c oxidase)
Mitochondrial complex IV is a terminal oxidation step in the mitochondrial respiratory 
chain. Complex IV is a heme-copper oxygen reductase which is involved in complete 
reduction of dioxygen to water therefore promotes the translocation of protons across the 
mitochondrial inner membrane and finally generates membrane potential across the 
mitochondrial membrane.
Plasmodium cytochrome c oxidase consists of 3 catalytic subunits; CoxI, CoxII and 
CoxIII. The subunits Coxl and CoxIII of the Plasmodium Complex IV are encoded by 
mtDNA, whilst the subunit Cox II is encoded by nuclear DNA (269).
The Plasmodium Complex IV belongs to the haem copper oxidase superfamily which 
is involved in the respiratory chain by accepting the electrons from cytochrome c. Electron 
pass to the Cua followed by transfer to the CUb copper within the CoxII subunit (64, 269). 
Protons are translocated across the inner mitochondrial membrane thus contributing to the 
membrane potential (A\|/) and membrane electrochemical gradient. Plasmodium CoxII 
consists two nuclear encoded subunits known as CoxIIa (PF14_0288) and CoxIIb 
(PF13_0327) (80). The role of CoxIII is not well understood and it is believed to be involved 
in proton translocation across the inner mitochondrial membrane (110).
Studies conducted by Krungkrai (1993), Srivastava, Rottenberg et al. (1997) Uyemura 
et al. (2000), Uyemura et al. (2004) show that the activity of Plasmodium Complex IV can be 
inhibited by potassium cyanide.
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1.8.2.3.5 FiFo-ATP synthase (Complex Y)
Complex V in eukaryotic cells is responsible for completing the process of oxidative 
phosphorylation. ATP is generated through serial steps in the inner mitochondrial membrane; 
mtETC, oxidative phosphorylation and the electrochemical gradient across the mitochondrial 
membrane and finally the generation of ATP from ADP and inorganic phosphate (Pi).
Complex Y contains Fi and F0 subunits. The Fi sector of the complex V is a 
detachable structure and consists of 3 a subunits, 3 J3 subimits, y, 5, £ and oligomycin 
sensitivity conferring protein (OSCP) subunits. The Fo subcomplex is integral membrane 
protein, acting as a proton channel and consisting of 3 subunits a, b and ~ 12 copies of c.
ATP is synthesised from energy derived from vectorial proton translocation from the 
mitochondrial matrix through the Fo a to the c subunits. Rotational movement in the c subunit 
is linked to a central stalk of the Fi portion and ATP is generated at the active site of the beta 
subunits.
The P. falciparum genome contains all of the ATP synthase subunits with the 
exception of Fo a and b subimits, which have yet to be identified (82, 265, 269). Subunit a 
has been identified as an essential part for the generation of ATP from FiFo-ATP complex. 
The absence of a and b subunits is also reported in other Plasmodium species (e.g P. yoelii) 
(30,266). Due to the absent of the complete set of F0Fi ATP complex, many researchers have 
hypothesised that the Plasmodium parasite does not rely on oxidative phosphorylation for 
ATP generation; however the “missing” subunits are not conserved at the primary sequence
65
level in any species, and therefore given that still ~40% of the genome is not annotated, their 
absence should not necessarily be concluded to mean that the complex is not functional.
1.8.2.3.6 Uncoupling Proteins (UCPs)
In eukaryotic cells energy conservation/transduction is performed by using the proton 
gradient to drive ATP synthesis and/or transport. As described a number of complexes can 
pump protons in order to generate a proton gradient, however in order to complete the circuit, 
enzymes/transporters are also required to allow protons back in to the mitochondrial matrix, 
i.e. the leak. In addition to Complex V, a number of proteins have been shown in eukaryotic 
cells to be able to perform this role: these proteins are known as uncoupling proteins (UCPs).
Evidence for the presence of UCPs in Plasmodium was presented by Uyemura et ah, 
(2004). The western blot analysis result showed that the UCPs in P. berghei using antibodies 
raised against plant uncoupling mitochondrial protein (PUMP). There have however not been 
any further studies to support/contradict this work and the presence and role of UCPs in 
Plasmodium remain at present undefined.
\.9 Plasmodium Mitochondria as A Drug 
Target
As described, the mitochondria of Plasmodium contain a number of typical 
components, which are not found in higher eukarytotic mitochondria, such as the PfNDH2 
and MQO dehydrogenases. The absence of these dehydrogenases in the human host has led 
some researchers to propose that these enzymes may be good drug targets for the 
development of new antimalarials. This work necessitates however the generation of
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functional enzyme either purified or from enriched heterologous expression systems in order 
to perform high-throughput screens or in silico rational-drug design. In the case of PfNDH2, 
recombinant enzyme has been reported (70) and a drug discovery project is currently in 
progress. In the case for MQO however, no recombinant protein is as yet available, and this 
knowledge gap is addressed in Chapter 5 of this thesis, where attempts to generate 
recombinant MQO are described.
The DHODH of Plasmodium has also been validated as a drug target and a number of 
studies have been performed to generate novel inhibitors (23, 37, 239). These studies rely on 
exploiting small differences in the active site of Plasmodium and human DHODH and 
currently these projects have advanced to the late pre-clinical phase (see Medicines for 
Malaria Venture portfolio, www.mmv.org).
As described earlier, the parasite bc\ is a bona fide drug target with atovaquone 
(constituent of Malarone™) a registered antimalarial drug. Due to the expense of atovaquone 
and the presence of resistant mutants strains, researchers are attempting to develop alternative 
compounds; these include (i) pyridones, analogues of clopidol (289, 291), (ii) acridines and 
acridinediones (18) and (iii) quinolones (284).
For the development of these bc\ inhibitors, it would be of benefit to have further
information regarding the mechanism of atovaquone resistance in the parasite bc\> as any
information is based on that derived from model organisms (e.g. yeast). This knowledge gap
is addressed in the first two results chapters of this thesis (Chapter 3 and 4) which describe the
molecular and biochemical characterisation of an atovaquone resistant isolate (TM902CB).
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1.10 Objectives
The general objective of the thesis was to take a multidisciplinary approach to study 
key bioenergetics enzymes of the malaria parasite mitochondria. Atovaquone sensitive and 
resistant parasites have been compared at the level of gene expression and at the biochemical 
level with the aim to uncover the complex mechanisms underpinning atovaquone resistance, 
both at the enzyme level and at the pathway/cellular level. In addition a major objective of 
this study was to isolate and purify the putative malate quinone oxidoreductase (MQO) of P. 
Falciparum 3D7 with the view to validating this enzyme as a potential drug target. 
Specifically the objectives of this thesis were;
1. To perform a comprehensive gene expression study detailing the expression 
profile of energy metabolism genes in atovaquone sensitive and resistant 
parasites.
2. To perform a detailed biochemical analysis of the parasite bc\ and related 
respiratory enzymes from atovaquone sensitive and resistant parasites and to 
relate these data to observe expression data obtained in the Chapter 3.
3. To clone, express and purify P. falciparum 3D7 parasite putative MQO in 
order biochemically to characterise this enzyme and potentially to generate 
small molecule inhibitors.
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Chapter 2: General Materials and 
Methods
2.1 In vitro Cultivation of the Blood Stage 
Malaria Parasite
Continuous in vitro cultivation of malaria parasites was maintained under appropriate 
conditions according to the method described by Trager and Jensen (1976). All the procedures 
were carried out under sterile conditions in a NUAIRE BioHazard Class II laminar flow 
cabinet. Using sterile equipment, blood stage parasites were grown in complete culture 
medium RPMI 1640 (Sigma Aldrich, UK) with added of 10% human O positive type serum 
which was compatible with the type of erythrocytes used, 25 mM HEPES, and 0.02 mg/ml 
gentamicin in 75-cm2 tissue culture flasks (Nunc™). The O positive serum used was 
continuously supplied by Royal Liverpool Hospital, UK.
2.2 Preparation of Uninfected Erythrocytes
Group O positive human blood was obtained from the regional Blood Transfusion 
Centre, Liverpool UK. The blood was screened for antibodies to pathogens such as Hepatitis 
virus (HBV) and human immunodeficiency virus (HIV). The RBCs were centrifuged at 3,000 
rpm for 5 minutes at room temperature. The serum and buffy coat were discarded and the 
RBCs were then resuspended in 30-40 ml RPMI 1640 medium with added of 25 mM HEPES 
and 0.02 mg/ml gentamicin (Sigma Aldrich, UK). The suspension was centrifuged at 3,000 
rpm for 5 minutes at room temperature. This step was repeated three times and the washed 
RBCs were kept at 4 °C and used within one week. After one week the remaining blood was 
disposed of following standard tissue and blood disposal procedure.
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2.3 Preparation of HEPES
One molar HEPES (N-[2-hydroxyethyl] piperazine-N’-[2-ethanesulfonic acid] stock 
solution (Sigma Aldrich, UK) was used to regulate the pH shift in culture media. The 
solution was prepared in distilled water and the pH was adjusted to 7.4 using 5 M NaOH. The 
maintenance of pH is critical to the in vitro growth: the HEPES buffer is used to maintain 
physiological pH despite the acidity problems that resulting from the large amount of lactic 
acid produced by the malaria parasite. The solution was filtered, sterilised and stored at 4 °C.
2.4 Maintenance of Parasite Growth
The parasite growth was monitored daily by Giemsa-stained thin smears and observed 
under a light microscope (100 x magnification). For this, one drop of the RBCs (~ 60 pi) were 
aseptically taken from the culture flask and transferred onto a glass microscope slide. The 
monolayer thin blood smear was prepared, fixed in absolute methanol for 10 seconds and 
subsequently stained in 10% Giemsa (BDH Chemical, UK) for 10 minutes. The percentage of 
parasitemia was counted in 500 cells (infected and non infected RBCs). The optimum level of 
the infected RBCs in a 75-cm2 culture flask should be in the range of 5-6%. After 
determination of parasitaemia, the parasite culture was centrifuged at 2,000 rpm for 5 minutes 
at room temperature. The supernatant was discarded and the parasitised RBC pellet 
resuspended in complete RPMI 1640 culture medium and flushed with a gas mixture. The 
parasite culture haematocrit was usually maintained at 2%.
2.5 Gas Phase
The parasites were gassed to reproduce the conditions usually encountered within 
human hosts. The composition of the gas during the gas phase is critical to the development
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of the parasite. The most favourable atmosphere was provided according to the protocol 
described by Scheibel et al. (1979), but using the following gas composition: 3% C02, 4% 02 
and 93% N2 (BOC, Guilford, UK) (230). This gas mixture was passed through a sterile pipette 
into the parasite culture for 30-60 seconds. For the drug sensitivity assay, malaria parasites 
were grown in 96 well plates and incubated in a humidified gas tight chamber. The chamber 
was gassed for approximately 3 minutes, followed by 48 hour incubation at 37 C.
2.6 Cryopreservation of Parasites
For cryopreservation, ring stage parasites at 6% parasitemia were stored in liquid 
nitrogen. Parasite cultures were centrifuged at 2,000 rpm for 5 minutes at room temperature, 
supernatant discarded and the pellet resuspended in an equal volume of filtered sterile 
cryopreservation solution consisting of 0.95% (w/v) NaCl (Sigma Aldrich, UK), 4.2 ^ D- 
sorbitol (Sigma Aldrich, UK) and 2% (v/v) glycerol (Sigma Aldrich, UK). The mixture was 
transferred into cryotubes and stored in a liquid nitrogen tank.
2.7 Retrieval of Cryopreserved Parasites
Parasite retrieval involved removing the cryotube from the liquid nitrogen tank and 
thawing either at room temperature or in a water bath at 37 °C. The culture was transferred 
into a 15-ml tube and centrifuged at 2,000 rpm for 5 minutes at room temperature. The 
supernatant was discarded and equal volume of thawing solution (3.5% NaCl) was added to 
the pellet. This resuspension was centrifuged at 2,000 rpm for 5 minutes. Again, the 
supernatant was removed, 10 ml of complete RPMI 1640 culture medium added and a repeat 
centrifugation done at 2,000 rpm for 5 minutes. Following the centrifugation, the supernatant 
was discarded and the parasite pellet resuspended in 15 ml RPMI complete culture media. The
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parasite mixture was then transferred into a 25-cm2 culture flask, the parasite culture gassed 
and incubated at 37 °C then closely monitored.
2.8 Synchronisation of Parasite Culture
A continuous parasite culture usually exhibits a mixture of parasites in different stages 
of their life cycle. Asynchronous cultures were therefore synchronised before use in drug 
sensitivity assays or when isolating DNA and RNA materials from the parasites. The 
synchronisation process was achivied by 5% w/v of D-sorbitol treatment (Lambros and 
Vanderberg 1979). The synchronisation of parasite culture was induced by a selective 
destruction of the trophozoite and schizont stages of the parasite. The effect of sorbitol on the 
parasite membrane cell is still not clear (146). For this procedure, the parasite culture was 
centrifuged at 2,000 rpm for 5 minutes at room temperature and the supernatant discarded. 
Approximately 1 ml of the parasite pellet was resuspended in 5 ml of 5% of D-sorbitol and 
incubated at room temperature with intennittent shaking. This was followed by centrifugation 
at 2,000 rpm for 5 minutes and the pellet was resuspended in 5 ml RPMI complete media. The 
mixture was centrifuged as above, the supernatant discarded and 35 ml of RPMI medium 
added to the parasitised RBC pellet then transferred into a 72-cm2 culture flask. The gassing 
phase was applied as described above and the flask incubated at 37 °C.
2.9 Preparation of Free Parasites from 
Erytrocytes
Prior to western blot and kinetic studies, the malaria parasites were extracted from the 
erythrocytes. The synchronised culture (-10% trophoziotes) was centrifuged at 2,000 rpm for 
5 minutes and the supernatant discarded. The pellet was saponised using PBS and 20 mM
72
glucose, using a final saponin concentration of 0.15%. The mixture was gently shaken for 30 
seconds then centrifuged at 2,500 g for 5 minutes at 4 °C. The supernatant was carefully 
discarded and the pellet resuspended in cold (filtered) sterile intracellular buffer (110 mM 
KC1, 30 mM NaCl, 2 mM MgCl2, 20 mM glucose and 5 mM HEPES) pH 7.4 followed by 
centrifugation at 3,000 g for 5 minutes at 4 °C. This step was repeated 3 times and finally the 
parasite pellet was resuspended in 1.0 ml intracellular buffer. This wet preparation was then 
used to check the viability of free parasites under a light microscope. The pellets were kept at 
-80 °C for future use.
2.10 Glycerol Bacterial Stock
E. coli glycerol stock was prepared using 50% (v/v) sterile glycerol stock and 500 pi 
of bacterial suspension in Luria Bertani broth (LB) consisting of tryptone, yeast extract and 
NaCl (Sigma Aldrich, UK) with appropriate antibiotics. The bacterial suspension was kept at 
-80 °C for future use.
2.11 Agarose gel electrophoresis
Agarose gels were used to separate the DNA fragments in the PCR products or from 
the restriction enzyme digestions. In this study 12.5% agarose gels were prepared (Sigma 
Aldrich, UK) in 1 x Tris.acetate.EDTA (TAE) consisting 40 mM Tris, 20 mM acetic acid, 1 
mM EDTA pH 8.0 (Sigma Aldrich, UK). The mixture was heated for 2 minutes in a 
microwave oven and cooled at room temperature before adding 0.5 pg/ml of ethidium 
bromide (Sigma Aldrich, UK), The gel solution was poured into a gel cast on flat surface to 
avoid bubbles. DNA samples and 6 x loading dye (Invitrogen, UK) were mixed in 1.5 ml tube 
and followed by quick centrifugation. The DNA samples were loaded and electrophorosed for
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30- 40 minutes at a constant current of 90 volts. Once completed, the gel was visualised by 
UV illuminator (SYNGENE BIOIMAGING, UK) and analysed using Genetools analysis 
software (Syngene Synoptics Ltd. Cambridge, UK). The DNA fragments were compared with 
DNA Molecular Weight marker (Invitrogen, UK).
2.12 Determination of Protein 
Concentration
The Bradford assay (Bradford, 1976) was carried out to determine the protein 
concentration used for SDS gel electrophoresis and to quantify the specific enzyme activity 
from free parasite preparations. The reaction was set up using the Bio-Rad Reagent (Bio-Rad, 
UK) and diluted with distilled water in a 1:4 ratio. A standard curve was generated using 
bovine serum albumin (Sigma Aldrich, UK) at concentrations ranging from 0.2-0.9 mg/ml. 
The protein samples were prepared in a serial dilution ranging from 1 in 2.5 to 1 in 35. In this 
assay, 2 pi of unknown protein concentration was used. For accuracy 3 replicates were 
performed. The automated dispenser, Varioskan (Varioskan™, Thermal Corporation),was 
used to resuspend 200 pi Bradford Reagent into a 96 well plate. The plate was incubated for 5 
minutes at room temperature. Finally, the protein concentration was analysed using Skant® 
Software (Varioscan™ , Thermo Corporation) with the absorbency was set at 595 nm.
2.13 SDS Gel Electrophoresis
SDS gel electrophoresis is a technique used to separate protein samples according to 
their molecular weight. In order to get good separation of protein samples, the right 
percentage must be selected. The percentage of resolving gels used included 12.5%, 10% or 
7.5%. The monomer solution of resolving gel consisted of Acrylamide/bis-acrylamide
74
solution, (30%/0.8% w/v) (Bio-RAD, UK) distilled H20, 1.5 M Tris-HCl (pH 8.8) (Sigma 
Aldrich, UK), 10% (w/v) SDS (Sigma Aldrich, UK), 20% ammonium persulphate (APS) 
(Sigma Aldrich, UK) and 10 pi N,N,N\N'-tetramethylethylenediamine (TEMED) (Fluka, UK) 
per 10 ml gel mix. The monomer solution was mixed gently and poured into glass plates 
assembled by instructions from the Mini-Protean III Electrophoresis Manual (Bio-RAD UK). 
The gel was overlaid with water-saturated n-butanol to ensure an even surface and reducing 
conditions for polymerisation. After the gel had polymerised, the butanol was removed by 
capillary action using a paper towel. The stacking gel, a 4% monomer solution, was prepared 
with the following: 0.6-ml 30% (w/v) arylamide/bis (Bio-Rad, UK), 3.05 ml H20, 1.25-ml 0.5 
M Tris-HCl (pH 6.8), 50-pl 10% (w/v) SDS, 25-pl APS and 5-pl TEMED. This mixture was 
poured over the resolving gel with the comb fitted and allowed to polymerise for 30 minutes
at room temperature.
2.14 Sample Preparation for SDS-PAGE
The different protein sample concentrations were determined using Bradford assays as 
described in section 2.12. For each sample, 20 to 50 pg of the protein sample was mixed with 
an equal volume of 2 x sample loading buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 10% (v/v) 
glycerol, 1% (v/v) (3-Mercaptoethanol, 12.5 mM EDTA, 0.02 % (w/v) bromophenol Blue). 
Prior to gel loading, the samples were boiled for 5 minutes at 90 °C. The proteins were 
separated on SDS-PAGE using 1 X SDS- running buffer (0.196 M glycine, 48 mM Tns-base, 
0.04% (w/v) SDS, pH 8.3) at a constant current of 60 milliamps for 60 minutes. For 
immunoblotting, protein samples were run on duplicate gels; one gel for immunoblotting and 
the other for stained with Expedion instant blue (a Comassie Blue based staining solution) 
(Expedion, UK). Staining was carried out for 30 minutes with slow agitation, followed by 
destaining in distilled water. The prestained, broad range protein marker Spectra™ Multicolor
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Broad Range Protein Ladder (Fermentas, UK) was then used to estimate the resulting protein 
band sizes.
2.15 Silver Staining
The eletrophorosed SDS gel used for silver staining was washed using distilled water 
for 30 minutes. The gel was then incubated in 0.03% (w/v) sodium hydrosulphite for 2 
minutes and again washed in distilled water. This was then incubated in 0.1% (w/v) silver 
nitrate solution (0.2 g AgNCh, 200 ml H2O, 0.02% formaldehyde) for 40 minutes before 
finally washing with distilled water. The reaction was stopped using silver stopping solution 
(5% (v/v) acetic acid) for 2 hours at room temperature.
2.16 Western Blot Analysis
For immunoblotting, the SDS gel was not stained but equilibrated in Towbin’s transfer 
buffer (20 mM Tris-HCl, pH 8.3, 150 mM glycine, 20% (v/v) methanol) for 15 minutes at 4 
°C. A sheet of nitrocellulose membrane and six sheets of 3-mm Whatman filter paper were 
cut to the size of the gel and soaked in transfer buffer for 5 minutes at 4 °C. The separated 
proteins were then transferred from the gel to the membrane using a Mini Trans-Blot® 
Electrophoretic Transfer Cell (Bio-Rad, UK) for 1 hour at 250 milliamps.
After the transfer, the membrane was immersed in blocking buffer consisting of 3% 
skim milk in TBS-T (137 mM NaCl, 20 mM Tris, 0.1% Tween-20) at 4 °C overnight, then 
incubated with primary polyclonal antibody in blocking buffer supplemented with 3% (v/v) 
skimmed milk at room temperature for 2 hours. The blot was washed 3 times (10 minutes per
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wash) in 1 x TBS-T. The membrane was incubated for 1 hour in horseraddish peroxidase 
conjugated secondary antibody at a dilution of 1:10,000 in blocking buffer and slowly 
agitated at room temperature. Following incubation, the membrane was washed 3 times (10 
minutes per wash) with 1 x TBS-T buffer. After washing, the membrane was incubationed 
with 1:4 ratio of developing solutions A:B (Amersham General Health, UK) for 5 minutes. 
The membrane was then placed in a cassette and exposed to Kodax BioMax MR Film 
(Kodax, UK). The intensity of the signal was adjusted depending on the time of exposure, in 
this case between 5 and 60 minutes.
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Chapter 3: The Expression Profiles of 
Selected Metabolic Genes of P. 
falciparum from Laboratory Adapted 
and Atovaquone Resistant Strains
3.1 Introduction
The completion of the P. falciparum genome revealed a large number of genes which 
provide new insights into the biology of the parasite, the parasite-host interactions and 
pathogenesis, and which may eventually lead to identification of potential of new drug targets 
and vaccines. The Plasmodium covers ~23 megabase pairs genome comprised of 14 linear 
chromosomes, a circular plastid-like genome (apicoplast) and a linear mitochondria genome 
(25). Sequencing study by Gardner et al. (2002) estimated that malaria genome consists of 
more than 60% of the 5,409 predicted open reading frames (ORFs) and lack of similiarity 
with other known organism. Furthermore, the genomic nucleotide composition contains more 
than 80% A/T in coding regions and 90% in non-coding regions.
Over the last decade gene expression profiling has become an important tool in 
functional genomics and drug discovery. The study of gene expression in the genome has 
been recognised as transcriptomics. Gene expression is a measurement of the expression level 
of the genes as a result of transcription of DNA into messenger RNA (mRNA). Several 
molecular techniques have been developed for the high throughput analysis of gene 
expression such as DNA microarray, real-time PCR, massive parallel signature sequencing 
(MPSS), and serial analysis of gene expression (SAGE). These technologies provided tools
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for researchers to address the roles of multiple genes in the complex cellular functions of 
Plasmodium (293).
The human malaria parasite P. falciparum expresses different types of proteins 
throughout of its life cycle. Mass spectrometry analyses reveal that at least 2391 genes are 
transcribed and translated into proteins in one or more stages of the parasite life cycle (74, 
147). Florens, et al. (2002) reported that sporozoites distinctively express proteins which are 
unique to this stage. The proteomics studies also reveals that proteins involved in processing 
mRNAs and in protein synthesis (translation) are expressed at higher levels in gametocytes 
particularly female gametocytes than in other stages (285). The housekeeping genes are the 
most common genes and are expressed throughout the life cycle of Plasmodium. The 
housekeeping genes encode approximately 136 housekeeping proteins which include 
ribosomal proteins, transcription factors, histones and cytoskeletal proteins (97). Apart from 
the housekeeping proteins, the parasite expresses 472 crucial proteins which involved in the 
development of the parasite during the asexual replicative stages and 234 proteins are 
involved in parasites binding to the human host cell (invasive stages). There are ‘host-specific 
genes that encode 229 proteins present in mosquito and 417 proteins in mammalian host 
(77).
Many studies on the transcriptome rely on the microarray results and are quantitatively 
measured using real time PCR. Comparison studies of the transcription profile of mRNA and 
the translated protein in P. falciparum are still limited. The malaria parasite has an S-shaped 
wave of transcript pattern where 3,000 genes are expressed during the intraerythrocytic stage 
(25, 150, 156). The transcriptional regulation is rigidly programmed (hard-wired) and is not
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greatly affected by environmental or drug perturbations (81, 112). This is unlike other 
organisms, such as S. cerevisae, M. tuberculosis and Candida albicans in which the mRNA 
transcription is more responsive to environmental or chemical perturbations (11, 24, 48, 81, 
283).
Like other eukaryotic cells, P. falciparum is also equipped with transcriptional 
regulatory components i.e RNA polymerase II (82), TATA binding protein (TBP) and other 
putative orthologs to regulate the general transcription machinery i.e TFIIA, TFIIB, TFIIE, 
TFIIF, TFIID and TFIIH complexes (28, 112). The transcription of mRNA in the parasite is 
strongly regulated by parasite genotype and the factors responsible for transcription which are 
distributed throughout the genome. However, data from the P. falciparum genome indicates 
P. falciparum has a limited number of transcription factors (82).
In this chapter we performed an analysis of the expression profiles of mitochondrial 
genes from major metabolic pathways: glycolysis, the TCA cycle, the mitochondrial electron 
transport chain and sexual development protein in P, falciparum 3D7, 3D7-YDHODH.GFP 
and TM90-C2B using the Genome Lab™ GeXP Genetic Analysis System by Beckman & 
Coulter. The sexual development gene profiling is used as an indicator to determine any 
interference from sexual stages to the parasites genome. The aim of this study is to get a better 
understanding of the molecular changes that may be present in atovaquone resistant parasites 
(TM90-C2B) compared to 3D7. The 3D7-YDHODH.GFP strain is a transgenic 3D7 strain 
containing the yeast dihydroorotate dehydrogenase gene (yDHODH) which has previously 
been shown to confer an atovaquone resistant phenotype (Painter et ah, 2007) and here is used 
as a control strain as it should have a similar gene expression profile to the parent 3D7. Of
particular interest in this chapter is to determine whether the putative Y268S mutation (as it
80
has not been confirmed) in the bc\ enzyme conferring atovaquone resistance in TM90-C2B 
parasites is accompanied by changes in gene expression of respiratory enzymes or related 
genes of energy metabolism.
3.2 Materials and Methods
3.2.1 Malaria Parasites
Three different Plasmodium falciparum malaria parasites were used in these studies; 
P. falciparum 3D7 (reference strain), TM90C2B the atovaquone resistant field isolate strain 
and 3D7-YDHODH.GFP. The atovaquone resistant TM90C2B was generously provided by 
Professor Dennis Kyle (College of Public Health, University of South Florida, USA) and was 
first isolated during a clinical phase 2 study to determine atovaquone efficacy in Thailand. 
3D7-yDHODH-GFP, a transgenic derivative of P. falciparum 3D7 containing yeast 
dihydroorotate dihydrogenase gene was generated through electroporation of purified 
pHHyDHOD-GFP plasmid into ring stages of P. falciparum using a BioRad GenePulser 
(BioRad, UK) was prepared by David Johnson, Molecular and Biochemical Parasitology 
Group, Liverpool School of Tropical Medicine, UK. Purified pHHyDHOD-GFP plasmid was 
generously provided by Professor Akhil Vaidya (Drexel University College of Medicine, 
Philadelphia, USA). This plasmid contains a human dihydrofolate reductase gene as a 
WR99210-selectable marker (203). The parasites were grown in complete culture medium as 
described in section 2.1.
3.2.2 Total RNA Extraction from P. falciparum
Total RNA extraction from ~10% synchronised trophozoite parasites of P. falciparum 
3D7, 3D7“yDHODH*GFP (TX13) and TM90C2B falciparum malaria were carried out
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following a modified protocol described by Lescuyer et al (1997). The parasites used for the 
RNA extraction were kept highly synchronous (>99% of tropozoite stage) using repeated 
cycles of the sorbitol-lysis technique (was described in section 2.9), in order to avoid any 
potential cell-cycle dependent differences in gene expression. For RNA extraction, parasites 
were sedimented by centrifugation (3,000 x g for 5 minutes) followed by washing the parasite 
pellet in 5 volumes of cold PBS pH 7.4 and lysis in 0.05% saponin. Once the lysis of RBC 
was observed, the mixture was quickly spun at 5,000 x g for 5 minutes at 4 °C. The 
supernatant was discarded and the pellet was re-suspended in 1 ml of TRIzol reagent 
(Invitrogen, UK) for 10 minutes. The suspension was transferred into 1.5 ml RNase free 
microcentrifuge tubes and stored at -80 °C. The TRIzol parasite suspension was thawed on ice 
and mixed with 200 pi of chloroform (l/5th of total reaction volume). The mixture was 
vigorously shaken and then centrifuged at 10,000 x g for 15 minutes at 4 °C. The aqueous 
phase was removed and RNA was precipitated by adding an equal volume of ice cold 
isopropanol and incubated for 15 minutes at room temperature. After 15 minutes at room 
temperature the RNA was recovered by centrifugation at 10,000 x g for 10 minutes at 4 °C. 
The pellet was then washed with 75% (v/v) ethanol followed by centrifugation at 10,000 x g 
for 10 minutes. The RNA pellet was air dried at room temperature in a laminar flow hood for 
10 minutes. The RNA pellet was re-suspended in 100 pi RNase-free water and followed by 
incubation at 60 °C for 10 minutes. The quality and concentration of extracted RNA was 
measured using NanoDrop spectrophotometer (NanoDrop Technologies, UK). The RNA is 
stored at - 80 °C until ready for cDNA synthesis. The RNA extraction from the P. falciparum 
strains was performed on at least 3 independent occasions. Aliquots of 75 ng from each pool 
of total RNA served as template for making target specific cDNA by reverse transcription in a 
single multiplex assay using the GenomeLab GeXP Start Kit (Beckman Coulter, UK) and the 
gene- specific primers.
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3.2.2 qPCR Expression Study
3.2.2.1 Primer Design
Primers were designed using GenomeLab express Profiler software (Beckman 
Coulter) following the GenomeLab TM User’s Guidelines. The multiplex primers and genes 
are listed in appendix Al. The 48 genes were identified and selected for multiplex primer 
design. 23 genes encode enzymes of glycolysis, 14 genes component of the mitochondrial 
electron transport chain, 8 genes enzymes of the Plasmodium TCA cycle, 1 gene a protein 
involved in sexual development and 2 were normalisation genes (housekeeping genes). 
Nucleotide sequences of the genes were obtained from PlasmoDB data base 
(WWW.PlasmoDB.org). As an internal control a kanamycin resistance gene (KANr) was used 
in the PCR reactions. Each primer has a gene specific sequence and each primer is appended 
with a universal primer sequence by the software. The multiplex primer sets were custom 
made by Invitrogen, UK. GeXPS primer stocks (forward and reverse primers) were diluted in 
Diethylpyrocarbonate (DEPC) treated water (AMBION, UK) to final concentrations of 500 
nM and 200 nM respectively.
3.2.3 RT and PCR
The RT reaction and PCR steps were carried out according to the manufacturer’s 
recommended protocol (GenomeLab TM GeXP Start Kit, Beckman Coulter). A summary of 
the RT and PCR reactions is illustrated in Figure 3.1. The RT reaction was carried out in a 20- 
pl total volume reaction with a final concentration of 1 x RT buffer, 1 unit/pl reverse 
transcriptase and 500 nM reverse primer plex. 5 pi of KANr RNA was added per reaction 
which consisted of 25 ng/pl of P. falciparum total RNA. The RT reactions were as follows: 
48 °C for 1 minute, 37 °C for 5 minutes, 42 °C for 60 minutes, 95 °C for 5 minutes and final 
hold at 4 °C. This was followed by PCR reaction of 20 pi volume with a final concentration
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of 1 X PCR buffer, 5 mM MgCl2, 200 nM forward primer, 0.7 pi of Thermo-Start DNA 
Polymerase (ABgene) and 9.3 pi of RT reaction sample. The PCR parameters were set at 95- 
°C for 10 minutes, 35 cycles of 94 °C for 30 seconds, 55 °C for 30 seconds, 68 °C for 1 
minute and a final hold at 4 °C. Both RT and PCR reactions were carried out in BIORAD 
thermal cycler.
3.2.4 Gene Expression Analysis
The 40-pl reaction for GeXP analysis contained 1 pi undiluted PCR product, 0.5 pi 
DNA Size Standard-400 and 3.8 pi sample loading solution and run on a GenomeLab TM 
GeXP Genetic Analysis System (Beckman Coulter). The fluorescently labelled PCR 
fragments are separated by capillary electrophoresis based on size and detected and quantified 
by the GeXP Frag-3 system. To validate the experimental assay, a minimum of 3 replicates of 
every Plasmodium strain were used in this study. The result of GeXP was initially analysed 
using the Fragment Analysis module of the Genome Lab GeXP software. The GeXP software 
matches each fragment peak with the appropriate gene, and reports peak height for all peaks 
in the electrophortogram. As an extra precaution, manual analyses of the results were also 
carried out to validate data from the GeXp software programme. The pre-analysed data were 
subsequently exported to analyses using express Profiler analysis software following 
manufacturer’s protocols (Beckman Coulter 2004). Non-specific peaks were filtered out and 
expression was normalised using PF13 0305 elongation factor 1 alpha as the house keeping 
gene. The normalised gene expression data were then exported to Microsoft Excel 2007 for 
further analysis. Finally, Mann-Whitney test was performed to analyse the expression data 
using GraphPad Instat 3.
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Figure 3.1: Schematic Illustration of Multiplex RT-PCR Assay
(A)Represents the reverse transcription and amplification using a universal tag at the 5’ end of the 
chimeric primers. This step is followed by the conversion of a single pair of amplicons to synthesise a 
double stranded DNA template using the universal primers. (B) The PCR products from multiplex 
amplification were analysed using fluorescence capillary electrophoresis. The peak location represents 
the gene identity, and the peak area represents the gene expression level. (C) The multiplex PCR 
amplification products were analysed by fluorescence capillary electrophoresis and gene expression 
profiling are analysed using GeXp software programme. Adapted from BeckmanCoulter-Genome 
LabIM Genetic Analysis System.
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3.2.5 Sequencing cytochrome b and the Rieske 
Iron-sulphur Protein of P. falciparum TM90C2B
The sequences of the primers used for P/x-mediated PCR amplification of the genes 
encoding cytochrome b and the ISP from TM90C2B cDNA were as follows: Cyt b (forward) 
S’-ATGAACTTTTACTCTATTAATTTAG; Cyt b (reverse) 5’-
TATGTTTGCTTGGGAGCTGTAATC; ISP (forward) 5’
ATGAATATTAAATATGTGGAAC; ISP (reverse) S’-TCCAATTTTTATCGTATTTTCAT. 
The PCR reaction consisted of 96 °C for 10 minutes followed by 25 reaction cycles with 
melting (45 seconds), annealing (45 seconds) and extension (2 minutes) temperatures of 96-, 
45- and 68 °C respectively, with a final 10 minute extension at 68 °C. The PCR reaction 
buffer contained 1 mM MgS04, 100 ng TM90C2B cDNA, 0.25 mM dA/C/G/TTP (1 mM 
total dNTP), lx Pfx proprietary reaction buffer (Invitrogen), 2 pM forward/reverse primers 
and 1 unit of PJx DNA polymerase (Invitrogen). Total reaction volume was 50 pi. The PCR 
reaction products were purified by 2% (w/v) agarose gel electrophoresis and sent for 
automated DNA sequencing (Lark Technologies, UK). Sequence chromatograms were 
inspected using the 4Peaks software package (mekentosj .com).
3.3 Results
3.3.1 Transcriptional Expression Profiles of 
Energy Metabolism Genes in Atovaquone Sensitive 
and Resistant Parasites
Quantitative RT-PCR was performed to determine the expression of energy 
metabolism genes from 3D7, 3D7-yDHODH*GFP and TM90C2B parasites. 48 candidate 
genes of energy metabolism from 3D7, 3D7-yDHODH GFP and TM90C2B parasites were 
analysed using GeXP multiplex PCR. Data from each expression gene were normalised with
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PF13-0305 elongation factor 1 alpha (housekeeping gene). Only 36 genes were able to 
generate amplifications that could be reliably analysed by eXpress Profiler analysis software. 
These 36 genes included those involved in glycolysis/fermentation, specific subunits of 
mitochondrial electron transport chain complexes, mitochondrial dehydrogenases and 
mitochondrial TCA cycle genes. Expression profiles from the various strains were measured 
from RNA taken from trophozoite-stage parasites on at least 3 independent occasions, 
expression was then normalised against the expression of a reference gene, elongation factor 1 
alpha (see methods). Mean expression levels (n > 3) for all of the genes from the three strains 
are given in appendix 3. Figure 3.2 and 3.3 depict the relative fold change in gene expression 
for (a) 3D7-yDHODH • GFP/3D7 and (b) TM90C2B/3D7. The transgenic 3D7- 
yDHODH*GFP strain was generated from the 3D7 parent strain, therefore as expected, there 
was relatively little difference in the fold change in gene expression expressed as 3D7- 
yDHODH*GFP/3D7 (Figure 3.2). From this data also show that the gene expression values 
fell at or near 1 with the exception of the gene for NAD glutamate dehydrogenase.
Analysis of the fold change in gene expression of the atovaquone resistant strain 
TM90C2B compared to the atovaquone sensitive 3D7 strain revealed some significant 
differences between the two strains. Of note was the ~2 fold increase in expression of 
Complex III and Complex IV genes which included cytochromes b, c and c\9 the Rieske (ISP) 
subunit of bc\, and subunits 1 and 2 of cytochrome c oxidase. Other genes also shown to be 
significantly up-regulated in expression by 2 fold included the hexose transporter, 
phosphoglycerate kinase and succinylCoA synthetase (Figure 3.3 and appendix 3). Both 
TM90C2B and 3D7 are able to generate gametocytes in the laboratory. Analysis of the sexual 
development gene pfsl6 (PF11_0318) revealed no change in expression levels during 
replicates or between strains as shown in Figure 3.3 and appendix 3.
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4Figure 3.2: Relative Fold Changes in Gene Expression of Energy Metabolism Genes 
between Wild type (3D7) and Transgenic (3D7-yDHODH-GFP) P.falciparum Parasites
The relative fold change in gene expression for 3D7-yDHODH GFP/3D7. Expression data is 
normalised against a reference gene (elongation factor 1 alpha) and is displayed as a mean fold change 
± S.D from w > 3 independent experiments. Mean expression data ± S.D. (« > 3) is shown in Table S2. 
Asterix denotes significant difference P < 0.05.
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Figure 3.3: Relative Fold Changes in Gene Expression of Energy Metabolism Genes 
between Wild type (3D7) and Atovaquone Resistant (TM90C2B) P. falciparum Parasites
The relative fold change in gene expression for TM90C2B/3D7. Expression data is normalised against 
a reference gene (elongation factor 1 alpha) and is displayed as a mean fold change ± S.D from « > 3 
independent experiments. Mean expression data ± S.D. {n > 3) is shown in Table S2. Dashed blue box 
indicates genes encoding for components of mitochondrial Complex III and IV. Asterix denotes 
significant difference P < 0.05.
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3.3.2 Automated Sequencing of bc\ Cytochrome b 
gene
Result from the automated sequencing of the mitochondrial cytochrome b gene PCR- 
amplified from P. falciparum TM90C2B cDNA confirmed the mutation of adenine to 
cytosine at nucleotide 803, resulting in the replacement of tyrosine by serine at amino acid 
position 268 (Figure 3.4). No additional mutations were observed in the nucleotide sequence 
of TM90C2B cytochrome b or the Rieske protein when compared to the control DNA {P, 
falciparum 3D7, data not shown).
3.4 Discussion
The GeXP analyser (Beckman Coulter) has been used for multiplex analysis of 
Plasmodium genes. The GeXP system uses capillary electrophoresis-based separation of 
modified endpoint PCR reactions to provide the relative intensity versus size for the targeted 
amplicons of RNA samples. The advantage of GeXP technology compared to the other 
technologies is that this system can analyse up to 35 genes using area under the curve (AUC). 
The AUC value represents the level of the transcription of individual gene. The expression of 
the individual genes will therefore be normalised with the house keeping gene which is also 
incorporated into the multiplexes (218). However, in this study only 36 out of 48 genes were 
able to be analysed confidently with n > 3. This is due to each multiplex primer requiring 
individual optimisation due to the dynamic range of the various genes. The quantitation of the 
expression level of the genes within the multiplexes is extremely variable. The level of gene 
expression is controlled by the abundance of the gene present in the genome. Some of the 
genes probably are low, moderate or highly abundant. Therefore removing or adding of 
multiplexes requires optimisation and this is an empirical process (218).
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Figure 3.4: Automated DNA Sequencing of the Mitochondrial Cytochrome b Gene of 
TM90C2B
Automated DNA sequencing of the mitochondrial cytochrome b gene PCR-amplified from P. 
falciparum TM90C2B cDNA confirmed the mutation of adenine to cytosine at nucleotide 803, 
resulting in the replacement of tyrosine by serine at amino acid position 268. The consensus line 
shows (★)indicate identical residues; (:) indicate semi-conserved residues; (.) designated conserved 
residues.
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In this chapter we have attempted to determine whether there is differential gene 
expression between the atovaquone resistant strains TM90C2B, 3D7-yDHODH ■ GFP (TX13) 
and the sensitive strain 3D7. Many studies have been conducted to investigate the underlying 
mechanisms of Plasmodium drug resistance. In many cases, the resistance mechanisms are 
mainly due to polymorphisms e.g mutation in the pfcrt gene for CQ resistance, point 
mutations in pfdhfr and pfdhfs conferring pyrimethamine and sulfadoxine resistance 
respectively, and cyt b point mutations conferring resistance to atovaquone.
The polymorphisms in the DNA sequence confer drug resistance through the changing 
of amino acid sequence of the protein product. Continuous exposure to the drugs may induce 
alternative mechanisms of gene regulation in the parasite genome to overcome the selective 
pressures of antimalarial drugs. The parasites regulate their gene function via the 
overexpression of transporter genes e.g pfcrt and pfindrl, induction of alternative pathways to 
bypass the effect of the drug and repression of genes that control deleterious effects of the 
drugs (156).
In general mutations in DNA sequence result in major physiological changes even if 
the amino acid coding region is unchanged (50). However, in Plasmodium parasite, the 
determinant transcriptional regulation is still remain elusive (89). In this study it was possible 
to amplify most of the important genes involved in the mitochondrial electron transport chain. 
The TM90C2B strain is a clinical isolate which previously showed resistance to atovaquone. 
From genetic sequencing data it was shown that atovaquone resistance in this strain is 
probably conferred by a point mutation at position 268 cytochrome b of the parasite where 
tyrosine is replaced by serine (Y268S). Mutations at this site conferring atovaquone resistance
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have been reported previously and have also included replacement of the tyrosine by 
asparagine or cysteine (29, 188, 241). This 268 codon of the cytb gene is a region encoding 
for the quinol oxidation site (Q0) (131, 135). This phenomenon is also documented in another 
Plasmodium species (P. yoelii) (246).
Chapter 4 of this thesis describes the biochemical characterisation of the TM902CB 
bc\ containing the Y268S point mutation. Therein it is hypothesised that the Y268S mutation 
affects the catalytic activity as well as the stability or folding of the bcj cytochrome 6. It is 
therefore of interest to note that the expression data in this Chapter reveals a significant 
increase (~2 fold) in the level of expression of cyt b, cyt ci and iron-sulphur Rieske protein 
genes (p< 0.05, Mann-Whitney, Figure 3.3) in TM902CB compared to 3D7, In addition to 
this other mitochondrial complex enzymes are also shown to have a higher level of expression 
in the TM902CB strain compared to 3D7 including the genes encoding PfNDH2, SQR 
flavoprotein SU, cytochrome c, Complex IY SU1 and SU2 and Complex V alpha subunit. 
These data may be interpreted as to suggest that either (i) the parasite has upregulated specific 
genes to accommodate the Y268S cyt b mutation or (ii) selective pressure has selected for 
Y268S parasites that contain higher respiratory enzyme expression, but that this is a through 
natural variation and not a response by the parasite to drug pressure.
An analysis of transcriptome studies of other P. falciparum resistance genes such as 
pfcrt, pfmdrl and pfdhfr-ts suggests that point mutations do not affect the mRNA transcription 
level of the gene. The changes in the phenotype of the translated gene are mainly due to post- 
transcriptional regulation of the genes. Study of P. falciparum chloroquine (CQ) resistance 
shows a single polymorphism at amino acid 76 where lysine is replaced by thereonine
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(K76T). The mutation ofpfcrt gene has been identified as responsible for the CQ resistance in 
P. falciparum. Previous study of the transcriptome profiles of the parasite response to CQ 
showed the amplification of the pfcrt gene which led to the development of resistant parasites 
(94). However, the recent finding from the same authors indicates the mRNA level of the 
pfcrt is not affected by the drug perturbation (93), therefore indicates that there is no 
correlation between the Pfcrt mRNA expression level and CQ sensitivity (32, 56).
Johnson et al. (2008) demonstrated that the expression of PGH1 protein is increased in 
parasites pre-treated with phenobarbitone. PGH1 is the protein product of pfindrl. This 
finding is supported by western blot analysis demonstrating a marked increase in the 
expression of the P. falciparum ABC transporter (118). However recent studies indicate 
increasing copy number does not necessarily confer drug resistance on its own (32). The drug 
resistance due to polymorphism of pfindrl has no direct effect on parasite resistance to 
antimalarial drugs but it may involve other genes in the Plasmodium genome (32,220).
Microarray and RT-PCR transcriptome studies on the pfdhfr conducted by Ganesan et 
al. (2008) demonstrated that DHFR-TS expression is slightly increased in Dd2 P. falciparum 
treated with WR99210. The Dd2 parasite clone was originated from clone W2 from Southeast 
Asia and is resistant to some antimalarial drugs but not WR99210. Results from their studies 
showed there are no significant differences between treated or non-treated cells with 
WR99210. They also demonstrated that the mRNA levels for the genes responsible for 
enzymes of pyrimidine or folate metabolism are not affected.
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From this study most of the TM90C2B genes responsible for glycolysis and TCA 
cycle were not affected by the mutation in the bc\ complex. This is in accordance with the 
finding from previous study by Llinas et al. (2006) which showed the genes belong to the 
functional categories such as glycolysis, cytoplasmic transcription, translation, the TCA cycle, 
the proteasome and plastid biosynthesis are tightly regulated in their gene expression profiles 
of 3 different P. falciparum strains (3D7, susceptible strain; Hb3, pyrimethamine resistant and 
Dd2, chloroquine resistant). From their findings gene regulation between species is similar. 
However, in a recent study genes responsible for specific metabolic pathways such as energy 
metabolism and nucleotide synthesis were shown to be down regulated at the ring stage of a 
P, falciparum artemisinin resistant strain and transcription of genes associated with protein 
metabolism significantly increased after the parasite matures (184). This is probably 
counteracting mechanisms of the parasite to fix the damage response caused by the the 
oxidative stress and/or protein alkylation of this drug (184).
Other genes which showed higher levels of expression in TM902CB compared to 3D7 
(and 3D7-yDHODH■ GFP) included the hexose transporter (PFB0210c), phosphoglycerate 
kinase and enolase. These are some of the genes whose products are responsible for the 
Plasmodium glycolytic pathway. The hexose transportor has been reported to be highly 
expressed during active stages in the Plasmodium life cycles (trophozoites and schizonts) 
(136). The hexose transporter is involved in the transport of fructose and glucose from the 
host plasma. From this finding we can hypothesise that atovaquone resistance may lead to a 
fitness cost (due to the reduced catalytic activity of the Y268 bc\) which can be offset by an 
increase in glucose catabolism facilitated by an increase in glucose uptake. Plasmodium is 
dependent on glucose supply for growth and uses more glucose to generate ATP via 
fermentation during the trophozoite and schizont stages (78, 136, 199). Consistent with this
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hypothesis our observation in the laboratory is that the growth rate of TM90C2B is slower 
than 3D7. This is in accordance with a study conducted by Fisher et al. (2004) who 
demonstrated that the growth rate of transgenic yeast with mutation at Y279C equivalent to 
the Plasmodium Y268 site(67, 127)had a two fold slower doubling time than the wild type 
yeast.
The gene expression of the 3D7-yDHODH GFP strain was almost identical to the 
parent 3D7 strain, providing quality assurance of the methodology and robustness of the 
study. The only gene that was shown to be differentially expressed between 3D7 and 3D7- 
yDHODH GFP was the putative (fungal-like) NAD-glutamate dehydrogenase (PF08_0132). 
Apart from this enzyme, Plasmodium also encodes another 2 genes for glutamate 
dehydrogenase (GDH); apicoplast NADP-dependent enzyme (PF14_0286) and cytosolic 
NADP-GDH (PF14 0164). Apicoplast NADP-dependent is targeted to the apicoplast in the 
generation of acetyl-coA for fatty acid metabolism and the cytosolic form is speculated to be 
involved in redox homeostasis in the Plasmodium mitochondria. To date there is very little 
information relating to the function of the fungal-like NAD-dependent GDH (199) and more 
studies will need to be conducted in order to explain the observed differential expression in 
the two strains. In this study some of the primers failed to amplify the targeted genes from the 
P. falciparum genome. Individual multiplexes would be required to optimise and probably 
some degree have to re-synthesis. Some of the primers used in this study were able to amplify 
the targeted gene in any of the P. falciparum strains, but there are some primer pairs fail to 
amplify. This is might be due to the small percentage of the targeted genes present in the 
genome, therefore leads to produce inaccurate expression value.
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To date various high throughput technologies have been invented to either 
qualitatively or quantitatively measure groups of genes in a single analysis. Microarray 
technology is the most widely used in transcriptomic profiling of thousands genes from 
various group organisms. However, this technology has disadvantages such as a difficulty in 
analysing results of individual gene and cross hybridisation of signal between genes which 
can produce false positive or negative results, lack of optimisation of standard procedures and 
also not being cost effective for large samples. Therefore the GeXP profiling system provided 
an alternative technology in the study of gene quantitation. The results from the expression 
study must be analysed carefully. Direct evidence studies must be carried out in order to 
validate the data obtained from qPCR studies. Biochemical studies on the upregulated genes 
can be monitored by enzyme kinetics study. The translated protein also can be measured 
qualitatively using western blotting analysis because mRNA levels do not necessarily 
correlate with protein translational levels due to the presence of post-transcriptional gene 
silencing in P. falciparum (150,237).
In conclusion, this chapter has described the transcriptional profile of energy 
metabolism genes from three strains with atovaquone resistant and sensitive phenotypes. The 
gene expression profile of the atovaquone resistant strain TM902CB showed higher levels of 
expression for genes encoding the bc\ complex and related respiratory chain enzymes e.g, 
complex IV, PfNDH2 and Complex II, relative to the 3D7 atovaquone sensitive strain. As the 
Y268 mutation causes a fitness cost to the parasite, it is hypothesised that the observed 
differential expression may help the parasite to accommodate this mutation. It is likely that 
the differential expression patterns observed are more probably a result of selection of natural 
variation rather than due to a specific upregulation of genes in response to atovaquone. In the 
next Chapter, a biochemical characterisation of the respiratory enzymes of the 3D7 and
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TM902CB strains is described and the results are discussed in context of the expression data
presented here.
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Chapter 4: Biochemical
Characterisation of Atovaquone 
Resistant P. falciparum TM90C2B
4.1 Introduction
Atovaquone is a potent and effective antimalarial drug when used as a fixed-dose 
combination with proguanil (Malarone™), either for treating children and adults with 
uncomplicated P. falciparum malaria (201) or as chemoprophylaxis for preventing malaria in
travellers (145).
Atovaquone, a hydroxynaphthoquinoe, is a competitive inhibitor of ubiquinone (CoQ), 
specifically inhibiting Plasmodium mitochondrial bcx activity (79). Loss of bc\ activity results 
in a loss of mitochondrial function as evidenced by the collapse of the trans-membrane 
electrochemical potential (19,246). It is believed that in asexual parasites, one of the essential 
functions of the mitochondrion is to provide orotate for pyrimidine biosynthesis through the 
activity of dihydroorotate dehydrogenase (DHODH). Consistent with this, inhibition of the 
bc\ complex by atovaquone results in an increase in carbamoyl-aspartate and a reduction m 
UTP CTP and dTTP (107, 292). A link between mitochondrial function and pyrimidine 
biosynthesis is further supported by the generation of an atovaquone resistant phenotype in 
transgenic P. falciparum parasites expressing CoQ-independent yeast DHODH (203). 
Atovaquone has also recently been shown to affect the conversion of fiimarate to aspartate, 
further linking mitochondrial function with pyrimidine biosynthesis and also possibly purine
metabolism (27).
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At the structural level, details of atovaquone binding to cytochrome b are based on 
studies performed on model organisms and molecular modelling since a crystal structure of 
Plasmodium cytochrome b with bound atovaquone is not available. This notwithstanding, 
EPR spectroscopy of the Rieske [2Fe2S] cluster, site-directed mutagenesis of model organism 
cytochrome b, and gene sequencing of atovaquone-resistant Plasmodium strains demonstrate 
that atovaquone is most likely a competitive inhibitor of the parasite’s cytochrome b Q0 
(quinone oxidation) site reviewed in (130) and (14).
Atovaquone-resistant isolates of P. falciparum have been described following 
atovaquone or Malarone™ treatment failures. In these parasite lines, atovaquone resistance is 
often associated with a missense point mutation at position 268 in cytochrome b, exchanging 
tyrosine for serine (Y268S) or, less frequently, asparagine (Y268N) (16, 68, 72, 135, 188, 
234) The resultant atovaquone resistant growth IC5o phenotype of these mutants is some 1000 
fold higher than sensitive strains.
Position Y268 in cytochrome b is highly conserved across all phyla. It is located 
within the ‘ef helix component of the Q0 site, and it is likely that the side chain of this residue 
participates in a stabilising hydrophobic interaction with bound ubiquinol. Similarly, 
molecular modelling indicates a stabilising interaction of Y268 in the binding of atovaquone 
to yeast cytochrome b (130). In yeast, the introduction of the Y268S mutation (Y279S) results 
in an increase in IC50 for atovaquone inhibition of bc\ enzymatic activity from 60 nM to 
>4000 nM (69). However, this is accompanied by a 70% reduction in bc\ turnover, with EPR 
analysis showing an alteration of the iron sulphur protein (ISP) signal, indicative of a 
perturbation of the Q0 site (69,276).
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To date there are no available data on the effect of the atovaquone resistance mutation 
on the parasite bc\ enzyme. Plasmodium cytochrome b shares a high degree of sequence and 
structural conservation with mammalian and yeast cytochrome 6, however there are notable 
differences in key regions of the malaria parasite Q0 site. These include a four-residue 
deletion in the cd2 helix, which based on a homology model of the P. falciparum cytochrome 
b (constructed using bovine cytochrome b atomic coordinates as the structural template (18)) 
results in a 13-A displacement of this structural element compared with the mammalian 
enzyme (18). Likewise, the a-carbon atom of the N-terminal proline of the ef helix 
(containing the catalytically essential 'PEWY' motif) is predicted to be displaced by 2 A 
compared with the mammalian enzyme. The differences in Plasmodium cytochrome b 
compared to yeast or mammalian cytochrome b are manifested by the varying degrees of 
susceptibility to Q0 site inhibitors e.g. WR249685 is active at 3 nM against P. falciparum bc\ 
compared to >13800 nM in bovine bc\ and >5600 in yeast bc\ (18).
In the previous chapter I reported the expression profile of energy metabolism genes 
from atovaquone sensitive and resistant parasites. In this chapter I have investigated the 
effect of mutation of tyrosine 268 on the enzymatic turnover and stability of P. falciparum 
bc\.
4.2 Materials and Methods4.2.1 Preparation of 
Drug Stock Solutions
10 mM of drug/inhibitor stocks were prepared according to their solvent solubility 
Table 4.1 shows the list of drugs and inhibitors used in this study. Stock solutions were 
prepared and kept at -20 °C for 1 month. The endoperoxide drugs (artesunate and arthemeter), 
atovaquone and pyrimethamines were dissolved in dimethyl sulphoxide (DMSO) (Sigma 
Aldrich, UK) whereas chloroquine and sodium azide were dissolved in 50% ethanol and
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distilled water respectively. These final drug dilutions and the rest of inhibitors (stigmatellin, 
myxothiazol, antimycin, thenyltrifluoracetylacetone (TTFA) and 5-fluro orotic acid) were 
diluted with culture medium (RPMI) and freshly prepared prior to studies being carried out.
4.2.2 Preparation of Parasite Inoculums
The preparation of the synchronised ring stage of malaria parasites used in drug 
inhibition assays was described in Chapter 2 section 2.8 The final parasitaemia (2%) and 
haematocrit (1%) were prepared using the following formula:
/Desired parasitaemia\ t f . ,
Vol. infected RBC required for parasitaemia = \ Actual parasitaemia / x^ota vo ' re(fuire^
Parasite inoculums were prepared by adding 100 pi packed cell volume of a mixture of 
infected red blood cells (IRBCs) and uninfected red blood cells (URBCs) to 10 ml of culture 
medium.
4.2.3 Drug Inhibition Assay (IC5o)
The following 2 to 4 fold serial dilutions were prepared to make 8 concentrations of 
drug. 50 pi of each diluted drug was dispensed in triplicate into 96 well microtitre plates 
(Microwell, Nunc, UK) followed with 50 pi of the parasite inoculum (2% parasitaemia, 1% 
haematocrit). Artemisinin was used at its highest concentration (1000 nM) as a positive 
control and complete culture medium served as the negative control. Plates were mixed by 
agitation and placed in a humidified chamber (Flow, UK), gassed for 3 minutes, and 
incubated at 37 °C for 48 hours. After 48 hours incubation, 100 pi of lysis buffer (20 mM 
Tris-HCl, pH 7.5, 5 mM EDTA, 0.008 % (w/v) saponin, 0.08 % (v/v) Triton X-100) 
supplemented with the fluorescent dye SYBR Green (0.2 pi of SYBR Green per 1 ml lysis 
buffer) was added to each well and gently mixed followed by incubation at room
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Table 4.1: List of the Drugs/inhibitors used in Drug Inhibition Studies (IC50) for 
Phenotypic Profiling of Atovaquone Sensitive and Resistant Strains of Plasmodium
falciparum
Drug/Inhibitor
Atovaquone
Myxothiazol
PS
Molecular weight Solvent Source
366.84 DMSO
' ■ ffl 'mm'.
Prof Paul O’Neill,
(Department of
Chemistry, Uni. of
Liverpool)
487.68 RPMI Sigma Aldrich, UK
Thenyltrifluoracetylacetone 114.03 Ethanol: water (90:10%) Sigma Aldrich, UK
(TTFA)
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temperature for 1 hour. After incubation, plates were read at 485 run (excitation) and 535 ran 
(emission) using a Varioskan fluorescence reader (Thermo Electron Corporation, Finland). 
The analysis is carried out by calculating fluorescence values and expressed in relative 
fluorescence units. IC50 values were calculated from the log of dose/response relationship as 
fitted with Grafit Software (Erithacus Software, Kent, United Kingdom). Results are given as 
the means of at least three separate experiments.
4.2.4 Preparation of free P. falciparum Cell Free 
Extracts
Free parasites were prepared from aliquots of infected erythrocytes (approximately 8 x 
109 cells ml'1) by adding 5 volumes of 0.15% (w/v) saponin in phosphate-buffered saline (137 
mM NaCl, 2.7 mM KC1, 1.76 mM K2HPO4, 8.0 mM Na2HP04, 5.5 mM D-glucose, pH 7.4) 
for 5 min, followed by three washes by centrifugation at 4,000 x g for 5 min. The pellet with 
parasites was resuspended in HEPES (25 mM) buffered RPMI containing a protease inhibitor 
cocktail (Complete Mini, Roche). Cell extract was prepared by repeated freeze-thawing in 
liquid N2, followed by disruption with a sonicator probe (Vibra Cell; Bioblock Scientific) for 
30s on ice with 15 pulses of 1 second (300 W each) at 1-s intervals.
4.2.5 reparation of Decylubiquinol
The artificial quinol electron donor was prepared based on a previously described
method (Fisher et ah, 2004). The 2,3-dimethoxy-5-methyl-n-decyl-l,4-benzoquinone
(decylubiquinone), an analogue of ubiquinone (Sigma), was dissolved (10 mg) in 400 \x\ of
nitrogen-saturated hexane. An equal volume of aqueous 1.15 M sodium dithionite was added,
and the mixture shaken vigorously until colourless. The upper, organic phase was collected,
and the decylubiquinol recovered by evaporating off the hexane under N2. The
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decylubiquinol was dissolved in 100 pi of 96 % ethanol (acidified with 10 mM HC1) and 
stored in aliquots at -80 °C. Decylubiquinol concentration was determined
spectrophotometrically from absolute spectra, using £288-320 ~ 4.14 mM cm .
4.2.6 Preparation of Reduced Cytochrome c
Reduced cytochrome c was prepared by mixing 100 pi of a 1 mM stock solution of 
equine cytochrome c (dissolved in 50 mM potassium phosphate, 2 mM EDTA, pH 7.5) with 
20 pi of freshly prepared 100 mM sodium ascorbate (pH 7.5). The mixture was left on ice for 
10 minutes to allow full reduction of the cytochrome. Ascorbate was removed by passing the 
reduced cytochrome through a PD-10 desalting column (Pharmacia) pre-equilibrated with 50 
mM potassium phosphate, 2 mM EDTA (pH 7.5). The concentration of the reduced 
cytochrome c was assessed by redox difference spectrophotometry £550-542 = 18.1 mM 1 cm
4.2.7 Measurement of Decylubiquinol: 
Cytochrome c Oxidoreductase Activity
Cytochrome c reductase activity measurements were assayed in a Cary 4000 
spectrophotometer at 500 versus 542 nm in a reaction buffer consisting of 50 mM potassium 
phosphate (pH 7.5), 2 mM EDTA, 10 mM KCN, and 30 pM equine cytochrome c (Sigma 
Aldrich, UK) at room temperature (67). The reaction volume was 700 pi. P. falciparum bc\ 
was present as a crude membrane preparation (‘cell-free extract’) at a total protein 
concentration of 30-60 pg/ml. Cytochrome c reductase activity was initiated by the addition 
of decylubiquinol (5 - 50 pM), and kinetic data collected for four minutes. Initial rates 
(computer-fitted as zero-order kinetics) were measured as a function of decylubiquinol 
concentration, using £550-542 =18.1 mM"1 cm"1.
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IC5o values of atovaquone against the bci activity were obtained by adding of 
atovaquone in the reactions before the assays were carried out. The amount of DMSO in the 
assays must not exceed 0.3% (v/v) to avoid the side effect of DMSO on the enzymes. IC50 
values were calculated using Kalidagraph and the equilibrium dissociation constant (£|) of the 
binding of inhibitor was determined using Cheng-Prusoff equation (Cheng and Prusoff, 
1973).
Kt =
IC50
1 + is]K,m
From this formular the binding affinity of atovaquone to bc\ complex was calculated using the 
atovaquone IC50 values. S is substrate concentration to initiate the initial reaction velocity (Ko) 
and Km is the half of concentration of the substrate that produces maximal velocity (Fmax).
4.2.8 Preparation of P. falciparum Mitochondria 
using Percoll® Density Gradient Centrifugation
The frozen trophozoite stages of the RBC free parasites were fractionated in Percoll® 
gradient, enabling separation of an active mitochondrial fraction. Percoll® fractionation was 
prepared according to the protocol described by Kobayashi et al. (2007). The parasite free cell 
extract was sonicated 3 times using sonicator probe (Vibra Cell; Bioblock Scientific) for 30s 
on ice with 15 pulses of 1 second (300 W each) at 1-s intervals and subsequently centrifuged 
for 30 minutes at 10,000 x g for 30 minutes at 4 °C. The supernatant was discarded and the 
mitochondrial pellet was resuspended in 1.5 ml of MSB buffer (225 mM mannitol, 75 mM 
sucrose, 0.1 mM EDTA, 30 mM Tris.HCl; pH 7.4) and complete Roche protease inhibitor 
tablet (ratio MSB to parasite pellet 1:5). 23% of Percoll® (Sigma Aldrich, UK) in the final 
volume of mixture was added into the mixture and followed by 18 ml of cold MSB buffer. All
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the procedures were carried out on ice. Percoll sample was centrifuged at 100,000 x g in 
Beckman 70Ti Beckman rotor for 1 hour at 4 °C. The mitochondrial gradient was fractionated 
from top to bottom using a plastic pipette (1 ml/fraction). The activity of 
decylubiquinolxytochrome c oxidoreductase of every fraction was measured using £550-542 
= 18.1 mM'1 cm*1 and the active fractions were pooled and kept at -80 °C for subsequent 
biochemical analysis.
4.2.9 The Specific Activities of Plasmodium 
Mitochondrial Respiratory Chain Complexes in 
Percoll® Fractionated Samples
The determination of direct specific activities of mitochondrial respiratory chain 
complexes were performed according to protocol described by Fisher et al. (2009). The direct 
PfNDH2 native assay was performed in a 1-mm cuvette contain 600 pi of 50 mM potassium 
phosphate, 2 mM EDTA (pH 7.5), 10 mM potassium cyanide and 15 mM NADH (prepared in 
assay buffer). 60 pi of the mitochondrial fraction was added to the cuvette, and the reaction 
was initiated by addition of 50 pM ubiquinone (Q1 Sigma Aldrich, UK) prepared in 100% 
ethanol. PfNDH2 activity was measured spectrophotometrically by monitoring the decrease in 
absorbance at 340 nm (NADH 8- 6.22 mM’^m*1). Oxidation by the other dehydrogenases 
(malate, DHODH, glycerol and succinate) were measured in 600 pi total reactions contain 
assay buffer, 50 pM ubiquinone and 60 pi mitochondrial fraction. The reaction were initiated 
by addition of 50 pM Q1 and spectrophotometrically measured at 283 nm.
The decylubiquinolrcytochrome c oxidoreductase activity of the bc\ complex 
cytochrome b and cytochrome c oxidation were performed according to the protocol
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described by Fisher et al (2004). The 600-^1 reaction consisting of 50 mM potassium 
phosphate, 2 mM EDTA, 1 mM KCN (pH 7.5) was carried out at room temperature. 60 pi of 
the mitochondrial traction and 30 pM of horse heart cytochrome c were added in preparation 
of the reaction mixture. The concentration of the stock solution of cytochrome c was 
determined spectrophotometrically at £550-542 ^l^.S mM1 cm ,dithionite-reduced minus 
ferricyanide oxidised difference spectra in a Cary 4000 UV-visible spectrophotometer 
(Agilent Technologies, UK) (70). The reaction was started by the addition of 50 pM 
decylubiquinol (dQH2). Data were fitted as initial rate estimates (cytochrome c reduction) at
£550—542 "l 8-5 mM cm .
The oxidation of cytochrome c was performed in a 600-pl reaction consisting of 50 
mM potassium phosphate, 2 mM EDTA, 1 mM KCN (pH 7.5), 500 pM antimycin and 60 pi 
of mitochondrial fraction. The assay was started by the addition of 30 pM reduced 
cytochrome c and data were fitted as initial rate estimates (cytochrome c oxidation) at at
£550-542 =18-5 mM'‘ cm'‘-
4.2.10 Western Blot Analysis
Western blot analysis was carried out to validate the finding of the specific catalytic 
activities of PfNDH2 and cytochrome c bc\ complex from the mitochondrial fractions. Two 
peptides based antibodies were customed made from GenScript Corp., Piscataway, NJ, USA. 
The peptide 77-ESIRNFLRKKNGYC-l 10 of the P. falciparum putative NADH 
dehydrogenase (Swissprot ACC. Q81302) and 322-SHYDNSGRIRQGPA-335 of the P. 
falciparum ubiquinol-cytochrome c reductase iron-sulphur subunit (Swissprot Acc. Q8IL75) 
were selected, synthesized and used for immunization in the rabbit and generation of an
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affinity-purified polyclonal antibody. The rabbit anti-PfNDH2 and anti-Pffci polyclonal 
antibodies were lyophilized in phosphate buffered saline (pH 7.4) with 0.02% sodium azide as 
preservative. Lyophilized antibodies were reconstituted with Milli Q water and aliquots were
stored at “20 °C until required.
Three type of protein samples from parasite cell free extract were used for western 
blotting analysis. The whole cell extract (PI), the soluble fraction (P2) and the insoluble 
membrane protein (P3) of P. falciparum 3D7 and TM90C2B were harvested from the 
trophozoite stage with a parasitaemia >8% by treatment with 0.15% (w/v) saponin in 
phosphate-buffered saline. After three washes in 25 mM HEPES-buffered RPMI 1640 
medium by centrifugation at 4°C at 6,000 x g for 5 min, the cells were disrupted with a 
sonicating probe for 30s on ice (15 pulses of 1 second (300 W each) at 1-s intervals) in lysis 
buffer (50mM Tris-HCl, 150 mM NaCl, 2mM EDTA, pH 7.4) in presence of protease 
inhibitor cocktail (Complete Mini, Roche, Mannheim, Germany). The complete parasite 
lysate was separated into two parts. The first part of the lysate was labeled as PI and kept at - 
80 °C until further analysis. The rest of the cell lysate was centrifuged at 17,000 x g for 30 
min at 4 °C. The supernatant was discarded and the pellet containing insoluble proteins of the 
parasites was resuspended in lysis buffer consisting of 1% (w/v) n-dodecyl maltoside 
(SigmaAldrich, UK). The mixture was incubated on ice for 30 min. Solubilised membrane 
proteins (P2) were recovered from the supernatant after centrifugation at 4°C at 17,000 x g for 
30 min. The pellet of the cell lysate (P3) which contained the insoluble part of the protein was 
resuspended in lysis buffer and finally both soluble and insoluble proteins were kept at -80 °C 
until further analysis. The protein concentrations were measured using Bradford assay using 
BSA as a standard following the method which was described in section 2.12. 50 pg of each 
protein sample preparation (PI, P2 and P3) of 3D7 and TM90C2B were separated on a 10%
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SDS-PAGE and transferred to Hybond ECL nitrocellulose (Amersham GE Healthcare UK) 
following the method which was described in section 2.14. PfNDH2 recombinant protein 
from E. coli membrane preparation was used a positive control for PfNDH2 analysis and 
bovine mitochondrial membrane particles were used as a positive control. PfNDH2 and 
bovine mitochondrial membrane samples were prepared by Nick Fisher in our laboratory. 
Membranes were saturated overnight at 4 °C in blocking solution (5% dry milk, 0.05% Tween 
20 in PBS solution) and immunodetection was carried out for 2 hours with the custom 
polyclonal antibody against the PfNDH2 and P. falciparum Rieske iron-sulphur protein 
respectively. HRP-conjugated goat anti-rabbit IgG secondary antibody (Abeam, UK) was 
used at 1:10000 dilution for 1 hour. The signal was visualized by chemiluminescence with 
ECL™Westem Blotting Detection Reagent Kit (Amersham Biosciences, Piscataway, NJ), 
followed by exposure of the membranes to Kodak® BioMax™ MR film. For the membrane 
subjected to the detection of P. falciparum Rieske iron-sulphur protein, a second incubation 
of 1 h with a rabbit primary polyclonal antibody against P. falciparum aldolase was used as a 
control.
4.3 Results
4.3.1 Phenotypic Studies of P. falciparum 
Atovaquone Sensitive and Resistance Strains
Growth inhibition assays were performed to confirm the phenotypic profiles of the 
wild type (3D7) and atovaquone resistant strains (TM90C2B and 3D7-yDHODH*GFP) to 
therapeutic drugs and various specific electron transport inihibitors. The P. falciparum 3D7 is 
the reference strain that sensitive to all antimalarial drugs. The P. falciparum TM90C2B strain 
is a clinical isolate presented with a point mutation in the parasite cyt b gene resulting in a
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Y268S substitution within the Q0 site (Smilkstein et al., 2008). Previous study shown this 
strain was resistant to inhibitors that targeted the Qo site include: atovaquone, myxothiazole 
and stigmatellin. However TM90C2B is fully sensitive to antimycin A. The 3D7- 
yDHODH GFP is a transgenic derivative of P. falciparum 3D7 expressing ubiquinone- 
independent DHODH (yDHODH) from yeast. Previous studies have demonstrated that 3D7- 
yDHODH GFP was highly resistant to atovaquone (Painter et al, 2007).
The IC5o analyses were carried out as described in section 4.2.5. As expected, 
TM90C2B and 3D7-yDHODH GFP were highly resistant to atovaquone with IC50 values 
12.4 X 103 ± 1.6 X 103 nM and 5.8 X 103 ± 2.2 X 103 nM respectively. Both atovaquone 
resistant parasites were also resistant to the other foi-targeting inhibitor stigmatellin which 
acts on the Q0 site of the parasite’s cytochrome b. TM90C2B was also confirmed to be 
resistant to other electron transport inhibitors (myoxothiazol and antimycin), 2- 
Thenoyltrifluoroacetone and also resistant to chloroquine and pyrimethamine (Table 4.2).
All three parasite strains are not resistant to the other inhibitors targeting the different 
mitochondrial respiratory complexes (sodium azide and 5-fluoro orotic acid) and were highly 
sensitive to artesunate which used as a positive control throughout of this study.
4.3.2 bc\ Complex Steady-state Kinetic 
Parameters for Atovaquone Sensitive and Resistant 
strains
Figures 4.1 and 4.2 show the steady-state cytochrome c reductase activity measured 
spectrophotometrically at 550- minus 542 nm in Plasmodium cell-free extracts as a function
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Table 4. 2: Growth Inhibition Profiles of P. falciparum 3D7, 3D7-yDHODH GFP and 
TM90C2B Parasites
The data are expressed as mean ± S.E., acquired from multiple replicates performed on at least 3 
independent occasions. The IC50 values were calculated by fitting of four-parameter logistic curves 
(Grafit software).
Drug Target 3D7ICS0 
(nM)
3D7-
yDHODHGF
P IC5o (nM)
TM90C2
B
IC5o
(nM)
Artesunate 1.6 ±0.4 1.1 ±0.13 0.5 ±0.1
Chloroquine 11.4 ±0.4 10.4 + 0,4 70.6 ±9.6
Atovaquone bc\ (Q0) 0.8 ±0.1 5.8 X 10^2.2
X 103
12.4 X 10J
± 1.6 X 103
Stigmatellin bc\ (Q0) 23.2 ±4.2 4.1 X 10J ± 425 107 ±13
Myxothiazol bc\ (Q0) 33.3 ±6.4 Not determined 564 ± 11
Antimycin bc\ (Qi) 13.8 ±2.2 Not determined 300 ±34
2-Thenoyltrifluoroacetone Succinate
dehydrogenase
1.5X103
±245
1.4X10^352 31.4 X103
±965
Sodium Azide Cyt aa-i 423 ± 45 X
103
586 X 10J ± 97
X 103
654 X lO3
± 102 X
103
5-fluoro orotic acid Dihydroorotate
dehydrogenase
6.1 ±0.9 5.5 ± 0.4 6.3 ±1.3
Pyrimethamine Dihydrofolate
reductase
31.5 ±6.9 35.9 X 10J± 9.9
X 103
>10,000
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of decylubiquinol concentration. The apparent Kmax and f°r decylubiquinol and IC50 for 
atovaquone were calculated via linear regression (Kaleidagraph, Synergy Software) using 
kinetic data obtained from initial rate measurements. The presence of contaminating 
hemozoin precluded spectrophotometric determination of bcl concentration in the 
Plasmodium cell-free extract, and so total protein concentration was measured using the 
Bradford method as describe in section 2.12.
The bci Fmax for the TM90C2B strain was 60.2 ±3.2 nmol cyt c reduced/min/mg 
protein and 62% of that observed in the control 3D7 strain (97.4 ± 5.1 nmol cyt c 
reduced/min/mg protein) using decylubiquinol and equine cytochrome c as substrates. The Km 
for decylubiquinol increased to 18.5 ± 2.6 mM in the TM90C2B be} c.f. 5.5 ± 1.1 mM in 3D7 
be] (Table 4:3). The IC50 value for atovaquone in the decylubiquinol:cyt c oxidoreductase 
assay increased approximately 100-fold in TM90C2B compared to 3D7 (6 ± 1.0 and 600 ± 90 
nM) .The presence of contaminating hemozoin precluded spectrophotometric determination 
of bc\ concentration in the Plasmodium cell-free extract, and so total protein concentration 
was measured using the Bradford method.
4.3.3 The Specific Activities of Percoll® Fraction 
of Plasmodium Mitochondrial Respiratory Chain 
Complexes
The subcellular location of the mitochondrial specific activities was determined by
fractionation on a Percoll®gradient. Figure 4.3 shows that the mitochondrial fractions were
detected in fractions 14—18, as determined by cytochrome c reductase activity
spectrophotometrically measured at 550-542 nm. The fractions containing mitochondrial
membrane (fractions 14-18) were pooled and kept followed by the bc\ enzyme kinetic assay
113
i—i—|—rT—T----- 1—T
‘ * * *i , I —t-
Figure 4.1: Steady-state decylubiquinol:cytochrome c oxidoreductase Activity of 3D7 
and TM90C2B
Steady-state cytochrome c reductase activity of 3D7 and TM90C2B were measured 
spectrophotometrically at 550- minus 542 nm. The points are the mean initial velocity obtained at each 
QH2 concentration indicated. The data were fitted to a Michaelis-Menten rectangular hyperbola using 
Kalidagraph (Synergy software). The reactions were started by the addition of decylubiquinol (5 - 50 
pM). The Km values were 5.5 ± 1.1 and 18.5 ± 2.6 for 3D7 and TM90C2B respectively.
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Figure 4.2: Determination of the ICso* for Atovaquone against Cytochrome C reductase 
activity in a Cell-Free Extract of 3D7 and TM90C2B Malaria Parasites
The IC5o values for atovaquone in the decylubiquinokcytochrome c oxidoreductase assay are 6 ± 1.0 
nM (3D7) and 600 ± 90 nM (TM90C2B). The data were fitted using a four-parameter sigmoidal 
function in Kaleidagraph (Synergy Software).
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Table 4.3: ‘Cell-free extract’ Steady-state Decylubiquinol:cytochrome c Oxidoreductase 
Activity and Atovaquone Sensitivity in P. falciparum strains 3D7 and TM90C2B
Enzyme activity was measured as described in Materials and Methods. The Ki values for atovaquone
inhibition were calculated using the Cheng-Prusoff equation. The mean and S.E of each were obtained
from three independent experiments.
P. falciparum 
strain
VmM (nmol cyt c 
reduced/min/mg 
protein)
Km
(dQH2, mM)
IC5O
(atovaquone,
nM)
Ki
(atovaquone,
nM)
3D7 97.4 ±5.1 5.5 ±1.1 6.4 ±1.2 0.6
TM90C2B 60.2 ±3.2 18.5 ±2.6 600 ± 90 162
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The specific activities of the mitochondrial Perco 11®fractionation were carried out as 
described in section 4.2.9. The specific activities of the mitochondrial respiratory enzyme 
complexes are expressed as nanomoles per gram per minute of mitochondrial protein as 
shown in Table 4.4. From the result quinone reductase activity was detected at 283 nm for all 
dehydrogenases except Complex II (succinate dehydrogenases). PfNDH2 displayed the 
highest turnover [(iWenzyme concentration)/time in seconds] amongst the dehydrogenases 
in both 3D7 and TM90C2B. The specific activities for both PINDH2 and the bc\ complex of 
TM90C2B were decreased by -50% with respect to 3D7.
4.3.4 Western Blot Analysis
Western blot analyses were carried out to validate the data from the specific catalytic 
activities of PINDH2 and hex complex of 3D7 and TM90C2B malaria parasites. Figure 4.4 
shows the comparison of the PfNDH2 expression in 3D7 and TM90C2B. Total protein (50 
pg) for each sample of PI, P2, P3 (3D7 and TM90C2B) and recombinant PfNDH2 were 
separated 10% SDS-polyacrylamide gel and transferred to nitrocellulose membrane depicts 
the expression of PfNDH2 is more abundant than to TM90C2B. This is shown by a thick 
protein band of ~61 kDa in sample prepared from total cell lysate (PI) and also in insoluble 
(P3) parasite protein. From the membrane the protein of ~ 61 kDa was not detected in samples 
loaded from the soluble part of the parasite protein. This indicates the protein was prepared 
well since no contamination was detected in the lane containing soluble protein. Figure 4.5A 
and 4.5B show the western blot analysis of the protein expression of Riske iron sulphur 
protein from atovaquone sensitive (3D7) and resistant strain (TM90C2B). 50 pg of total 
protein for each sample of PI, P2, P3 (3D7 and TM90C2B) and aldolase were separated by 
10% SDS-polyacrylamide gel and transferred to nitrocellulose membrane. Mutation of
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Figure 4.3: Percoll Density Gradient Centrifugation of Free-parasite Fractionations of 
TM90C2B falciparum Malaria Parasites
Picture A shows the formation of gradient separation of mitochondrial fractions in a 23% Percoll® 
gradient. Twenty one parasite fractions are generated and the numbers indicated are the fractions 
which produced the highest bc\ activities. (B) The activity of bci started appearing in fraction 14 and 
the highest activity was detected in fraction 15. The activity started decreasing in fraction 17 and was 
completely undetected in fraction 19. The positive fractions (fraction 14-18 were pooled together and 
kept at -80 °C. Assay was performed in medium consisting of 50 mM potassium phosphate (pH 7.5), 2 
mM EDTA and 10 mM KCN at room temperature. Quionol: cyt c oxidoreductase assay was done by 
adding 30 pM horseheart cyt c in the assay medium before adding 50 pM decylubiquinol to start the 
reaction (A=550 nm - 542 nm).
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Table 4. 4: The Specific Activities of 3D7 and TM90C2B P. falciparum Mitochondrial 
Respiratory Enzyme (Percoll fractionations)
Mitochondrial
respiratory
enzyme
complexes
3D7
(nmole/mg/min)
TM90C2B
(nmole/mg/min)
NADH-Q1 12.85 + 0.83 6.41 +1.53
QH2-cyt c 6.88 + 1.31 2.84 ±1.54
Gly.-3~
phosphate
3.99 ±0.37 3.69 ±1.07
Malate 5.99 ±0.83 1.02 ±0.54
DHODH 5.90 ±2.10 3.07 + 2.67
Cytochrome C 
oxidase
2.85 + 0.12 0.83 ±0.35
The specific activities of mitochondrial respiratory enzyme complexes were performed using Percoll® 
fractionations of P. falciparum 3D7 and TM90C2B. The quinone reduction rate was 
spectrophotometrically monitored at 283 nm (quinone reduction) for PfNDH2, glycerol-.3-.phosphate, 
malate and DHODH. The cytochrome c reductase activity and cytochrome c oxidation were measured 
spectrophotometrically at 550- minus 542 nm. Results are expressed as mean nanomoles per gram per 
minute of mitochondrial protein from at least 3 independent repeats.
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cytochrome b can result in destabilisation of the bcx complex, with subsequent loss of the ISP 
(67).
The structural stability of the bc\ complex in cell-free extracts prepared from the 
TM90C2B strain was assessed by monitoring ISP content via western blots as describe in 
section 4.2.10. From the western blot analysis results show that the 3D7 bc\ protein 
expression is higher compared to TM90C2B as indicated by a clear protein band at -41 kDa. 
The western blot analysis was carried out to determine the amount of loaded protein was 
standardised using aldolase protein antibody. As shown in Figure 4.4B, aldolase protein bands 
have similar intensity in 3D7 and TM90C2B respectively.
4.4 Discussion
In this chapter the effect of the mutation in the bcx complex of P. falciparum 
TM90C2B was biochemically analysed and compared to the wild type 3D7 bc\. An in silico 
model of atovaquone docked at the Q0 site of yeast cytochrome b has been described by Kessl 
et al. (2005). Cytochrome b mutations that modify the ubiquinol-binding pocket of the 
cytochrome complex and confer anti-malarial drug resistance in S. cerevisiae have also been 
described Kessl et al (2005). In these models, atovaquone is represented as a ‘haem-distal’ Q0 
inhibitor, binding in a manner strongly reminiscent of stigmatellin, consistent with available 
EPR data (129). In the model, the hydroxyl moiety of the hydroxynaphthoquinone ring of 
atovaquone forms a hydrogen bond to the N atom of the imidazole group of His-181 in the 
Rieske iron-sulphur protein (lowering the redox potential of the [2Fe2S] cluster). A second H- 
bond is formed between atovaquone’s hydroxynaphthoquinone carbonyl group and the 
carboxylate of the cytochrome b ef-loop residue Glu-272 via a bridging water molecule.
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3D(P1) 3D(P2) 3D|P3) TM{P1)TM(P2) TMjP3) PfNDH2Rec
Figure 4.4: Western Blot Analysis of the Plasmodium Cell Free Extracts of 3D7 and 
TM90C2B Strains Using Polyclonal Antibodies against P. falciparum Putative NADH 
dehydrogenase
Western blot analysis of the Plasmodium cell free extract (PI), soluble protein (P2) and insoluble 
protein (P3) of PfNDH2 protein of 3D7 (3D) and TM90C2B (TM). The protein of ~ 61 kDa was 
visible in the PI and P3 protein samples of 3D7 and TM90C23B respectively. The level of PfNDH2 
protein in 3D7 was abundant compared to TM90C2B as shown on the membrane. No protein bands 
were detected from the soluble protein of 3D7 and TM90C2B indicating that PfNDH2 is in an 
insoluble form. PfNDH2 recombinant protein was used as a control to validate the specificity of the 
PfNDH2 polyclonal antibody against PfNDH2 Plasmodium protein samples.
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3D7{P1) 3D7<P2)3D7<P3) TM90(P1) TM90(P2) TM90(P3)
(B)
kDa 3D7 TM90C2B
Figure 4.5: Western Blot Analysis of the Plasmodium Cell-Free Extract of 3D7 and 
TM90C2B Strains Using Polyclonal Antibodies against P. falciparum Ubiquinol- 
cytochrome c Reductase Iron-sulphur subunit and Polyclonal Antibodies against P. 
falciparum aldolase
Panel A shows the Western blot analysis of Plasmodium cell free extract (PI), soluble protein (P2) and 
insoluble protein (P3) of P. falciparum 3D7 and TM90C2B. The protein size ~41 kDa was detected in 
PI and P3 protein samples from both 3D7 and TM90C2B and no protein bands were visible from the 
soluble preparation (P2). As shown on the membrane the expression of bc\ protein of TM90C2B low 
compared to 3D7. This indicates the protein is affected by the presence of a point mutation at Y268S. 
(B) The same western blot analysis was carried out to determine the amount of loaded protein was 
standardised using aldolase protein antibody as a control. From the membrane shown the 3D7 bc\ 
protein expression is higher compared to TM90C2B as indicated by a clear protein band at ~41 kDa. 
The positive control (aldolase) shows similar intensity bands in 3D7 and TM90C2B respectively.
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The chlorophenyl ring of atovaquone in Kessl’s yeast model sits in a hydrophobic 
pocket within cytochrome b formed from the side chains of Phe-121(transmembrane helix C), 
Phe-278 (ef loop) and Tyr-359 (transmembrane helix H). A similar pocket is likely to be 
formed by the conesponding residues in P. falciparum cytochrome b (Phe-115, Phe-267 and 
Phe-352). Y268 (Plasmodium notation), located within the ef helix, is highly conserved. In 
yeast, it has been suggested that the tyrosyl side chain of this residue participates in the 
positioning of Q„-bound ubiquinol, and it has been postulated to contribute to stabhsmg 
hydrophobic interactions with the naphthoquinone group of atovaquone (204) The structure of 
the yeast cytochrome 6c, complex with a hydroxyquinone anion Q„ site inhibitor bound has 
been determined by (128, 204). Studies with mutant forms of 6c, from the bactenum 
Rhodobacter sphaeroides indicated that an aromatic or large hydrophobic side-chain residue 
is required at this position within the ef helix for efficient catalytic activity (42). In addition, 
mutation of the equivalent residue in man (Tyr-279) has been linked with a variety of 
mitochondrial disorders that have been studied in yeast models (67,280).
Data from phenotypic studies show that the TM90C2B strain is resistant to all 
mitochondrial electron transport inhibitors and also chloroquine. The chloroquine resistance 
mechanism is not addressed in this study. The resistance is probably due to a multi-drug 
resistance phenomenon which is rampant along the Thai/Cambodian border (177). This study 
also demonstrated the P. falciparum 3D7-yDHODH GFP, the transgenic parasite bearing 5. 
cerevisae DHODH was highly resistant to atovaquone. This finding is in accordance with the 
study conducted by Painter et al. (2007).
From the steady state study of free cell extracts of showed, Vmax of crude preparations
of TM90C2B bci (60.2 ± 3.2 nmol cyt c reduced/min/mg protein) compared to the control
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3D7 strain (97.4 ± 5.1 nmol cyt c reduced/min/mg protein) were similar to that observed for 
the yeast Y279C and S mutants (turnovers of 47 s'1 and 30 s'1 respectively, compared to the 
wild type value of 80 s'1: (68). A confirmation study was conducted using a yeast model 
system which conferred Q„-site mutations in cytochrome b (67, 69, 280). It should be noted 
that more deleterious effects on the yeast enzyme activity have been noted in Y279S 
preparations in other laboratories (127).
The three-fold increase in Km observed for decylubiquinol in TM90C2B bci coupled 
with the decrease in K,„a, suggests that the binding and/or positioning of the substrate 
ubiquinol within the Q„ site is impaired in TM90C2B compared to the wild type, consistent 
with mutation studies of this residue in other organisms. We note with interest the apparent 
instability of the ISP in TM90C2B as revealed by western blotting, which suggests a 
weakened interaction between this subunit and cytochrome b. This may be due to perturbation 
of the ef helix and surrounding protein structure at the Q0 site due to the introduced serinyl 
side chain, which may result in an increased electron transfer distance between bound 
ubiquinol and the ISP [2Fe2S] cluster and weakening or abolition of the hydrogen bond 
between ‘haem-distal’ Q„ ligands and His-181 of the ISP. The differences in be, complex 
integrity observed in TM90C2B and the yeast Y279S mutant may arise from the potentially 
peculiar stracture of the Q„ site and ISP docking surface in Apicomplexa (i.e. the four residue 
deletion in the N-terminal region of the cd2 helix (18).
We have shown that in P. falciparum the point mutation at codon Y268S affected the
function of Complex 1. Results from the specific activities of the mitochondrial respiratory
complexes showed that the PfNDH2 and bcx cytochrome b activities of TM90C2B were
decreased (~ 50%) compared to 3D7. Plasmodium complex II is not detected using direct
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measurement of succinate oxidation to fumarate. The measurement of succinate oxidation is 
performed spectrophotometrically at 283 nm measuring the reduction of dQi as an electron 
acceptor. Potassium cyanide was used to block the normal path of electrons in the 
Plasmodium respiratory complex. The measurement of Plasmodium Complex II also can be 
performed using an artificial electron acceptor such as 2,6-dichlorophenolindophenol 
(DCPIP) measured at 600 nm or using PMS (phenazine methosulfate)s or MTT (3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) measured at 570 nm (180). The 
activity of succinate oxidation in 3D7 is measurable by linked assay with MTT and can be 
inhibited with atpenins (TTFA) and malonate (data not shown). However the catalytic 
efficiencies of the Complexes II were relatively low with K^\/Km— 600 and 5000 respectively 
when compared with other Plasmodium mitochondrial respiratory enzymes (134).
Western blot analysis was carried out to validate the kinetic studies of the 
dehydrogenases. Two peptide antibodies against Plasmodium NDH2 and Riske iron sulphur 
protein were designed and synthesized. The attempts to generate specific antibodies against 
cytochrome b were unsuccessful. The other mitochondrial dehydrogenases were not included 
in this analysis due to unavailability of the antibodies against the proteins. From the western 
blot analysis of complete lysates of cell free extract and membrane proteins, 3D7 PfNDH2 
and Rieske iron sulphur protein were highly abundant compared to TM90C2B (Figure 4.4 and 
Figure 4.5). As described, the Y268S mutation in the parasite bc\ may give rise to complex 
instability and difficulties in protein folding, resulting in the reduced western blot signal. At 
this stage however, it is not clear why the TM902CB strain has reduced expression of 
PfNDH2. One possibility may be that the two enzymes exist as a supercomplex, however no 
data is available at this stage to support this hypothesis. Supercomplexes have been identified 
in other species such as bovine and rat, fungi (S. cereviasae and Podospora anserine) and
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Caenorhabditis elegans (reviewed by Lenaz and Genova, 2010), In these species, 
supercomplexes have been identified using techniques such as blue native PAGE (BN-PAGE) 
containing the enzymes Complex I, dimeric Complex III and Complex IV (Acin-Perez et ah, 
2008). In addition, supercomplexes have also been shown to contain Complex II and ATPase
(2).
The interaction between Complex I and III (I.III) and Complex I, Complex III and 
Complex IV are the most described in the literature related to supercomplex studies. Bultema 
et al. (2009) proposed supercomplex forming megacomplexes of the inner mitochondrial 
structure in potato mitochondria. However the characterization of the supercomplexes by 
direct functional analysis via kinetic studies is still poor. Researchers speculated that the 
interaction between Complex I and Complex III is through electron flow by direct channeling 
of ubiquinone (152). The activity of the interaction between I and III is greater compared to 
the interaction between I, III and IV (229).
The effect of mutations in mitochondrial Complex III was reported recently by 
Suthammarak et al. (2010). For the first time they reported that presence of mutations in 
complex III of C. elegans affected the activity of the Complex I. Results from silver staining 
of native-PAGE gel and quantitative measurement of the amount of Complex IV indicated a 
significant loss of Complex IV from the I.II.IV supercomplexes compared to the wild type. 
The dissociation of Complex IV from the supercomplexes thus reduces the Complex I 
activity. From this finding mutations in one of the components of supercomplexes may lead to 
an imperfect confirmation and dysfunction of the proton pumping module.
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The physical association between Complex I and Complex III is thought to involve the 
iron sulphur protein (ISP) (252). Western blot analysis of ISP content in cell-free extracts 
prepared from TM90C2B cultures revealed decreased levels of this subunit compared to the 
control 3D7 strain, with ISP content in the corresponding yeast mutant (Y279S) 
indistinguishable from wild type. Similarly, no loss of ISP content was observed m the yeast 
Y279A and Y279C mutants, although the Y279W mutation was found to be structurally 
destabilizing (67). A study by Kessl et al. (2005) demonstrated cytochrome b mutations 
modified the ubiquinol-binding pocket of the cytochrome bc} complex and conferred anti- 
malarial drug resistance in S. cerevisiae.
In conclusion, the mutation of codon Y268S in TM90C2B affects the binding of 
ubiquinone at Qo site in the Plasmodium bc} complex. Therefore extremely low turnover rates 
for the bci activity of TM90C2B compared to 3D7 were observed. The mutation also affected 
the catalytic activities of other respiratory enzyme complexes. We speculate this might be due 
to supercomplex interactions between the enzymes in the respiratory chain of the 
Plasmodium. However the presence of supercomplexes in Plasmodium is not yet established. 
More research is needed to establish the relationship between mutations in one of the 
complexes affecting the allosteric mechanisms in the catalytic core of the putative
supercomplex assembly.
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Chapter 5: Molecular Characterisation 
of P .falciparum 3D7 Malate Quinone 
Oxidoreductase
5.1 Introduction
Malate or malic acid is a biochemically important organic compound with the 
chemical formula C4H4O5 (Figure 5.1). Whilst chemical synthesis of this chiral compound 
yields both L- and D- enantiomers it should be noted that in nature only the L- enantiomer 
occurs.
Figure 5.1: The Chemical Structure of L-malate
http://pubchem.ncbi.nlm.nih.gov.
In eukaryotes malate is involved in many biochemical reactions such as the TCA
cycle, the malate-aspartate shuttle, and shuttling of acetate from the mitochondrial matrix to
the cytosol. Malate is found in both the mitochondria and cytoplasm of many eukaryotic
organisms. In the TCA cycle of eukaryotic organisms C4 carbon is fixed and malate is
oxidised to oxaloacetate (OAA) by malate dehydrogenase in the mitochondrial matrix
resulting in C02 production (Figure 5.2). OAA cannot be transported directly into the
mitochondrial matrix or transported back to the mitochondrial intermembrane space and is
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effectively trapped. Therefore, OAA must be reduced to malate via the malate dehydrogenase 
enzyme. Reduced malate is transported through a malate ct-ketoglutarate transporter, and 
subsequently oxidised to OAA. Malate also acts as a substrate for malic enzyme in the 
cytoplasm to form pyruvate. Pyruvate, the end product of the glycolysis pathway is 
transported to the mitochondrial matrix and subsequently oxisidised to form OAA (159).
COO- Malate dehydrogenase
HO—C —H + NAD+ t * 0
I
ch2
coo-
coo-
C + NADH + H+
ch2
coo-
L-Malate Oxaloacetate
Figure 5.2: Oxidation Reaction of L-malate to OAA
Malate dehydrogenase catalyses the reversible conversion of L-malate to OAA. L- malate is oxidised 
to OAA and coupled with the reduction of NAD+ to NADH + H+.
Malate dehydrogenase (MDH; EC 1.1.1.37) is found in both eukaryotic and 
prokaryotic organisms. In eukaryotes malate is a substrate for distinct cytosolic and 
mitochondrial malate dehydrogenases whilst in prokaryotes, mitochondrial malate 
dehydrogenase (mtMDH) is replaced by the isozyme malate quinone oxidoreductase. In 
eukaryotic cells, MDH isozymes have been found in the cytosol as well as in other organelles 
such as mitochondria, chloroplasts, peroxisomes and glyoxysomes. MDH plays a major role 
in oxidative metabolism and other physiological functions depending on its biochemical 
characteristics and intracellular location (27, 176). This enzyme is involved in the aspartate 
aminotransferase reaction, which transfers the reducing equivalent (NADH or NADPH) from
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the cytosol to mitochondria. mtMDH is a primary anaplerotic enzyme and reversibly 
interconverts malate and oxaloacetate (OAA) (159).
The other malate dehydrogenase isozyme from Plasmodium spp is malate:quinone 
oxidoreductase (MQO; E.C.l.1.99.16). MQO is a lipid-dependent, peripheral membrane- 
bound flavoprotein which catalyses the oxidation of L-malate to oxaloacetate. The PfMQO 
gene is encoded by chromosome 6 of P. falciparum. From the biochemical characterisation, 
MQOs can be divided into two major families. The ‘actinobacteriaT MQO including 
Mycobacterium spp., Corynebacterium spp., Streptomyces spp., Nocardia spp. and 
Rhodococcus spp. belong to one major bacterial MQO family (MQOl), while most Z- 
proteobacterial {Helicobacter pylori, Campylobacter jejuni) and apicomplexan (P. 
falciparum. Toxoplasma gondii, Babesia bovis) enzymes are members of the second group 
(MQ02) (182). MQO is identified to co-exist with an alternative complex I NADH 
dehydrogenase (NDH2) which is present in bacteria, fungi and plants (126). Gardner et al. 
(2002) predicted the presence of the NDH2 and MQO genes in the P. falciparum genome and 
both enzymes were predicted in the TCA cycle of P. yoelli and P. falciparum.
The role of MQO in the Plasmodium TCA cycle is as a substitute for other 
mitochondrial MDH isozymes (262, 269), In MQO, FADfh has been identified as the 
cofactor that donates electrons to the respiratory chain. This contradicts what occurs in 
cytoplasmic MDH, where NADH is oxidised to NAD+ thus reduces OAA to malate. Electrons 
from FADH2 are donated to ubiquinone which is subsequently oxisidised in the electron 
transport chain (185,260,262,269).
130
In Plasmodium spp., studies conducted by Uyemura et al. (2004) showed the addition 
of malate as substrate generated a high membrane potential in P. Yoelii, whereas the addition 
of pyruvate, glutamate and other endogenous substrates produced low membrane potential. 
They showed the generation of membrane potential is through the stimulation of rotenone- 
insensitive respiration (NADH). They also reported the highest activity of membrane potential 
was completely inhibited after addition of antimycin A. Plasmodium malate quinone 
oxidoreductase is an FAD dependent enzyme which supplies electron to the electron transport 
chain, therefore no electrons are supplied from NAD (185). The presence of MQO in P. yoelii 
mitochondria is supported by the detection of a significant membrane potential when fumarate 
is used as a substrate. The recent studies conducted by Bulusu et al. (2011) indicate the 
presence of fumarate not a metabolic waste in Plasmodium spp. excretion products, but 
converted to aspartate by fumarase via malate and OAA intermediates. They also suggest the 
presence of another pathway whereby fumarate is converted directly to aspartate bypassing 
MDH pathway.
Recently the metabolomic evidence of the role of malate in P. falciparum was 
obtained by Olszewski et al. (2010). They have illustrated malate pathways in the P. 
falciparum TCA cycle (Figure 5.3). The metabolomic studies indicate malate is an end 
product for both oxidative and reductive branches of Plasmodium spp TCA cycle. The 
Plasmodium spp TCA cycle does not follow the canonical pathway where the TCA cycle is a 
cyclic pathway. Instead, a branched or bifurcated TCA cycle uses glutamate or glutamine as 
the major carbon source. These two amino acids donate their carbon skeleton to form 2- 
oxoglutarate. The 2-oxoglutarate either follows the cyclic pathway of TCA (oxidative 
branched) or the reducing branch of TCA cycle. In the oxidative branch fumarate is oxisidised
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by fumarase to form malate, whilst in the reducing branch OAA is reduced by MQO to 
generate malate.
However, Tripathi et al. (2004) showed that PfMQO is functional only in combination 
with PfMDH, which is the sole supplier of malate to the Plasmodium TCA cycle. They 
demonstrated that PfMQO is significantly higher as compared to PfMDH (260). Study by 
Bulusu et al. (2011) demonstrated that the activity of MQO in the oxidation of malate to OAA 
is essentially irreversible. MQO cannot catalyse the reduction process of OAA to malate and 
we know OAA cannot be transported in or out of the intermembrane space to the 
mitochondrial matrix. OAA must be reduced by malate dehydrogenase in the mitochondrial 
intermembrane space, and subsequently transported into mitochondrial matrix through a 
malate-a-ketoglutarate transporter. In the mitochondrial matrix malate is re-oxidised by MQO 
to form OAA. OAA is then oxidised to form aspartate and finally transported out from the 
mitochondrial matrix through a glutamate-aspartate transporter.
The objective of this study was to characterise the malate quinone oxidoreductase 
enzyme from P. falciparum strain 3D7. The characterisation process involved several 
molecular biology techniques such as polymerase chain reaction, cloning and sequencing. 
This was followed by an expression study of the cloned gene in the E. coli host. The 
purification study of the overexpression of PfMQO recombinant protein in E. coli was 
performed and followed by subsequent biochemical assays such as steady-state enzyme 
kinetics. The information generated during this study will provide new insight into the 
molecular and biochemical properties of this protein. Due to the absence of this enzyme in
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Figure 5.3: Topology of MQO in the Plasmodium Mitochondrial Inner Membrane
MQO is a single subunit enzyme and peripheral membrane protein where one part of the enzyme 
surface faces the mitochondrial matrix and the other part is embedded in the inner mitochondrial 
membrane. The TCA cycle of P. falciparum consists of oxidative pathway (red arrow) and reductive 
pathway (black arrow). Both pathways produce malate as the end product of the TCA cycle. MQO 
catalyses the reduction of OAA to malate and fumarate is oxidised by fumarase (fumarate hydratase) 
to malate in the oxidative pathway. FADH2 is reduced to FAD , donating electrons to ubiquinone pool 
in the P. falciparum respiratory chain. Abbreviations: Q, ubiquinol; QH2, ubiquinone; 200, 2- 
oxoglutarate; Succ CoA, succinyl-CoA. Figure is adapted from Olszewski et al. (2011).
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mammalian mitochondria, we believed PfMQO may be a potential target for the development 
of new antimalarial drugs which selectively target the malarial mitochondria.
5.2 Materials and Methods
5.2.1 Bioinformatics
Bioinformatic studies were carried out using various applications freely available 
online. The database of the nucleotide and amino acid sequences of the putative PfMQO 
(Acc. No. PF3D7_ 061680) were extracted from PlasmoDB 8.0 website 
(www.plasmodb.org). The open reading frame (ORF) of the PfMQO gene was predicted using 
Biology WorkBench 3.2 programme hosted at http://workbench.sdsc.edu. The protein 
molecular weight and isoelectric point of PfMQO were predicted using the ProtParam 
programme hosted at http://www.expasv.org.
The prediction of subcellular location of PfMQO was performed using PFMpred 
(http://www.imtech.res.in/raghava/pfinpred) and PlasMit (http:// gecco.org.chemie.uni- 
frankfurt.de) programmes. P. falciparum 5 aminolevulinic acid synthetase (PfALAS, Acc. No. 
PF3D7_1440300) and P. falciparum malate dehydrogenase (PfMDH, Acc. No, 
PF3D7 0618500) were used as positive and negative controls.
The prediction of the internal transmembrane domains was performed using the 
TMHMM 2.0 prediction programme (http://www.cbs.dtu.dk) and the secondary structure of 
PfMQO was predicted using PSIPRED VIEW software (http://bioinf.cs.ucl.ac.uk) hosted by
University of Collage London, UK. P. falciparum dihydroorotate dehydrogenase 
(PfDHOODH) and type I phosphatidylserine decarboxylase (PfPSD) were used as positive 
and negative controls.
Multiple sequence alignment of MQO amino acid sequences from respective 
organisms was performed using ClustalW software (http://mobyle.pasteur.fr) using 
programme default parameters. The percentage of similarity of the PfMQO amino acid 
sequence (Uniprot Acc. no gi|46361119|emb|CAG25406.1) was determined by aligning the 
sequence with other MQOs encoded in other Plasmodium species and also from bacteria. The 
aligned sequences were putative MQO from P. vivax (Uniprot Acc. No. 
gi| 148805058|gb|EDL46457.1), putative MQO from P. berghei (strain Anka) Uniprot Acc. 
No. tr|Q4Z5Gl|Q4Z5G1_PLABA), putative MQO from P. chabaudi (Uniprot Acc. No. 
tr|Q4XW30|Q4XW30_PLACH), putative MQO from P. knowlesi (strain H) (Uniprot Acc. 
No. tr|B3L7N6|B3L7N6_PLAKH), probable MQO fragment from P. yoelii yoelli (Uniprot 
Acc. No.tr|Q7RE35|Q7RE35_PLAYO), MQO from E. coli (strain K12) (Uniprot Acc. No. 
sp|P33940) and MQO from M smegmatis (strain ATCC 700084 / mc(2)155) (Uniprot Acc. 
No. sp|AOQVL2|MQO_MYCS2).
5.2.2 DNA Extraction
Genomic DNA was isolated from trophozoite stage synchronised P. falciparum (3D7)
strain using a phenol chloroform extraction technique with modifications (153). Synchronised
parasites were cultured in a 75-mm2 flask containing complete RPMI medium until a
parasitaemia of 7-8% was reached. Cells were centrifuged at 3000 x g for 5 minutes. The
supernatant was discarded and the resultant pellet resuspended in 5 volumes of cold PBS pH
7.4. Subsequently, cells were centrifuged at 3000 x g for a further 5 minutes. The pellet was
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resuspended in cold 5% (w/v) saponin (prepared in PBS). Following centrifugation at 3000 x 
g for 5 minutes, cells were digested with 50 pi proteinase K (0.1 mg/ml) in lysis buffer (40 
mM Tris-HCl / 80 mM EDTA pH 8.0/ 2% (w/v) SDS). The mixture was incubated at room 
temperature for - 3 hours with intermittent shaking after which an equal volume of 
phenol/chloroform/isoamyl alcohol (25:24: l;v/v/v) was added, vigorously shaken and then 
centrifuged at 13,000 x g for 1 minute at room temperature. The aqueous phase was removed 
and DNA was precipitated by adding 1/10 volume 3M sodium acetate (pH 5.2) and 2.5 
volumes of ice cold absolute ethanol with an overnight incubation at -20 °C. On the following 
day, the mixture was centrifuged at 13,000 x g for 30 minutes at 4 °C, followed by washing 
with 70% v/v ethanol. The mixture was centrifuged again at 13,000 x g for 5 minutes at 4°C. 
The supernatant was discarded and the DNA pellet was dried in a laminar flow hood. The 
DNA pellet was re-suspended in 100 pi DEPC-treated water (Ambion, UK) and stored at -80 
°C until required.
5.2.3 Estimation of Nucleic Acid Concentration
The concentration of nucleic acids was estimated by measuring absorbance at 260 nm 
using a NanoDrop Nd-1000 UV/Vis Spectrophotometer (Labtech International, UK). DNA 
preparations which had a ratio of O.D. 260/280 in the range of 1.7-2.0 were regarded as pure 
and protein free (215).
5.2.4 Designing PCR Primers for P. falciparum MQO 
Gene
Each primer described herein was designed from the published genome sequence of
the P. falciparum MQO putative gene (PF3D7_0616800) freely available from the PlasmoDB
data base (http://plasmodb.org). Primers were custom synthesised by Invitrogen, UK. Five
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primers were designed to cater for the different cloning processes to be used to incorporate the 
gene into the expression vectors. Two expression vectors were used in this study namely pET- 
15b (Novagen®, UK) and pUC19 (Invitrogen, UK). Two sets of primers were designed for 
each expression vector. One primer set was used to amplify the whole PfMQO gene and the 
second set was used to amplify the PfMQO gene region without the putative mitochondrial 
leader sequence. The leader sequence is a stretch of amino acid residues (~ 17-3 5 residues) 
located at the N-terminus of the mitochondrial protein. The signal of the leader peptides 
allows pre-proteins to be transported into the mitochondrial matrix. The transported protein 
eventually will be processed by matrix proteases (MPP) located in the mitochondrial matrix 
(97). The prediction of the putative PfMQO signal peptides was performed using SignalP 4.0 
Server (www.cbs.dtu.dk). The primers used in this work are summarised in the following 
Table 5.1 Primer PF222MQO was a reverse primer for all primer sets.
5.2.5 Amplification of PfMQO Gene
The amplification of the PfMQO gene was carried out using a BIORAD PCR 
Thermocycler using genomic DNA (10 ng) obtained as per section 5.2.2. High fidelity PCR 
reactions were prepared using Platinum® Pfx DNA Polymerase (Invitrogen, UK) according 
to protocol described by Invitrogen. This enzyme is a proprietary enzyme preparation 
containing recombinant DNA polymerase from Pyrococcus sp. Platinum® Pfx DNA 
Polymerase possesses a proofreading 3’-5’ exonuclease activity which is highly possessive 
and thus increases the extension rate capability. The specificity and accuracy offered by this 
enzyme is higher than standard Taq DNA polymerase and therefore it is suited for PCR 
applications such as site-directed mutagenesis, expression and cloning. High fidelity of PCR 
reactions were performed in a final volume of 50 pi containing 1 x Pfx Amplification Buffer, 
200 nmoles of primer (Invitrogen, UK), 10 mM dNTP mix (NewEngland Biolab,UK), 1 mM
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MgSC>4, 10 ng DNA template and 1 unit Pfx DNA Polymerase. The PCR parameters were as 
follows; denaturation of templates at 95 °C for 3 minutes, annealing of primers at 46 °C for 30 
seconds, and extension at 72 °C for 3 minutes and 15 seconds. After 30 cycles a final 
extension of 10 minutes was performed at 72 °C. The PCR products were visualised by 
electrophoresis using a 1.2% agarose gel stained with 0.5 jig/ml of ethidium bromide (120).
5.2.6 Purification of PCR Products
Prior to the cloning procedure, PfMQO PCR products were purified in order to remove 
agarose, excess nucleotides and primers. The PCR purification was carried out using 
Wizard® SV Gel and PCR Kit (Promega, UK). The membrane binding solution was added in 
an equal volume to PCR products and transferred into an SV minicolumn with a collection 
tube and incubated at for 1 minute at room temperature. The column assembly was 
centrifuged at 13,000 x g for 1 minute. The SV minicolumns were removed from the spin 
column assembly and the liquid in the collection tube discarded. 700 pi of membrane wash 
solution were added to the SV minicolumn. The SV minicolumn assemblies were centrifuged 
for 1 minute at 13,000 x g. The collection tubes were emptied as previously described and 
placed back on the SV minicolumns in the collection tubes. 5 pi of membrane wash solution 
were added followed by centrifugation for 5 minutes at 14,000 x g. The collection tubes were 
emptied and the column assemblies re-centrifuged for 1 minute with the microcentrifuge lid 
open to allow evaporation of any residual ethanol. The SV minicolumns were transferred to 
clean 1.5 ml microcentrifuge tubes and 50 pi of DEPC-treated water (Ambion, UK) was 
applied directly to the centre of the column. The reactions were incubated at room 
temperature for 1 minute. This was followed by centrifugation for 1 minute at 13,000 x g. The 
eluted PCR products were kept at 4 °C or -20 °C until required for cloning purposes.
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Table 5.1: List of Primers Sequences used for PCR Analysis of P. falciparum MQO Gene
List of primers designed to amplify the targeted PJMQO gene from genomic DNA of P. falciparum. 
The highlighted sequences identify in bold the restriction sites incorporated during primer design.
Primer
Name
Sequence Incorporated
Restriction
Enzyme site
Expression Vector
P221LMQO
(Forward)
5 ’-CATATG ATGATATGTGTTAAAA
ATATTTTG-3’
Ndel pET-15b
P222MQO
(Reverse)
5 ’GGATCCTCATAAATAATTAACGGG
ATATC-3’
Bamm pET-15b
PM225SM
QO
(Forward)
5 ’ ACCATATGTTAAACGAACTACGTAAT
AATAGG-3’
Ndel pET-15b
PM227LM
0
(Forward)
5 ’ ACCTGCAGG ATGATATGTGTTAAAAA
TATTTTG-3’
Pstl pUC19
PM226SM
0
(Forward)
5’ACCTGCAGGTTAAACGAACTACGTAAT
AATAGG-3 ’
Psil pUC19
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5.2.7 TA Cloning
PCR products amplified with primer pairs P221LMQO/P222MQO, 
PM225SMQO/P222MQO (incorporating restriction sites Ndel and itawHI; Table 5.1) 
PM227LMO/P222MQO and PM226SMO/P222MQO (restriction sites Pstl and £amHI; Table 
5.1) were directly ligated into linearised pCR®ITTOPO (Invitrogen, UK). The ligation 
reaction consists of 1 pi plasmid pCR®II-'TOPO (25 ng/pl) and 3 pi PCR product, 1 pi salt 
solution (1.2 M NaCl and 0.06 MgCh) and 5 pi DEPC-treated water (Ambion) in 10 pi of 
final volume.
5.2.8 Transformation of One Shot® TOPIC 
Chemically Competent E. coli
The ligation mixture of pCR®II-TOPO and the MQO gene amplicon were 
transformed into competent E. coli Top 10 (Invitrogen, UK) by the heat shock method. 2 pi of 
the ligation mixture were added and mixed gently and incubated on ice for 30 minutes. Heat 
shock of the cells was carried out at 42 °C for 30 seconds followed by incubation on ice for a 
further 2 minutes. 250 pi of super optimal broth (SOC) medium were added into the reaction 
and tube was shaken horizontally at 37 °C for 60 minutes. SOC is commercially available 
from Invitrogen UK and consists of 2% Tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM 
KC1, 10 mM MgCl2, 10 mM MgS04 and 20 mM glucose. 50 to 100 pi of the transformation 
reaction were spread on Luria Bertani (LB) agar plates consisting of 50 pg/ml ampicillin and 
IPTG/X-gal (40 pi 100 mM isopropyl-p-D thiogalactoside/40 pi 40 mg/ml 5-bromo-4-chloro- 
3-indoyl-P-D-galactosidase). Plates were incubated at 37 °C overnight. IPTG is known as an 
inducer of the lac operon and X-gal is a colourless chromogenic indicator containing a p-1,4 
linkage to glucose. X-gal is metabolised by p-galactosidase to form 5-bromo-4-chloro-indoxyl 
which is spontaneously oxidized to the bright blue insoluble pigment 5,5,-dibromo-4,4'-
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dichloro-indigo, and thus functions as an indicator. Efficiency of transformation was 
determined by examining the number of blue versus white colonies formed on LB-ampicillin- 
IPTG/X-gal agar plates. Only white colonies were chosen for analysis because blue colonies 
do not carry any insert. Screening was carried out on colonies selected from the LB-ampicillin 
agar plates. The selected colonies were subjected to a plasmid isolation step (miniprep or 
maxiprep) using a DNA purification system (Qiagen, UK).
5.2.9 Mini Preps of Plasmid DNA fom E. coli Cells
Mini preps of plasmid DNA from bacterial cells were carried out using QiaAmp kits 
(Qiagen, UK). A white colony from a fresh of LB agar plate was used to inoculate 10 ml LB 
medium containing appropriate antibiotics and incubated overnight at 37 °C in a shaking 
incubator. The bacterial culture was pelleted by centrifugation for 5 minutes at 10,000 x g. 
The supernatant was poured off and 250 pi of Cell Resuspension Solution (PI) was added and 
transferred to a microcentrifiige tube. This was followed by adding 250 pi of buffer P2 and 
mixing by inverting the tubes 4 times. Tubes were then left to stand for 5 minutes until the 
cell suspension turned blue indicating lysis of the cells. The mixture was neutralized by 
addition of 350 pi Buffer N3 neutralisation solution and immediately mixed thoroughly by 
inverting the tube. The bacterial lysate was subjected to centrifugation at 13,000 rpm for 10 
minutes at room temperature. The cleared lysate was transferred into QIAprep spin column 
and was centrifuged at 13,000 rpm for 1 minute and the flow through discarded. The column 
was washed two times with 750 pi and 250 pi of buffer PE solution and centrifuged for 1 
minute and 2 minutes, respectively, at 13,000 rpm at room temperature. Finally, the plasmid 
DNA was eluted in 100 pi DEPC-treated water by centrifugation at 13,000 rpm for 1 minute 
at room temperature. The DNA was quantitated using a NanoDrop spectrophotometer and 
was kept at -20 °C until required.
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5.2.10 Screening of Positive Clones by Restriction 
Enzyme Analysis
Screening of the positives clones was carried out throughout this study to validate 
successful cloning and subcloning of the inserted gene into the vectors. This technique was 
also applied to assess the successful transformation of the ligated gene into the E. coli host. 
Generally, 1 pg of the plasmids were digested with 20 units of enzyme in 30 pi total volumes 
consisting of buffer and incubated at 37 °C for 1 hour. Bovine serum albumin (BSA) was 
added in some of the reactions. Each restriction enzyme composition in the digestion reaction 
will be described in detail in the following section. Enzymes and buffers were purchased from 
New England Biolabs. (UK). 10 pi of digested plasmid with 2 pi of 6 x loading dye were 
loaded onto a 1.2% agarose gel. Electrophoresis was conducted in 1 x TBE running buffer at 
90 volts for 30 minutes and the gel was visualised under UV light.
5.2.11 Analysis by Automated Sequencing
200 ng of plasmid DNA that produced positive results by PCR and restriction enzyme 
analysis were sent for automated DNA sequencing (Cogenics, UK), where universal T7 
primers were used for the sequencing reaction. The pCR®II/inserts then were designated as 
TOPO/pETPfLMQO, TOPO/pETPfSMQO, TOPO/pUCPfLMQO and TOPO/pUCPfSMQO. 
PfLMQO represents a complete nucleotide sequence of putative PJMQO gene and PfSMQO 
represents a putative PfMQO gene where the first 46 of the 1566 nucleotides have been 
removed from the putative PfMQO nucleotide sequence. These 46 nucleotides were predicted 
as a putative leader sequence signal of PfMQO using SignalP 4.0 Server software 
(www.cbs.dtu.dk).
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5.2.12 Maxi Prep of Plasmid DNA fom E.coli Cells
Maxi preps of plasmid DNA from bacterial cells were carried out in order to get good 
yields of recombinant plasmid DNA for sub-cloning of TOPO/PfMQO into pET-15b and 
pUC19 expression vectors. A Qiagen Maxikit was used to purify recombinant plasmid from 
bacterial cells. A single colony of ToplO competent cells containing a PJMQO bearing 
plasmid from a streaked LB agar plate was inoculated into a starter culture of 5 ml LB/50 
jig/ml ampicillin/25 fig /ml chloramphenicol and incubated overnight at 37 °C with vigorous 
shaking at 200 rpm. 200 pi of the starter culture were added into 100 ml LB/50 pg/ml 
ampicillin/25 pg /ml chloramphenicol broth and incubated at 37 °C overnight with vigorous 
shaking at 200 rpm. The culture was harvested by centrifugation at 6000 x g at 4 °C. The 
supernatant was discarded, and the bacterial pellet was re-suspended completely in 8 ml of 
Buffer PI followed by 8 ml Buffer P2. The tube was mixed by inverting several times and 
then incubated at room temperature for 5 minutes. For the subsequent steps, all the mixing 
was carried out by inverting the samples 6 times. 8 ml of chilled Buffer S3 were added to the 
bacterial lysate and at this time the fluffy white precipitate containing genomic DNA, 
proteins, cell debris and SDS was produced. The lysate was poured into the barrel of a 
QIAfilter cartridge and incubated for 10 minutes at room temperature. The plunger was gently 
inserted into the QIAfilter Cartridge and the cell lysate was filtered into a 50 ml tube. 5 ml of 
Buffer BB 1 were added to the filtered lysate and the mixture was inverted 4-6 times. The 
lysate was transferred to a QIAGEN Plasmid Plus spin column attached to a vacuum pump. 
Approximately - 300 mbar pressure was applied until the liquid has been drawn through all 
the columns. 0.7 ml of Buffer ETR was added into the column and a vacuum was applied 
until the liquid had been drawn completely. This was followed by adding 0.7 ml Buffer PE 
and the same procedure was applied. The DNA column was centrifuged at 10,000 rpm for 1 
minute to remove the residual wash buffer completely. The DNA was eluted in 400 pi of
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Buffer EB and centrifuged at 10,000 rpm for 1 minute. The DNA purity was measured, 
followed by storage at -20 °C.
5.2.13 Double Restriction Enzyme Digestion
Double restriction enzyme digestion was carried out using specific enzymes that cut 
DNA at specific sites in the plasmids. The DNA fragments are cut at their unique recognition 
sequence at the recognition site by the specific enzyme. In this study the restriction enzyme 
digests were carried out to isolate the MQO fragments (TOPO/pETPfMQO and 
TOPO/pUCPfMQO) from the TOPO replication vector. The same procedure was also carried 
out on both expression vectors pET-15b and pUC19 to prepare for subsequent sucloning 
procedure. The TOPO plasmids encoding pETMgO genes (pETPfLMQO and pETPfSMQO) 
and pET-15b vector were digested with 20 units of Ndel and BamKl, respectively. Reactions 
consisted of 3 pi NEB buffer III and 3 pi BSA in 30 pi total volume. The TOPO plasmids 
encoding pUCM0O and pUC19 vector were digested with 20 units Psil and BamBl in 30 pi 
total volume containing NEB buffer III. All reactions were incubated at 37 C for 1 hour. 20 
pi of digested plasmid mixed with an appropriate volume of 6 x loading dye were loaded to a 
1,2% agarose gel. Electrophoresis was conducted in 1 x TAE running buffer at 90 volts for 30 
minutes and the gel was visualised under UV light.
5.2.14 Agarose Gel Extraction
Agarose gel extraction was carried out using QIAquick®Gel Extraction Kit (Qiagen, 
UK). The -1566 bp MQO DNA bands were excised from the agarose gel with a sterile 
scalpel. The gel slice was weighed in a 1.5-ml tube. 3 volumes of Buffer QG were added to 1 
volume of the gel slice followed by incubation at 50 °C for 10 minutes. The mixture was
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vortexed intermittently until the gel fragment was completely dissolved. After incubation, the 
sample was transferred into QIAquick spin column in a provided 2-ml collection tube and 
spun at high speed (13,000 rpm) for 1 minute. The flow through was discarded and the 
Qiaquick column was put back in the same collection tube. 0.5ml of Buffer QG was added to 
QIAquick column and centrifuged for 1 minute to remove all traces of agarose. The flow 
through was discarded and the QIAquick column was centrifuged for an additional 1 minute 
at 13,000 rpm. The QIAquick column was transferred into a clean 1.5-ml microcentrifuge 
tube and 50 pi DEPC-treated water (Ambion, UK) added before and centrifuging at maximum 
speed (13,000 rpm) for 1 minute. The DNA was checked for purity and concentration and
subsequently kept in -20 °C.
5.2.15 Dephosphorylation of Linearlised Vector
Dephosphorylation of linearlised vector was carried out to prevent the religation of the 
double-digested expression vectors pET-15b and pUC19. 40 pi of double digested vector 
were incubated with 0.1 units Antarctic Phosphatase and 1 x Antarctic Phosphatase Buffer 
(NewEngland BioLabs, UK) in a total volume of 50 pi. The reaction was incubated at 37 °C 
for 30 minutes and then 65 °C for 5 minutes to terminate the enzymatic reaction.
5.2.16 Sub-cloning Reaction
The ligation process was carried out at vector: insert ratio of 1:3. The ligation mixture 
contained digested pET-15b, pUC19 and respective DNA fragments of pETPfLMQO, 
pETPfSMQO, pUCPfLMQO and pUCPfSMQO. The ligation reaction recipe was followed 
standard ligation reaction mixture that contained 1 unit of T4 DNA ligase and. 1 x T4 DNA 
ligase reaction buffer (50 mM Tris-HCl, 10 mM MgC12, 10 mM Dithiothretol and 1 mM
145
ATP). Ligations were carried out at 14 °C for 2 hours. T4 DNA Hgase was inactivated at 65 
°C for 10 minutes prior to transformation into TOP 10 chemically competent E. coli cells.
5.2.17 Transformation of Ligated Expression 
Vectors and PJMQO gene into One Shot® TOPIO 
Chemically Competent E. coli
The ligated expression vectors and PJMQO genes were transformed into E. coli 
TOPIO cells following the protocols as described in section 5.2.8 with the exception of an 
addition of X-gal for blue and white screening. The ligation mixture was transformed using 
heat-shock transformation into TOPIO chemically competent E. coli cells and plated on LB 
agar containing 50 pg/ml ampicillin.
5.2.18 Selection of Recombinants
7 colonies from each transformants were selected randomly for further analysis by 
restriction digestion. The colonies were subjected for small scale culture (5 ml LB containing 
50 pg/ml ampicillin) and grown for overnight at 37 °C. This was followed by minipreparation 
using a QiaAmp (Qiagen, UK). This protocol was described in section 5.2.9. The selected 
clones then were validated by digesting with EcoRV (pET-15b vector) and Sphl (pUC19 
vector) respectively. The positive clones were designated as pET/PfLMQO, pET/PfSMQO, 
pUC/PfLMQO and pUC/PfSMQO.
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5.2.19 Preparation of Competent E. coli BL21 
(DE3) pLysS cells
The preparation of competent cells was carried out according to protocol described by 
(120). Non-competent BL21 (DE3) pLysS cells (Promega, UK) were plated on LB agar 
containing of 25 pg/ml chloramphenicol. The agar plate was incubated at 37 °C overnight. On 
the following day, a single bacterial colony was inoculated in 100 ml of LB/amp (25 pg/ml). 
The culture was incubated at 37 °C for 3-6 hours with vigorous shaking at 200 rpm. The 
bacterial growth was monitored spectrophotometrically at 600 nm. The growth of the cells 
was arrested by incubation on ice for 10 minutes after the OD6oo reached 0.4. This was 
followed by centrifugation at 2700 x g for 10 minutes at 4 °C The supernatant was discarded 
and the bacterial pellet resuspended in 30 ml ice cold MgCL-CaCL (80 mM MgCl2/20 mM 
CaCl2). The mixture was centrifuged at 2700 x g for 10 minutes at 4 °C. The supernatant was 
discarded and the pellet was resuspended in 2 ml ice cold buffer contain 0.1 M CaCb and 500 
pi of glycerol and mixed by gentle swirling. The resuspended cells were aliquoted into sterile 
1.5 tubes and kept at -80 °C until ready to use.
5.2.20 Transformation of pET/PfMQO and 
pUC/PfMQO into E. coli BL21 (DE3) pLysS cells
The recombinant plasmids were transformed into the expression host E. coli BL21 
(DE3) pLysS cells. 1-50 ng of recombinant PfMQO bearing plasmids (pET-15b and pUC19 
clones) was added into 50 pi of competent BL21 cells. The mixtures were incubated on ice for 
30 minutes, followed by heat shock at 42 °C for 45 seconds in a water bath. The mixture was 
incubated on ice for 5 minutes, 250 pi of SOC medium were added and the tube was shaken 
horizontally at 37 °C for 60 minutes. 50 to 100 pi of the cultures were spread on LB agar 
plates with 50 pg/ml ampicillin and 25 pg/ml chloramphenicol and incubated overnight at 37
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°C (120). The positive clones form each transformant were screened by restriction enzymes 
analysis using EcoRV (pET expression system), Sphl, Afllll and BamHl (pUC expression
system).
5.2.21 Transformation of pET/PfMQO and 
pUC/PfMQO into E. coli Rosetta ™ (DE3)pLysS 
cells
The study of the protein expression of pET/PfMQOs and pUC/PfMQOs was also 
carried out in E. coli Rosetta™ (DE3)pLysS cells (Novagen, UK). Rosetta™ is a strain of 
BL21 designed to enhance the expression of eukaryotic proteins that contain codons rarely 
used in E. coli. The E. coli LysS contains tRNA genes argU, argW, ileX, glyT, leuW, proL, 
metT, thrT, tyrU, and thrU. The tRNA of the bacterial cells are supplied with seven rare 
codons (AUA, AGO, AGA, CUA, CCC, CGG and GGA) on a compatible chloramphenicol- 
resistant plasmid. The pLysS plasmid encodes T7 phage lysozyme, an inhibitor for T7 
polymerase which reduces and almost eliminates expression from transformed T7 promoter 
containing plasmids when not induced (194). 1 pi of recombinant DNA from a transformed 
TOPIC cell minipreparation was directly applied to the cells and gently mixed. The tube was 
incubated on ice for 5 minutes and subsequently transferred to 42 °C water bath for heat shock 
for 30 seconds. 80 pi of SOC media was added and the tube was shaken horizontally at 37 °C 
for 60 minutes. 50 to 100 pi of the cultures were spread on LB agar plate with 50 pg/ml 
ampicillin and 25 pg/ml chloramphenicol and incubated overnight at 37 °C. The positive 
clones form each transformant were screened by restriction enzyme analysis using EcoRV and 
Sphl (pET-15b vector), 4/7III (pUC19 vector) and double digestion with Pstl and BamHl for 
the pUC expression system.
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5.2.22 Determination of PfMQO Expression in E. 
coli Rosetta™ (DE3)pLysS Cells
Small scale preparation of positive clones harbouring pET/PfLMQO and 
pET/PfSMQO, pUC/PfSMQO were carried out to determine the expression of the PfMQO 
recombinant protein in K coli Rosetta cells. The glycerol stock of a PfMQOs positive clone 
were plated onto LB/50 pg/ml ampicillin/25 pg/ml chloramphenicol and incubated overnight 
at 37 °C. A single colony was used to inoculate 10 ml LB/50 ng/ml ampicillin/25 pg/ml 
broth. The cultures were incubated overnight at 37 °C in a shaking incubator at 200 rpm. 2.5 
ml of the overnight cultures were inoculated into 50 ml LB/ 50 pg/ml ampicillin/ 25 ^ig/ml 
chloramphenicol and incubated at 37 °C with vigorous shaking at 200 rpm. The growth of the 
bacterial cells was monitored spectrophotometrically at 600 nm. Induction of protein 
expression by the addition of IPTG to a final concentration of 1 mM occurred once the ODeoo 
reached 0.5-0.7. The cultures were continuously grown for an additional 4-5 hours. 1 ml of 
culture was pelleted and resuspended in 100 pi lx SDS-PAGE sample buffer. Duplicate 
samples of bacterial lysates were prepared for Rapid Coomasive Blue Staining and western 
blot analysis. Samples of bacterial lysate were electrophorosed by 10% SDS-PAGE for 1 hour 
at 60 milliamp constant current. For western blot analysis, gel was electroblotted onto 
nitrocellulose membrane as previously describe in section 2.16. The blotted membrane was 
incubated with monoclonal anti-polyhistidine antibody (Sigma Chemical Co. UK) at a 
dilution of 1:5000 for 2 hours in blocking buffer (5% skimmed milk powder in TBS-T). The 
blotted membrane was then washed 3 times in 1 x TBS-T, for 10 minutes each per wash. The 
membrane then was incubated for 1 hour with slow agitation with secondary antibody 
horseradish peroxidase (HRP) conjugated anti-mouse Ig antibody (Nordic Immunology) 
(1:10,000) in blocking buffer. Visualisation was performed using ECL reagent (Amersham,
G.E Healthcare).
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5.2.23 Determination of PfMQO Protein Solubility
This study was carried out to determine the solubility of the recombinant PfMQO 
protein using sample preparation as in previous section 5.2.22. The bacterial pellets bearing 
for PfLMQO and PfSMQO were dissolved in 5 ml of lysis buffer (150 mM NaCl, 50 mM 
Tris.HCl, 1 mM EDTA pH 7.4). The bacterial suspension was centrifuged at 17,000 x g for 
30 minutes at 4 °C. The supernatants were separated and the pellets were resuspended into the 
same lysis buffer (insoluble part). The insoluble part was divided into 2 (insoluble fraction 
and inclusion body). 20% of Triton X-100 was added into the inclusion body fraction to 
remove lipid and membrane associated protein but not solubilise the inclusion body. The 
mixture was incubated on rotary incubator for 30 minutes at 4 °C. This was followed by 
centrifugation at 17,000 x g for 30 minutes at 4 °C. The supernatant was carefully discarded 
from the pellet. The pellet was homogenised using glass tissue homogeniser to get a good 
yield. The homogenised pellet was resuspended in lysis buffer and kept at -80 °C. The 
soluble, insoluble and inclusion body fractions were diluted in 1% SDS loading buffer and 
electrophorised onto a 10% SDS polyacrylamide denaturing gel for 1 hour at 60 milliamp 
constant current and followed by rapid blue staining.
5.2.24 Time, Temperature and IPTG Induction 
Courses of PfMQO
The purpose of this study was to determine the optimal post-induction growth 
duration, temperature and IPTG concentration required for high level expression of soluble 
PfMQO. Only the positive clones of pET/PfLMQO and pET/PfSMQO were subjected to this 
study. The starter bacterial cultures were prepared as described in section 5.2.22. The 
recombinant PfMQO was then designated as PfLMQO and PfSMQO. The parameters 
investigated were 22 °C, 30 °C and 37 °C, and 0.5 mM and 1 mM IPTG for the each
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temperature. 5 mi bacterial culture was sampled at 3 hours and 5 hours, and overnight (post- 
IPTG induction). The samples were centrifuged at 3000 rpm for 20 minutes. The supernatants 
were discarded and pellets were resuspended in lysis buffer (150 mM NaCl, 50 mM Tris.HCl, 
1 mM EDTA pH 7.4). Samples were kept on ice and sonicated using Vibra Cell probe 
sonicator at 80 ampitude 3 times for 10 seconds each until the sample was no longer viscous. 
The sonicated samples were centrifuged at 13,000 x g for 30 minutes. The supernatant 
containing soluble proteins was separated and the pellet (insoluble proteins) was resuspended 
in 1 ml of lysis buffer. Both soluble and insoluble fractions were diluted in 1% SDS loading 
buffer and electrophorised on a 10% SDS polyacrylamide denaturing gel for 1 hour at 60 
milliamp constant current and followed by rapid blue staining.
5.2.25 Overexpression of PfMQO Recombinant 
Proteins
The overexpression of PfMQO protein was carried out based on the result obtained 
from the time and IPTG induction course study. 5 ml of starter culture of PfLMQO and 
PfSMQO bearing cells were inoculated into 100 ml LB/50 pg/ml ampicillin/25 pg/ml 
chloramphenicol growth media and grow at 37 °C in a shaking incubator at 200 rpm. The 
growth cultures were monitored spectrophotometrically at ODeoo as described in section 
5.2.21. 1 mM of IPTG were added into the bacterial culture after OD6oo of fermentation 
reached 0.6 to 0.8. The incubation temperature was reduced to 30 °C and the cultures were 
grown for an additional 3 hours. The cells were harvested by centrifugation at 3000 x g for 20 
minutes at 4 °C. The cell pellets were frozen at -80 °Ctill further use.
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5.2.26 Preparation of Clear E. coli Lysates under 
Native Conditions
Stored bacterial cells prepared as in section 5.2.25 were thawed on ice and 
resuspended in 5 ml of lysis buffer (150 mM NaCl, 50 mM Tris.HCl, 1 mM EDTA pH 7.4). 1 
mg/ml lysozyme was added and the mixture kept on ice for 30 minutes. The cell mixture was 
sonicated on ice using a probe sonicator for 3 times at 80 amplitude with a 10-second cooling 
period between each burst. This was followed by centrifugation at 17,000 x g for 30 minutes 
at 4 °C. The supernatant was removed and divided into 2; Cl the soluble fraction which kept 
for SDS-PAGE analysis and S3 the soluble fraction which subjected to purify under native 
conditions. The pellet was resuspended in 500 pi of lysis buffer and divided into 2; insoluble 
fraction (C2) and insoluble fraction which was subjected to native purification (P3). Finally 
50 pi of 100 % glycerol was added to the S3 and P3 samples. The mixtures were mixed 
thoroughly ready for purification under native condition.
5.2.27 Purification under Native Conditions
A 1:4 ratio 50 % Ni-NTA resin (Qiagen) was added to the soluble S3 and P3 fractions 
of PfLMQO. The mixtures were gently rotated for 60 minutes at 4 °C. Prior to loading the 
bacterial mixtures, the Ni-NTA columns were equilibrated three times with 600 pi sample 
wash buffer (50 mM NaH2P04, 300 mM NaCl, 20 mM imidazole, pH 8.0) and centrifuged at 
3000 rpm for 2 minutes at 4 °C . The mixture of of lysate and Ni-NTA was loaded into the 
column (Qiagen) and centrifuged at 16,000 g for 5 minutes at 4 °C. The flow through was 
collected and labelled as S4 and P4. The soluble and insoluble fractions were denoted as S 
and P throughout of this study. The columns were washed with wash buffer three times, 
followed by centrifugation and the flow through was collected. The flow throughs then were 
labelled as S5, S6, S7, P5, P6 and P7. Finally, the column was eluted twice with elution buffer
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(50 mM Na2P04, 300 mM NaCl, 20 mM imidazole pH 8.0) at 3000 rpm for 5 minutes at 4 °C 
. The samples were labelled as S8 and S9 (soluble) and P8 and P9 (insoluble). The eluted 
samples were diluted in 1 x SDS buffer and 1 x SDS loading buffer. Samples were subjected 
to electrophoresis on SDS-polyacrylamide gels containing 10% acrylamide for 1 hour at 60 
milliamp constant current. The electroporated gels were stained using Expedion instant blue 
rapid staining (Expedion Protein Solutions, Cambridge, UK) and also using silver staining as 
described in section 2.15.
5.2.28 Preparation of PfLMQO Inclusion Body for 
Purification under Denaturing Conditions
The cryostored bacterial cells bearing PfLMQO as in section 5.2.5 were thawed on ice 
and resuspended in 5 ml of lysis buffer (150 mM NaCl, 50 mM Tris HC1, 1 mM EDTA pH 
7.4) and labelled as IB1. The resuspended cells were homogenised using Constant Systems 
Cell Disrupter (Constant Systems Ltd, UK) twice at 25 K. The cells were collected and 2 pi of 
DNAse I (Sigma Co., UK) and 0.5 mg/ml lysozyme (Sigma Co., UK) were added. The 
homogenised cells were labelled as IB2. The suspension was incubated for 20 minutes at 
room temperature on a rotating incubator for 20 minutes at room temperature. Triton X-100 
was added to a final concentration of 2% v/v. The mixture was incubated on a rotating 
incubator for 30 minutes at 4 °C. After the incubation, the mixture was centrifuged at 17,000 
x g for 30 minutes at 4 °C. The supernatant was separated and labelled as IB3. The pellet was 
resuspended in 1 ml of lysis buffer with complex protease inhibitor (Roche Co., UK) and 
followed by homogenised the cells using glass tissue homogenizer. The homogenised mixture 
was spun at 17000 x g for 30 minutes at 4 °C. The supernatant was discarded and the pellet 
was labelled as IB4 and kept at -80 °C. 1 ml of IB4 pellet was resuspended with buffer A (50
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mM NaH2P04, 300 mM NaCl, 5 mM Tris.Cl, 5 M GuHCl, pH 8.0) and followed by 
incubation overnight at 4 °C on the rotating incubator.
5.2.29 Purification under Denaturing Conditions
The purification began by equilibration of the Ni-NTA column by washing with 600 
pi of Buffer A 3 times and centrifugation at 3000 rpm for 2 minutes at room temperature. The 
overnight inclusion bodies were centrifuged at 17,000 x g for 30 minutes at 4 °C and the 
supernatant was collected. The supernatant was separated and labelled as IBS. The pellet was 
resupended in 50 pi of lysis buffer contain Roche complex protease inhibitor. The mixture 
was labelled as IB6. 500 pi of IB6 was loaded to the spin column (Qiagen) and spun at 16,000 
rpm for 5 minutes at room temperature. The flow through was collected and labelled as IBL1. 
This process was repeated and the second flow through was collected and labelled as IBL2. 
The column was washed 3 times with 600 pi of buffer A consisting 20 mM imidazole pH 8.0 
and spun at 2,900 rpm for 2 minutes at room temperature. Every flow through was collected 
and labelled as IBW1, IBW2 and IBW3. Finally the column was eluted twice with 200 pi of 
Buffer B (50 mM NaP04, 5 mM Tris.Cl, 500 mM imidazole, 30 mM NaCl and 5 mM GuHCl 
pH 7.5) and the elutes were labelled as IBE1 and IBE2. GuHCl should be separated from the 
samples by trichloroacetic acid (TCA) precipitation prior to SDS-PAGE analysis. A 100 pi of 
diluted samples were diluted to 10 pi of 10% TCA v/v with vortexing. The mixture was 
incubated for 20 minutes at 4 °C followed by centrifugation at 15,000 x g for 15 minutes at 4 
°C. The supernatant was discarded and the pellet resuspended in 100 pi of cold ethanol. The 
sample was dried at 95 °C and subsequently resuspended in 1 x SDS sample buffer. 20 pg of 
proteins were separated under denaturing conditions on a 10% SDS polyacrylamide 
denaturing gel for 1 hour at 60 milliamp constant current and visualised by rapid blue staining 
and also stained by silver staining according to protocol described in section 2.15.
154
5.2.30 Preparation of E. coli Rosetta Membranes
The PfLMQO expressed in E. coli Rosetta cells was prepared from LB broth 
containing 50 pg/ml ampicillin and 25 |ig/ml chloramphenicol. As a control, E. coli Rosetta 
cells not transformed with the PfMQO gene was grown in LB broth containing only 25 pg/ml 
chloramphenicol. 10 ml of both bacterial cells were grown overnight at 37 °C at 200 rpm in a 
shaking incubator. The following day these cultures were propagated in 400 ml LB broth 
containing appropriate antibiotics and grown at 37 °C with 200 rpm until an OD 600 of 0.6 
was reached (approximately 3 hours).The cells were induced with 1 mM IPTG and incubated 
for 4 h. The cells were harvested by centrifugation at 4000 x g for 20 min. Cells were 
resuspended in the 50 mM KPi /2mM EDTA pH 7.4) containing Roche protease inhibitor 
cocktail and kept on ice. This was followed by cell disruption using a cell disrupter at 25 K. 
The cell lysate was centrifuged at 10,000 rpm for 20 min at 4 °C to remove unbroken cells. 
Membranes were recovered from the supernatant by ultracentrifuging at 100,000 x g at 4 °C 
using Beckman Rotor JA 25.5 for 1 hour. The membranes were resuspended in 500 pi of 50 
mM KPi/2 mM EDTA pH 7.4 contains protease inhibitor cocktail. The protein concentrations 
for both E. coli Rosetta control and E, coli Rosetta encoding PfMQO were carried out using 
Bradford assay as described in section 2.12 using BSA as a standard.
5.2.31 Measurement of MQO Enzyme Activities
Measurement of MQO activities either in native form in E. coli Rosetta cells or the 
recombinant PfMQO expressed in E. coli Rosetta were carried out using 2 types of electron 
donor. Both assays were perfomed spectrophotometrically using a Cary 300 Bio UV visible 
spectrophotometer. The first method is direct measurement using Q1 as electron acceptor and 
donor. The reaction was carried out in total volume of 700 ul of assay buffer (50 mM KPi/2 
mM EDTA) pH 7.4, 50 pM Q-12,3-dimethoxy-5-methyl-6-(3-methyl-2-butenyl)-1,4-
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benzoquinone (Sigma-Aldrich, UK) and 10 mM potassium cyanide (KCN) (Sigma-Aldrich, 
UK) at room temperature. The reaction was started by addition of L-malate (Sigma-Aldrich, 
UK) and the rate of Q1 reduction was determined by measuring the absorbance change at 273
run.
The second assay was performed using 2,3-dicMorophenolindophenol (DCPIP) as an 
electron donor as described by (185). The MQO assays were carried out in a total reaction 
volume of 700 pi of assay buffer (50mM KPi/2 mM EDTA) pH 7.4 and 50 pM 2,3-
dimethoxy-5-methyl-6-(3-methyl-2-butenyl)-l,4-benzoquinone (Sigma-Aldrich, UK) at room 
temperature. The first MQO assay was conducted by measuring the reduction of 50 pM 2,6- 
dichloroindophenol (DCPIP) (Sigma Aldrich, UK). The reaction was started by addition of 10 
mM L-malate (Sigma, UK). The reduction of DCPIP was measured at 600 nm, and a 
differential absorption coefficient between oxidised and reduced DCPIP of 22 cnf'.mM was 
assumed. The activity of DCPIP reduction was measured by subtracting the value of control 
activity (without the presence of substrate) in the reaction.
5.3 Results
5.3.1 Bioinformatic Analyses
The primary and secondary structure analyses of PfMQO were carried out using 
bioinformatic applications hosted by various domains online. The open reading frame and the 
molecular mass size of MQO were predicted using The Biology WorkBench 3.2 
fhttp://workbench.sdsc,edu) and ProtParam programme hosted at http://www.expasY.org. The 
PJMQO gene shows an open reading frame (ORF) of 1566 bp with a predicted protein of 521
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amino acids. The predicted molecular mass of PfMQO and isoelectric point (pi) are 59506.9 
Da and 9.2 respectively.
The probability of PfMQO mitochondrial subcellular location was predicted using 
PFMpred (http://www.imtech.res.in/raghava/pfmpred) and PlasMit
(http://gecco.org.chemie.uni-ffankfurt.de/plasmit/) softwares that are freely available online. 
These softwares were used mainly to analyse Plasmodium subcellular protein. P. falciparum 
5-aminolevulinic acid synthase and P. falciparum malate dehydrogenase (PfMDH) were used 
as positive and negative controls respectively. Table 5.2 shows the support vector machine 
(SVM) score of PFMpred result of 1.30 compared to 0.96 for 5-aminolevulimc acid 
synthetase and 0.0 for PfMDH. Similar analysis with PlasMit software using a neural network 
method shows that PfMQO and Pf 5-aminolevulinic acid synthase are mitochondrial proteins 
with a 91% reliability index (R.I) and that PfMDH is not a mitochondrial protein with a R.I of
99%.
Prediction of the transmembrane domains of P. falciparum proteins was carried out by 
TMHMM fhttp://www.cbs.dtu.dk/services/TMHMM/). PfDHODH and PfSD were selected as 
positive and negative membrane proteins control. The predictions of transmembrane domains 
plot of putative PfMQO, PfDHODH and PfSD are presented in Figure 5.5. Figure 5.5A shows 
the prediction result of PFMQO exhibiting only one transmembrane domain at amino acids 
position at 74-94 with a probability index of less than 0.75, suggesting that the PfMQO is 
unlikely the mitochondrial protein. In comparison, the PfDHODH m Figure 5.5B exhibits 
probability index 1, indicating that amino acids position 143-162 is likely the
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MICVKNI LKRYKNSPLNELR
atgatatgtgttaaaaatattttgaaaagatataaaaatagtccgttaaacgaactacgt
NNRKYYEGSFVKSIKFSTSN
aataataggaaatattatgaagggtcatttgtaaaaagtataaaatttagtacatcaaat
YGSNEKKPNDIEKNKNVSIN
tatggaagtaatgaaaaaaaaccaaatgatattgaaaagaataagaatgtatctataaat
LNEGNILQSEIYDTVVIGGG
cttaatgaaggtaatattttacaaagtgaaatatatgatacagttgtcataggaggaggg
VTGTALFFLLSKFTNLKKLA
gtaacaggtactgctttgttttttttattatctaaatttactaatttaaaaaagctagcc
I IERRDNFALVASHGKNNSQ
ataattgaaagaagagataattttgctttagtagcatcacatggaaaaaataatagtcaa
TIHCGDIETNYSFEKAKF IK
acaattcattgtggtgatattgaaaccaattattcttttgaaaaagccaaatttataaaa
RYADMLRNYLTNIPKEKREN
agatatgctgatatgttaagaaattatttaacaaatatacctaaagaaaaaagagaaaac
ISSVTQKMVLGVGEKECQFL
atatcaagtgttacacaaaaaatggttttaggtgtaggtgaaaaggaatgtcaattttta
EERYPVFRQLFNSMKLYNKD
gaagaaagatatcctgtatttagacaattatttaattccatgaaattatataataaagat
DIHEVEPRVALKDSHTLREE
gatatacatgaggtagaaccacgggttgctttaaaggattctcatacgttaagagaagaa
QLSALYMPPELTTCDYQKLS
caattatcagcattatatatgccaccagaattaaccacatgtgattatcaaaaattatcg
ESF IESARTVPNKTISINLL
gaaagttttattgaatctgcacgtactgtacccaataaaactatatctataaatttatta
TEVINIEEVNDSLYKIHTNK
acagaagtaattaatattgaagaagttaatgatagtttatataaaatacatacaaacaaa
G I INSRFVVVCACGHSLMIA
ggaatcattaattcgcgttttgttgtagtctgtgcatgcggacattcattaatgattgca
QKMNYGLEYSCMPVAGSFYF
caaaaaatgaattatggattagaatatagctgtatgcctgtagctggaagtttttatttt
TDNILKGKVYTIQNPALPFA
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961 acggataatattttaaaagggaaagtatatactattcaaaatccagccttaccatttgca 1020 
AVHGDPDI IEKGKTRFGPTA 
1021 gccgtacatggagatccagatattattgagaaaggtaaaacgagatttggaccaacagct 1080 
IPLPLLERDNIKTLLDFLKV 
1081 atacctttaccattgttagaaagagataatataaaaacattattggattttttaaaagta 1140 
WNPDLSLFQVYYNLFKDMTM 
1141 tggaatccagatctaagtttatttcaagtatattataatttattcaaagatatgacaatg 1200 
LKYVARNVLFEIPVLNKYLF 
1201 ttaaaatatgtagcacgtaacgttttatttgaaatcccagttttaaataaatatttattt 1260 
LKDVKKI IPSLTIKDLTYCV 
1261 ttaaaagatgttaaaaaaattattccatcattaaccataaaagacttaacatattgtgtt 1320 
GYGGVRPQLINKKSKKLILG 
1321 ggttatggaggtgttcgaccacaactcataaataaaaaaagtaaaaaattaattcttgga 1380 
EGKIDPGKNI IFNITPSPGA 
1381 gagggaaaaatcgatccaggaaaaaatattatctttaacattacaccttcacctggagca 1440 
TTCLGNGEFDMNTICERLNA 
1441 accacatgtttaggtaatggagaatttgatatgaacacaatatgtgaaagacttaacgca 1500 
KINKNDVKKYLYEGEYPVNY 
1501 aaaattaacaaaaatgatgtgaaaaaatatttatatgaaggcgaatatcccgttaattat 1560 
L *
1561 ttatga 156
Figure 5.4: Analysis of the Predicted Putative PfMQO Open Reading Frame (ORF), 
Start and Stop Codons
Analysis of the predicted PfMQO Open Reading Frame (ORF), Start and Stop Codons. 
PfMQO open reading frame of 1566 bp encoding a polypeptide 521 amino acid residues in 
length. Start and stop codons are underlined. The PfMQO gene was predicted using The 
Biology WorkBench 3.2 (http://workbench.sdsc.eduT
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Table 5.2: Subcellular Location Predictions of PJalciparum Mitochondrial Proteins
PFMpred PlasMit
Protein SVM
score
Final Prediction R.I (%) Final Prediction
Malate quinine 
oxidoreductase 
,putative 
PJalciparum 
3D7
1.30 MP 91 Possibly MP
Malate
dehydrogenase, 
P falciparum 
3D7
0.0 NMP 99 NMP
6-
aminolevulinic
acid
synthetase, P. 
falciparum
3D7 (PfALAS)
0.96 MP
,________________ _
91 Possibly MP
______________________
Subcellular location predictions of PJalciparum mitochondrial proteins using PFMpred and 
PlasMit bioinformatic methods. The prediction was done at default parameters of the web 
server. This table show the SVM score MitPred and R.I PlasMit analyses indicate the putative 
PfMQO is likely a mitochondrial protein. Pf 5-aminolevulinic acid synthetase and PfMDH 
proteins used as positive and negative controls. Abbreviations: SVM, Support Vector 
Machine; R.I, Reliability Index; MP; mitochondrial protein; NMP, non-mitochondrial protein.
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transmembrane protein. Meanwhile, Figure 5.5C exhibits the transmembrane protein negative 
control plot. The PfSD probability index value is less than 0.75 indicates the amino acids 
sequence is unlikely the transmembrane protein.
The secondary structure of PfMQO was predicted using PSIPRED software 
(http://bioinf.cs.ucl.ac.uk/psipredt hosted by University of Collage London, UK. A grapic 
output of the predicted secondary structure of the putative PfMQO is shown in Figure 5.6. 
The stuctural composition is predicted to be 26% alpha Helix content, 22% strand and 52% 
coil.
The multiple alignment of MQO amino acid sequence from representative organisms 
was performed using ClustalW Multiple sequence alignment (http://mobyle.pasteur.fr/cgi- 
bin/portal.py) web server. The MQO amino acid sequences of Plasmodium spp., E. coli and 
M. smegmatis were extracted from sequence database of UniProt Knowledgebase UniProtKB 
(www.uniprot.org) website.The putatitve PfMQO amino acid sequence was compared with 
MQO amino acid sequences from other Plasmodium species, E. coli and M. smegmatis. 
Figure 5.7 shows that the putative PfMQO has 80% similiarity to putative PvMQO and 
putative PcMQO , 74% to PbMQO, 75% to putative PkMQO, 77% to probable PyMQO, 7% 
to EcMQO and 10% to MsMQO.
5.3.2 Amplification of PfMQO Gene
Using specific primers, as mentioned in materials and methods section 5.2.5., genomic 
DNA of P. falciparum strain 3D7 was subjected to amplification by PCR. The primers
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Figure 5.5: Graphical Representation of the Predicted Topologies of Putative PfMQO, 
PfDHOODH and PfPSD
Graphical representation of the transmembrane helices prediction in P.falciparum PfMQO, PfDHODH 
and PfPSD proteins. The plot was generated with TMHMM Server v. 2.0 
(www.cbs.dtu.dk?services/TMHMM) shows the posterior probabilities of inside/outside/TM helices. 
The red lines indicate the number of predicted transmembrane helices, the blue lines indicate the 
inside region of the protein and the pink lines indicate the outside region of the the protein. X-axis 
indicates the amino acid number, Y-axis indicates the probability that the amino acid is located within 
the membrane, outside the cell or in the cytoplasm. The prediction gives the most probable location 
and orientation of transmembrane helices in the sequence at the top of the plot (between l and 
l.2).The probability >0.75 indicate significant results and the maximum probability is l to indicate 
that amino acids are the transmembrane protein. The transmembrane regions of the PfMQO and 
PfPSD proteins have a probility lower than 0.75 and PfDHODH is close to l. Therefore, suggesting 
that PfDHODH is most likely the transmembrane protein whereas PfMQOand PfPSD are no
162
Psiprcd Residue Predictions (results displayed against the tirst ot the input sequences)
Conf: Confidence
Pred: Predated secondary structure
AA: Target sequence
0 =How
m -hehx
*high
-strand
>4: CCCSRBMSVIS C C < CC C
S41SSYCS
CCCSSSSS cccccccc ccccccccccccc
:«4: CCCCCCCCCC C S St S I I 
sat ISKSBlltfK l X ST V V l VTfTALrr
I c c
x r T V 1 X X
cccccccccccc
XOKF&IVXIICK
• 4: CCCCCCCC CC 
Ihz TISCSBXSTS 
its
c c c c c c c c c c 1 B S S C C
T 8 rets BTIOMXBS rTOXMViSYsexx
s s a
Q r t
BX: B B X V P ▼
X c c c 
X Q L r
1 » s
C C X B B X BBC
B V X
c c c
L K D
c c c c c BSBCCCCCSK CCB 
Xl.TMSSt2.T7 COT
m a ■
■ x a 
2 4 0
* 4 : « * T H B B H T * C
Ik. ItriCSXXTY
c c
X T
CttlXIBl
TSVIXtCX
c c s t • CCtSBBCCCCCt
farVVVCXCBBS NIX 
2 • •
• 4; BBCCCCCCC 
Bit QKNBT01.tr
a i
CCCCCCCC
P V X C f 0 B X t X 6 K S D P » I
c c c
P T X
14 0
cccccccccc
IPIPLLCXDK
C C C B I B II
2 R T L L 0 r
c c c c c » b a| 
BVFOISLr
^BaitBBBa
VTTBLFKOM
■■■■■■■■■a«* *
VXBB7LFIC IYLB
mu
f x r 
t 2 c
■■■■■■Ic
IKDVXBXZf S
C C C C C C C
1. T I K 0 1 T
CCCCCCCK
CTBBVXPQ
BBCCCCCXB 
IBKB S R K L I
KCCCCBBXKBCCC 
xopbxbx xrixri
■■■
tax
« • «
wai C « « I B ■
XX: ITCLSBCXrOH 
« • 0
B 1 X C B X XXBXBSVK
B C
T I
c c c c c
6 B T P V
Conf:
Pred:
Pred:
AA:
■E
CCCHHHHHHHHCCCCCCCCCCCCEEEEEEECCCCCCCCCC
MICVKNILKRYKNSPLNELRNNRKYYEGSFVKSIKFSTSN
10 20 30 40
Conf:
Pred: L _ ____
Pred: CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC EE EEE ECCC
AA: YGSNEKKPNDIEKNKNVSINLNEGNILQSEIYDTWIGGG
50 60 70 80
Conf:
Pred:
Pred:
AA:
31 ■E
HHHHHHHHHHHCCCCCCEEEEEECCCC CCCCCCCCCCCCC 
VTGTALFFLLSKFTNLKKLAIIERRDNFALVASHGKNNSQ
90 100 110 120
163
Conf:
Pred:
Pred:
AA:
Conf:
Pred:
Pred:
AA:
Conf:
Pred:
Pred:
AA:
Conf:
Pred:
Pred:
AA:
Conf:
Pred:
Pred:
AA:
Conf:
Pred:
Pred:
AA:
kiuml
CCCCCCCCCCCCHHHHHHHHHHHHHHHHHHHHCCCCCCCC
TIHCGDIETNYSFEKAKFIKRYADMLRNYLTNIPKEKREN
130 140 150
lllll
160
ml
________
CCCCCCCEEEEECCCCHHHHHHHHHHHHCCCCCEEEECCC
ISSVTQKMVLGVGEKECQFLEERYPVFRQLFNSMKLYNKD
170 180 190 200
|[
-J____ -
CHHHHCCCCCCCCCCCCCCCCEEEEECCCCCEECCHHHHH
DIHEVEPRVALKDSHTLREEQLSALYMPPELTTCDYQKLS
210 220 230 240
■IE
HHHHHHHHHCCCCCEEEECCCEEEEEEEECCCEEEEEECC
ESFIESARTVPNKTISINLLTEVINIEEVNDSLYKIHTNK
I !
250 260 270 280
jllllMlIlNllHlIllllllllllll.lllHHillE
EEEECCEEEECCCCCHHHHHHHCCCCCCCEEEEEEEEEEE
GIINSRFVWCACGHSLMIAQKMNYGLEYSCMPVAGSFYF
290 300 310 320
kmilliiMilllllliBiiliHiiiallilllllllE
ECC CCCCCCCCCCCCCCCCEEE E EEC EE ECCCC E EECCCC 
TDNILKGKVYTIQNPALPFAAVHGDPDIIEKGKTRFGPTA
330 340 350 360
164
Conf:
Pred:
Pred:
AA:
] wmmm[
CCCCCCCCCCCCCHHHHHHCCCCCCHHHHHHHHHHHHHHH
IPLPLLERDNIKTLLDFLKVWNPDLSLFQVYYNLFKDMTM
370 380 390 400
Conf:
Pred:
Pred:
AA:
]\
HHHHHHHHHHHHHCCCHHHHHHHHHHHCCCCCCCCCCCCC 
L KYVARN VLFEIPVLN KYLFL KDVKKIIPSLTIKOLTYCV
410 420 430 440
Conf*
Pred:
Pred:
AA:
Conf:
Pred:
Pred:
AA:
31 ,E
CCCCCCCEEEECCCCCEECCEEEECCCCEEEEECCCCHHH 
GYGGVRPQLIN KKSKKLILGEGKIDPGKNIIFNITPSPG A
450 460 470 480
IE
>
HCHHHHHHHHHHHHHHHHCCCCCHHHHHHHHHCCCCCCCC
TTCLGNGEFDMNTICERLNAKINKNDVKKYLYEGEYPVNY
490 500 510 520
Conf: 3IE
Pred:
Pred: C
AA: L
Legend:
- helix Conf: 3 1 1 1 f = confidence of prediction
= strand Pred: predicted secondary structure
= coll A/\: target seguence
Figure 5.6: The Amino Acid Sequence of the Putative PfMQO with Predicted Secondary 
Structure by PSIPRED
(A) Schematic of putative PfMQO residue prediction. The H stands for helix, C for coil and E for 
strand. The structural composition of the protein is predicted to be 26% helix content, 22% strand and 
52% coil content. (B) Grapical output of putative PSIPRED for PfMQO. The blue bars for each amino 
acid represents the confidence of each prediction. The taller the bar indicates the higher level of 
confidence. ‘Pink cylinder’ corresponds to a helix, ‘yellow arrow’ to a strand and ‘black line’to a coil 
and finally ‘ AA’ stands for the target sequence.
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(Table 5.1) were designed to facilitate cloning into the expression vectors pET-15b and 
pUC19. The two sets of primers incorporated restriction enzyme sites as follows: Nde\ and 
BamYil for pET-15b and Pstl and BamRl for pUC19. The putative PfLMQO gene and 
PfSMQO without leader sequence (signal peptide sequence) were amplified by PCR and 
yielded single amplicon of-1566 bp (LMQO) and -1529 bp (SMQO) respectively. Figure 5.8 
indicates that the PCR conditions have been optimised and primers are specific for the 
targeted gene. The size of the PfSMQO fragment is smaller than PfLMQO due to a deletion of 
the putative leader sequence from the putative PJMQO gene. The predicted putative leader 
sequence comprising “catatatgatatgtgttaaaaatattttgaaaagatataaaaatagtccg” nucleotides were 
predicted using Signal? 4.0 Server programme (www.cbs.dtu.dk).
5.3.3 Screening of Positive Clones of PfMQQ in 
TOP 10 E. coli host
The amplicons of the PJMQO gene were initially cloned to the Invitrogen pCR®II- 
TOPO® vector using the TOPO TA cloning kit (Invitrogen). TOPO TA cloning providing fast 
and efficient cloning strategies for direct cloning of the PCR products into a plasmid vector. 
Taq polymerase which was used in PCR reaction has added a single deoxyadenosine (A) at 
the 3’ ends of the PCR products thus facilitating the direct cloning into the T overhanging 3' 
deoxythymidine sites located in the multiple cloning site (MCS) of the linearised TOPO 
vector as shown in Figure 5.9. The cloning of PCR products into the TOPO vector created 
5,571 bp TOPO/PfLMgO and 5,529 bp TOPO/PfSMgO respectively.
The success of the PfLMQO and PfSMQO cloning were validated using restriction
enzyme analysis as described in section 5.2.13. White colonies from each transformantion
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M 1
12,216 bp-
2,036 bp- 
1,636 bp ■
1,018 bp
Figure 5. 8: Amplification of P. falciparum 3D7 MQO .
Agarose gel electrophoresis showing PCR amplification of putative PJMQO gene from P. falciparum 
3D7 Lane M contains 1 kb DNA molecular weight marker (Invitrogen), lanes 1, 2, 3, and 4 show the 
PCR products of PfpETLMQO, PfpETSMQO, PfpUCLMQO and PfpUCSMQO. Lanes 1-4 show a 
single band of size ~ 1.6 kb. The PCR products were visualised on a 1.2% agarose gel.
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Figure 5.9: Plasmid Map of pCR®II-TOPO® Bearing the P. falciparum MQO gene within 
the Multiple Cloning Site (MCS)
pCR®lI-TOPO® (Invitrogen) has been used to construct the recombinant PJMQO directly from a 
PCR reaction. The pCR®II-TOPO® Invitrogen vector is a 4.0-kb linearised vector with a overhanging 
deoxythymidine (T) residue at the 3’ ends to make it easy for the PCR products that possess single 
deoxyadenosine (A) at 3’ ends to ligate efficiently with the vector. The pCR®II-TOPO® vector 
contains a lac promoter to allow the expression of the lacZ gene gene which encodes the first 146 
amino acid of p-galactosidase. Interruption of lacZ by the insertion of PCR product may give rise to 
white colonies. The presence of both the kanamycin and ampicillin resistance genes in the vector 
allows for selection and maintainance in E. coli. The vector contains a fl origin of replication for 
propagation in E. coli. The vector also carries the T7 promoter and M13 forward and reverse priming 
sites for in vivo and in vitro transcription of sense RNA and sequencing of the insert. The plasmid map 
was generated using NetPlasmid software hosted by http://www.iustbio.com
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were picked and cultured overnight in LB medium containing 50 pg/ml ampicillin. The white 
colonies represent the recombinant lacZ gene with foreign DNA, whereas the blue colonies 
The recombinant plasmids were sent to Cogenics Ltd, UK for automated sequencing using 
their M13 primers. The positive PfMQO clones showed 100% identity when aligned with the 
published putative PfMQO gene sequence using the BLAST programme 
(http://blast.ncbi.nlm.nih.gov). The recombinant plasmids were designated as 
TOPO/pETPfLMQO, TOPO/pETPfSMgO, TOPO/pUCPfLMQO and TOPO/pUCPfSMgO.
5.3.4 Subcloning of TOPO/pET and TOPO/pUC 
(PfLMQO and PfSMQO) into pET-15b and pUC19 
Expression Vectors
The plasmids TOPO/pETPfMQOs and TOPO/pUCPfMQOs were subcloned into 
pET-15b and pUC19 expression vectors. This was carried out by double digestion of the 
plasmid to excise the MQO fragment from the TOPO vector and subsequent ligation to the 
appropriate vector (pET-15b or pUC19). The TOPO/pETPfMQOs were double digested using 
Me\ and Barrim, whilst the TOPO/pUCPfMQOs were digested with Pstl and Barrim. Figure 
5.10A shows the results of the digests with DNA fragment size of ~4.0 kb and ~1.6 kb 
corresponding to the pCR®-TOPO vector and PfMQO fragments respectively. Figure 5.1 OB 
shows the 3 DNA fragments - 4.0 kb, ~ 1.6 kb and 1118 bp that corresponding to bands 
corresponding to pCR®-TOPO vector, PfMQO and the second Pstl restriction site within the 
pCR®-TOPO vector. All clones were produced expected band size in agreement with the 
predicted DNA fragment size generated using NEBcutter V2.0 programme 
(tools.neb.com/NEBcutter2). The DNA fragments were excised, as described in section 5.2.14 
from 1.2% agarose gels and pooled together in order to achieve a higher concentration of the 
PfMQO gene. The PfMQO fragments from pETPfLMQO and pETPfSMQO were ligated to
linearised pET-15b and PfLMQO and pUCPfSMQO to pUC19 expression vectors.
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Figures. 10: Restriction Enzyme Digestion Analysis of Transformed Colonies of 
pCR®II-TOPO/PfMQO
Panel A: Lanes 1 TOPO/pETPfLMQO and lane 2 TOPO/pETPfSMQO produced 2 bands of 
approximately ~4 kb and ~1.6 kb corresponding to pCR®-TOPO vector and PfMQO fragment 
respectively when digested with Nde\ and BamW\. Panel B: Lane 2 and 3 are undigested 
TOPO/pUCPfLMQO and TOPO/pUCPfSMQO. Lanes 4 and 5 contain digested TOPO/PfLMQO and 
TOPO/PfSMQO, respectively. The digest used Pst\ and BamW\ and produced 3 bands sizes of —4 kb, 
—1.6 kb and —1118 bp corresponding to pCR®-TOPO vector, PfMQO and the second Pst\ 
restriction site within the pCR®-TOPO vector. Lanes designated M contain 1 kb DNA ladder 
(Invitrogen)
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The ligation of the expression vector and plasmid was described in section 
5.2.16. The ligated plasmid and insert created the 7274 bp and 7229 bp plasmids (pET- 
15/pETPfLMQO and pet-15b/pETPfSMQO) respectively and 4257 bp and 4218 bp plasmids 
(pUC19/pUCPfLMQO and pUC19/pUCPfSMQO) respectively. The DNA fragment of 
PjMQO was cloned between the restriction sites of Ndei and BamRl for pET-15b and Pstl 
and BamRl for pUC19. The cloning of the insert into the vector is diagrammatically 
illustrated in Figure 5.11 (pET-1 b) and Figure 5.12 (pUC19).
The ligation reactions were transformed into E. coli TOP 10 cells as described in 
section 5.2.16, and plated on LB agar plates containing 50 pg/ml ampicillin which were 
incubated overnight at 37 °C. Colonies were picked and subjected to overnight culture 
followed by miniprep DNA isolation. Figure 5.13A shows results of the positive colonies of 
pET/PfLMQO and pET/PfSMQO that produced 3 bands sizes -4229 bp, -1897 bp and -1153 
bp, and -4229 bp, -1855 bp and -1153 bp respectively when digested with EcoRV. Figure 
5.13B the positive clones of pUC/PfLMQO and pUC/PfSMQO produced 2 bands of 
approximately 3253 bp, 1004 bp.and 3243, 965 bp respectively when digested with Sphl. 
Positive clones were processed for glycerol stock cryopreservation. The positive recombinant 
plasmids were designated as pET/PfLMQO, pET/PfSMQO, pUC/PfLMQO and 
pUC/PfSMQO.
5.3.5 Transformation of pET/PfMQOs and 
pUC/PfMQOs into BL21 (DE3)pLysS E. coli
The positive recombinant plasmids were subjected to transformation into the 
expression E. coli BL21(DE3)pLysS cells. E. coli BL21(DE3)pLysS cells are under the 
control of T7 promoter expression system which allows higher protein expression. This strain
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Nde\ Bom HI
Met
pET-15b 5 'CA TATG
Stop
TGACCTAGG 3'
\
His tag
Terminator
t o n i n
pET/PfLMQO 
7274 bp
pET/PfSMQO 
7229 bp
Figure 5.11: Schematic Representation of the pET-15b Expression Vector Bearing P. 
falciparum MQO gene
The pET-15b plasmid contains a T7 promoter region, a lacl gene, a sequence coding for six 
histidine residues and an ampicillin resistance gene that enables selection. The plasmid 
construction was carried out by excising the PFMQO from pCR®II-TOPO® vector and ligated into 
Nde\ and Bam\\\ restriction sites under the control of T7 promoter. The sucessfull of the PfMQO 
cloning into the expression vector, yielding the N-terminal His-tagged recombinant protein.The 
plasmid map was generated using NetPlasmid software hosted by http.7/www.iustbio.com.
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pUC19
x
5 2 c 73
5 ^ .Q. O 
QQ 0-1 v
fVl et Stop
pUC/PfLMQO 
4257 bp
pUC/PfSMQO 
4218 bp
Figure 5.12: Schematic Representation of the pUC19 Expression Vector Bearing P. 
falciparum MQO gene
The pUC19 plasmid contains a lacZ gene which has similar features to pCR®II-TOPO® vector. The 
presence of the lacZ gene allows recombinants to be selected by blue/white screening. pUC19 also 
possesses the ampicillin resistance gene (Apr) that enables selection. The plasmid construction was 
carried out by excising the PfMQO from pCR®H-TOPO® vector and ligating into the pUC19 multiple 
cloning sites (between Pst\ and BamW\ restriction sites). The plasmid map was generated using 
NetPlasmid software hosted by http://www.iustbio.com.
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carries both the DE3 lysozyme and the plasmid pLysS. DE3 consists of T7 bacteriophage 
gene I encoding T7 RNA polymerase under the control of the lac UV5 promoter. pLysS 
carries the gene encoding for T7 lysozyme which lowers the expression level of recombinant 
genes by inhibiting basal level of T7 RNA polymerase but does not affected the expression 
level of recombinant protein following induction by IPTG. The transformants were plated 
onto the LB agar plate consisting 25 pg/ml chloramphenicol and 50 pg/ml ampicilhn. The 
same procedure was repeated where single colonies were picked and used to inoculate LB 
broth consisting 50 pg/ml ampicillin and 25 pg/ml chloramphenicol and subjected to 
minipreps preparation. Results from Figure 5.14A show that the positive pET/PfLMQO and 
pET/PfSMQO clones produced 3 bands of approximately 4229 bp, 1897 bp and 1153 bp, and 
4229 bp, 1855 bp and 1153 bp respectively when digested with EcoRV. Whilts m Figure 5.14B 
positive clones for pUC/PfLMQ and pUC/SMQO produced 3 bands of approximately 2079 
bp, 1224 bp and 954 bp and 2079 bp, 1185 and 954 bp when digested with4/ZIII.
5.3.6 Transformation of Pet/PfMQOs and 
PUC/PfMQOs into E. coli Rosetta (DE3) pLysS
The positive recombinant DNAs were retransformed into E. coli Rosetta (DE3) after 
expression in BL21(DE3) pLysS cells was not detectable. The ‘maxi prep’ preparations were 
carried out to get the highest purity and concentration of plasmids. The same screening 
procedures were carried out as described in section 5.2.13. Figure 5.15A and 5.15B produced 
similar results as described in section 5.3.5. Restriction enzyme analysis using Sphl was 
carried out and from the finding showed that the positive clones of pUC/PfLMQO and 
pUC/PfSMQO produced 2 bands with approximately 3253 bp, 1004 bp.and 3243, 965 bp
respectively.
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12,216bp 
4,072 bp
M 1 2
(A)
2,036 bp 
1,636 bp
^ ^ i % ,
(B)
12,216bp- 
5.090 bp- 
3.054bp- 
2 036bp-
1,018bp-
506 bp-
Figure 5.14: Screening of Positive Clones of pET-15b and pUC19 Transformed into 
BL21 (DE3) pLysS E. coli
Panel A; Lanes 1 and 2 consist of pET/PfLMQO and pET/PfSMQO. The positive clones for 
pET/PfLMQO and pET/PfSMQO produced 3 bands of approximately 4229 bp, 1897 bp and 1153 bp, 
and 4229 bp, 1855 bp and 1153 bp respectively when digested with EcoRV. Figure B; lanes 1 and 2 
consist of undigested pUC/PfLMQO and pUC/PfSMQO. The positive clones for pUC/PfLMQO and 
pUC/PfSMQO (lanes 3 and 4) produced 3 bands of approximately 2079, 1224 bp, 1224 bp and 2079 
bp, 1185 bp, 954 bp respectively when digested with AfRW. Lanes designated M contain 1 kb DNA 
ladder (Invitrogen).
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5.3.7 Expression Studies of PfMQOs in E. coli 
Rosetta (DE3) pLysS
Small scale cultures of positive clones selected from restriction enzyme analysis were 
subjected to 1-mM IPTG induction at 30 °C to express the predicted ~60 kDa PfMQO protein. 
Immunodetection using monoclonal anti-polyhistidine antibody as primary antibody followed 
by secondary antibody horseradish peroxidase (HRP) anti-mouse Ig antibody (Nordic 
Immunology) was carried out to determine the expression of recombinant PfMQO in both 
pET-15b and pUC19 expression vectors. Figure 5.16 (lanes 1 and 2) show both PfLMQO and 
PfSMQO cloned into pET-15b expression vector were producing a band ~ 60 kDa as analysed 
on a 10% SDS-PAGE. From Figure 5.18 it is also evident that PfSMQO was less expressed 
compared to PfLMQO.
5.3.8 Solubility Studies of PfLMQO and PfSMQO 
Recombinant Proteins
The solubility assay of the proteins was carried out to determine the presence of 
overexpressed protein in a soluble fraction, insoluble fraction or in the form of an inclusion 
body. The fractions of soluble material, insoluble material and inclusion bodies of 
homogenised E. coli Rosetta cells producing PfLMQO and PfSMQO were analysed on a 10 ^ 
SDS-PAGE and stained with InstantBlue ™ (Expedon) stain. Results from Figure 5.17 shows 
the expressed proteins are found exclusively associated with the insoluble fractions (i.e. in the 
pellet fraction and in inclusion bodies). Inclusion bodies are insoluble and biologically 
inactive aggregates of partially folded protein. This is frequently seen when a recombinant 
protein is overexpressed either in the cytoplasm or periplasm of the E. coli bacterial host. This 
is usually associated with high initial expression of the protein thus forming a homogeneous 
aggregate of the overexpressed protein.
178
(A) (B)
Ml 2 3 4
1 2,216 bp ■
4 ,072 bp 
3.054 bp
2,036 bp 
1,636 bp
1,018 bp - 
506 bp-
Figure 5.15: Screening of Positive Clones of pET-15b and pUC19 Transformed into 
Rosetta (DE3) E. coli
Panel A; Lanes 1 and 2 consist of pET/PfLMQO and pET/PfSMQO. The positive clones for 
pET/PfLMQO and pET/PfSMQO produced 3 bands sizes 4229 bp, 1897 bp and 1153 bp, and 4229 bp, 
1855 bp and 1153 bp respectively when digested with EcoRW. Figure B; lanes 1 and 2 consist of 
pUC/PfLMQO and pUC/PfSMQO. Lanes 3 and 4 represent the positive clones of pUC/PfLMQO and 
pUC/PfSMQO produced 2 bands of approximately 3253 bp, 1004 bp.and 3243, 965 bp respectively 
when digested with Sph\. The positive clones for pUC/PfLMQO and pUC/PfSMQO produced 3 bands 
approximately 2079, 1224 bp, 1224 bp and 2079 bp, 1185 bp, 954 bp respectively when digested with 
AjRW. Lanes designated M contain 1 kb DNA ladder (Invitrogen).
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1 2
Figure 5.16: The Expression Study of PfMQO
Lanes 1 and 2 consist of pET/PfLMQO and pET/PfSMQO expressed in E. coli Rosetta . The ~ 60 kDa 
proteins were visible in the pET-15b expression system after immunodetection with monoclonal anti- 
oligohistidine antibody.
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5.3.9 Time, Temperature and IPTG Induction 
Studies of Recombinant PfLMQO and PfSMQO in 
E. coli Rosetta (DE3) Cells
Time, temperature and IPTG induction studies of recombinant PfLMQO and PfSMQO 
expressed in the pET-15b system were carried out to determine the optimal post-induction 
duration, temperature and IPTG concentration as described in section 5.2.24. The bacterial 
cells were grown in LB broth containing of 50 pg/ml ampicillin and 25 pg/ml 
chloramphenicol. The cells were grown at three different temperatures (22, 30 and 37 °C), 
and two IPTG concentrations (0.5 and 1 mM). SDS-PAGE gels stained with InstantBlue ™ 
(Expedon) stain exhibit the recombinant PfLMQO protein in the insoluble fraction. A band of 
~60 kDa became visible after 3 hours post-induction at all temperatures and IPTG 
concentrations (Figure 5.18A). However, the level of protein expressed is less at the 0.5 mM 
IPTG concentration at all temperatures. An IPTG concentration of 1 mM and a post-induction 
time of 3 hours were found to be optimal for the maximal expression of PfLMQO. This is 
shown by the appearance of bands of ~ 60 kDa with higher intensities compared with other 
protein bands after eletrophoresis onto a 10% acrylamide SDS-PAGE (Figure 5.18A). The 
level of expression started to decline after 5 hours incubation (Figure 5.19A) and the protein 
was completely degraded after overnight incubation (Figure 5.20A) in all test conditions. At 
the same time, results on the expression level of PfSMQO shown the recombinant PfSMQO 
protein is less compared to PfLMQO. This is shown in Figure 5.18B and Figure 5.19B which 
the protein band ~60 kDa is barely visible compared to PfLMQO. This is observed in 
different temperatures and IPTG concentions.
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(A) (B)
M 1 2 3 M 4 5 6
260kDa.
Figure 5.17: Solubilty Study of PfLMQO and PfSMQO
Solubility study of PfLMQO and PfSMQO grown at 30 °C with 1 mM IPTG. Panel A (PfLMQO) : 
Lane 1, soluble fraction, lane 2, insoluble fraction and lane 3, inclusion body. Panel B (PfSMQO) : 
Lane 4 insoluble fraction, lane 5 inclusion bodies and lane 6 soluble fraction. Lane M, protein 
molecular weight Spectra Broad Range Protein marker (Fermentas). The recombinant protein’s ~ 60 
kDa are clearly visible in the lanes containing insoluble fractions and in the inclusion body preparation 
of PfLMQO. The recombinant protein ~ 60 kDa is clearly visible in the inclusion body preparation and 
only a small band of the expected protein size is present in the insoluble preparation of PfSMQO. It 
clearly shows that the ~ 60 kDa recombinant protein was not detected in soluble fractions of either 
PfLMQO or PfSMQO.
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5.3.10 Purification of PfLMQO Recombinant 
Protein
The PfLMQO recombinant protein was expressed in Rosetta E .coli cells grown in LB 
medium consisting 50 |ig/ml ampicillin and 25 pg/ml chloramphenicol. The expression of 
protein is under the control of T7 promoter in the pET-15b plasmid. The pET-15b vector 
carries a oligo-histidine (His-tag) sequence which is located at the N-terminus of purified 
protein. Most His-tag purification systems work efficiently with 6xHis-tagged proteins under 
denaturing and native conditions in low or high salt buffers. The protein binding to Ni-NTA 
matrices can be eluted by imidazole. Low concentration of imidazole are suggested to reduce 
non-specific binding of host proteins with histidines. From the SDS-PAGE gels (Figure 5.21 
A and B) the PfLMQO was not purifiable using a Ni-NTA column (Qiagen). No single band 
size ~60 kDa is visible from eluted samples from either soluble or insoluble fractions loaded 
as seen on lane S8 and lane S9 (soluble fraction) and P8 and P9 (insoluble). The clear 
recombinant protein bands were detected from the pellet preparation which is presented at the
at the positions C2 adn P3.
Based on this finding, purification under denaturing conditions was carried out. The 
purification under denaturing conditions was started by inclusion bodies preparation from the 
insoluble fractions of the bacterial cells. The inclusion bodies preparation was described in 
section 5.2.28. The SDS polyacrylamide gel (Figure 5:22) shows the PLMQO purified from 
inclusion bodies under denaturing condition. As shown, ~ 60 kDa protein bands were evident 
in eluted samples El and E2 of the inclusion body preparation. Using a strong denaturant such 
as 6M GuHCl the N terminal 6xHis tag of the recombinant protein is exposed thus improve 
binding of the protein to the Ni-NTA matrix. Therefore, improving the efficiency of the
purification and potential nonspecific binding is minimised.
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5.2.11 Measurement of MQO Activity
The enzyme activity study of recombinant PfMQO and the native form of MQO were 
measured spectrophotometrically using direct and indirect enzyme assays as described in 
section 5.2.31. The direct assay was performed to monitor the level of Q1 reduction measured 
at 23 nm. The Q1 reduction is not measurable for either PfLMQO or MQO protein expressed 
in E, coli cells. Following this, the indirect linked assay was performed to measure the Q1 
reduction by indirectly measuring the reduction rate of DCPIP. The results produced by this 
assay were very inconsistent when the same parameter was repeated.
5.4 Discussion
Malate quinone oxidoreductase (MQO) is a dehydrogenase enzyme presumably 
located in the inner mitochondrial membrane of P. falciparum. MQO is involved in the 
respiratory chain of the Plasmodium mitochondria and donates electrons to co-enzyme Q 
using FADH2 as a co-factor. Recently a study conducted by Olszewski et al. (2010) showed 
the role of MQO in the branched architecture of the Plasmodium TCA cycle. MQO has been 
demonstrated as an enzyme which reduces OOA to malate.
PfMQO has been partially characterised using bioinformatic and genomic approaches. 
The characterisation of PfMQO was performed using computational analysis due to the 
absence of direct evidence of PfMQO protein. The characterisation of PfMQO started with 
prediction of the open reading frame (ORF) of the putative PfMQO sequence which is 
available from PlasmoDB. This was followed by prediction of the molecular weight and the
187
o
r<->
O
HCu
-a
c
o
o
u
I/)
O'
C/5
^ c 
CQ .2
•O =3 
§ ^
— ic:
oo
C/5
X>
3
CJ
c
o
CO
3
o
£
o
'3-
a.
_D
3
P .2 o
Q-
Q \=
X3
3
-ac
O'a.
-o
c
3
OO
Cl
O'"
C/5
oo'
C/5
0)cKJ
-o
0)-a
a
o
JD
a.
E
-oco
U
a
S3
Z
uSJ
-3
C
3
■3
13
*n
3
C-
O
a
_a> QJ
X5
3
2 <-o
<u
E
03
c
£
o
1-00
<u
o
3
(L)CO
O
(3
O
c
T3
<U
-O
3
•o
cc3
O •-
.E
<N ^ 
O o
X) 
_3
13 S 
§ .2 
Cl
a>>
-4—*
o
(Ua.
CN
P
CQ
13
c
3
CL
C'i
c3
r-
C/5
-occd
cd
'O
C/5
T3
B
_3
0)
E
Ct-
■o
<D
a>
-a
CO
cd
£
"O
c
cd
JO
COc
o
32
C'i
<u
_3
a>
t^-
Q,
"Oc
cd
a>u,
_s_>
_3 J=CO
<L)
L—i CL O 3 3o X CO o a>
C/i
t/3
<D L-
O
c
-C VO
Cl
>> _c r.*3 _c ‘a3>-•o o mJZ’534—* i_Cl •^r cocd
P
oi_
o.o
tD
<U
CO
CO
C/5
<u
ed
£
r~-~
CL
<
Cm
1
a cd
ico
CO
<N
x:
C/5
Q
C/3
d
CL VO
Id
‘m
<u <—>
C
cd
«+-
O
o
cd
X)
VO
CL
1/5
c
3
c
_o mC/5 -
0/
L.
E
o
*3
cdo C
x:CO
c33
.Sf
<u £*C
3
O
*-»
_3
Z
cn
bM < CL <U CL Sp
ec
tra
 br
oa
d r
an
ge
 pr
ot
ei
n m
ar
ke
r. T
he
 ~6
0 k
D
a b
an
ds
 w
er
e v
isi
bl
e in
 lan
es
 co
nt
ai
ni
ng
 in
so
lu
bl
e f
ra
ct
io
n (
C2
) a
nd
 ce
ll ly
sa
te
 sa
m
pl
e (
P3
) in
di
ca
tin
g t
ha
t th
e 
Pf
LM
Q
O
 pr
ot
ei
n i
s n
ot
 pu
rif
ia
bl
e u
nd
er
 n
at
iv
e c
on
di
tio
ns
.
CO
GOC t3‘CQ
"Oco
U
WD_C
3-w
c<U
Q
o>
*3
C
3 <uCu 0)"O D.
■o
o <Dc/l-EC/l 'E
CQ a>00
-o oc £3 o
< XI«4-
13 oc3 cQ- 3
0 3Co <uO Q.m 3
3 c/l
o CQ
H —Cu“ _o
13
E Q-_ _ *3
£oc
3
m
m
13ccGCu
c
E
_3
Oo<
GOC
T3c3O
<U -C
'c> 0) 
GO£ o 
3 E
^ CM 
cqcP ~
0)X)
CQ
o'OltA-occdD
h~
ula>
cd
E
_c
'oj
O
<u
GOCcdL.
-ocdOi—JD
cdu.■*->o<uQ.oo
c/i(U •—r;O
<u
-accdwCcd•4—•cdcI—(UD.3c/l
£o
-a(U-acdo
E3
•5<i)
E
CQ XI3
— O c J2 
£ •£ o
GO
<ua.
T3<U*ac<DQ.
c/l
LQ
CQ
-occd
x: 3
■^r~ oq CQ — UJ
CQ
3 a> < t .
c o3 13
c
3
<N
a
£
3uC/lo
c30-
3
E<U
QOc3
d
Oh
•3Q>
cti
oo
c/5a>
'-5oX)
CL3c/l
tro
s
tN
CQ
IS kq c —T
c o < X
3
C-
Cm
*o(Uc/lc/l
_3
oc
cPqQ3
c/l3
£
o
C/l
<U
CuX
«Mo
X
X
5
CQ<u C/l
.£
'I ‘ 1
fi
c/l3 '534—*o cCD
■§)3
< _C Cl E Ol_
w
o
'S
oCa
"3<UGO
3
g
Xa—*
< a. 60 o
Oh O 3*-> IDc3 CQ
CO a Jo 3 "Oc
a.
Ecd
c/l
Eo
-ac
cdxi
<L>x:
H
a.
E
cd
c/l
■a<D
~oc
cd
"OOx>
co
c*-o
a>a.
-a<u-o
cdo
a.
E3
Q
co
fN<S
<yi-
3GO
X>
Eoo4>
C£i
ffiXVO
C4->o
co’■*->
cdo
HE*c
3a.
a>a.
-oo
Oo<uwi
<N
CQ
I 4 ><i>b.3
3
QXi w
as
h sampl
es
. This 
in
di
ca
te
s the 
in
cl
us
io
n body 
de
riv
ed
 PfLMQ
O
 is su
cc
es
sf
ul
ly
 purified
 under 
de
na
tu
rin
g condi
tio
ns
isoelectric point of the protein using the amino acid sequence of the PfMQO. The final 
destination of the targeted protein was predicted using PFMpred and PlasMit softwares that 
was mainly invented to predict the sublocation of plasmodial protein. PFMpred is using 
Support Vector Machine (SVM) model to predict Plasmodium membrane proteins type based 
on split amino acid composition (SAAC) and position-specific scoring matrix (PSSM) profile 
therefore offering better prediction results (272). Another prediction system (PlasMit 
prediction system) is used a neural network system that predicts the subcellular P. falciparum 
protein (Bender 2003) location based on the relative frequencies of amino acids in different 
regions. The probability of PfMQO targeting the mitochondria was compared to two other 
known Plasmodium proteins; PfALAS and PfMDH. Selection of controls is based on known 
subcellular location of Plasmodium proteins from selected publications which predicted that 
the PfALAS located in Plasmodium mitochondrial membrane (270) and PfMDH is a 
cytoplasmic protein (213). Both results (PFMpred and PlastMit) predicted that PfMQO is 
located in Plasmodium mitochondrial membrane with the probability SVM score and RJ of 
1.30 and 91% respectively. Therefore, these analyses indicate that PfMQO is likely a 
mitochondrial protein. This result is in agreement with 2 control proteins where PfALAS 
(positive control) SVM score was 0.96 and 91% R.I showing that the PfALAS protein is 
probably located in the mitochondrial subcellular membrane. Whereas, the negative control 
showed a 0.0 SVM score and a 99% R.I showing that PfMDH is 99% not a mitochondrial
protein.
Determination of membrane protein topology is a fundamental aspect in the process of 
characterisation of unknown protein. However, the prediction of membrane domains only 
provides the structural predictions e.g number of transmembrane segments and their 
orientation across the membrane. The topology of PfMQO was carried out using TMHMM,
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Split 4.0 server software. This programme is based on a hidden Markov model algorithm that 
predicts the location of the transmembrane topology of targeted protein with 97-98% accuracy 
(137). Figure 5.5, shows the graphical presentation of predicted transmembrane helices results 
of PfMQO in comparison with PfDHOODH and PfPSD proteins. This result showed that the 
probability score of PfMQO was less than 0.7 compared to PfDHOODH and PSD probability 
scores. The probability score for PfDHOODH (positive control) was close to 1 and 0.6 for 
PfPSD (negative control). Therefore, it is clearly demonstrated that the PfDHOODH is most 
likely the integral protein while PfMQO and PfPSD are most likely non-membrane proteins. 
This prediction result has been supported by secondary structure prediction using PSIPRED 
software indicating the presence of alpha helices, beta sheet and coil although no 
trasmembrane helices were predicted. These bioinformatic data indicate that PfMQO is not an 
integral mitochondrial membrane protein but most likely a peripheral membrane protein. The 
peripheral membrane protein is often found in close association with integral membrane 
protein (100). As a peripheral membrane protein, PfMQO is associated with the membrane 
but does not penetrate the hydrophobic core of the membrane. Part of PfMQO is exposed to 
mitochondria matrix and part of it is bound to the mitochondrial membrane. Hence, this 
protein can be removed without the disruption of the membrane structure. This is in 
accordance with study conducted by Molenaar et al. (1998) which demonstrated that the 
MQO is a peripheral mitochondrial membrane protein in G glutamicum.
From the multiple alignment of the putative PfMQO amino acid sequence it is 
indicated that the PfMQO is highly conserved within the Plasmodium genome with 85% 
similarity to putatitive PvMQO and putative PyMQO, 74% to putative PcMQO and 75% to 
putative PkMQO.
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It has also been demonstrated that the PfMQO has low similarity to prokaryotes MQO 
(less than 10% similarity to EcMQO and MsMQO). This low similarity provides major 
advantages for future characterisation of the protein expressed in the prokaryotic host system.
In this study, the putative PfMQO genes (PfLMQO and PfSMQO) were 
successfully amplified using designated primers. PfLMQO and PfSMQO fragments produced 
band sizes approximately 1566 bp and 1529 bp respectively. Result on the agarose gel 
showed that the DNA fragment size of PfSMQO was sligltly lower than PfLMQO. This is due 
to the absence of the leader sequence from the putative PfSMQO gene sequence. The 
expecting leader sequence was carried out using SignallP 4.0 programme. The prediction 
result showed that the signal peptide cleavage site was located at N-terminus (1-37 amino acid 
sequence) of the putative PfMQO. The forward primer for PfSMQO was designed to start at 
the start codon (ATG) located at the end terminus of the expecting leader sequence. In 
general, the role of the leader sequence coding region is involved in the stability of the mRNA 
and for its efficient translation. The Plasmodium mitochondrial and apicoplast genome are 
generally encoded by nuclear genes and the products are targeted into the organelles (82, 169, 
269). Nucleated synthesised proteins must be imported into the mitochondria via various 
pathways. The most common pathway is through an N-terminal leader peptide or presequence 
(96, 269). The leader protein signal eventually will be removed by the action of a 
mitochondrial processing protease (MPP) once the protein reached the mitochondrial matrix. 
From this study, it is shown that the absence of leader sequence in the putative PfSMQO gene 
does affect the level of the expression recombinant protein as shown in Figure 5.17. The 
removal of leader sequence from the putative PfMQO gene does affect the expression of the 
recombinant protein. Figure 5.19 shows that the band size of ~60 kDa appear clearly on SDS- 
PAGE for PfLMQO and less for PfSMQO. The molecular mass size of the protein calculated
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using Protparam indicated that the size of PfSMQO is 57 kDa less 2 kDa than PfLMQO (59 
kDa). However this was not obviously seen on the SDS-PAGE gels in solubility studies.
To produce recombinant PfLMQO and PfSMQO in E. coli, the PfMQO genes were 
cloned into pET-15b and pUC19 expression vectors. The constructs for PFLMQOs and 
PfSMQOs for the pET-lb vector were fused to an oligo-histidine tag at the N-terminus which 
facilitates purification. The rationale of using 2 different expression systems is to optimise the 
translation of the protein under different promoters. The pET-15b possesses a T7 promoter 
whilst pUC19 has a lac promoter. The pET system is the most powerful system developed for 
the cloning and expression of recombinant proteins in E. coli. This system has been provided 
with a strong bacteriophage T7 promoter which controls the translational and transcriptional 
process of the inserted gene. The expression of the targeted protein is controlled by host T7 
RNA polymerase which under the control of laclJV gene which inducible by addition of 
IPTG. This system has a capability to produce up to 50% of the total protein after a few hours 
post induction. Unlike in pET-15b, the expression of recombinant PfMQO in pUC19 was 
controlled by the lac promoter. PfLMQO and PfSMQO DNA segments were inserted in­
frame with lacZ gene and expressed as a fusion protein consisting a portion of the beta- 
galactosidase. Similarly to lacUV gene in pET-15b, lacZ gene is also inducible with IPTG. 
However the expression studies of the PfLMQO and PfSMQO using pUC19 expression 
vector did not show satisfactory results.
Two E, coli hosts, BL21 and Rosetta, have been used in this study. The
PfMQO recombinant proteins were not expressable in BL21 cells. Therefore, the constructed
PfMQO clones were retransformed into E, coli Rosetta. Substantial expression of PFLMQO
was obtained in the E. coli Rosetta (DE3) strain, which is specifically engineered to enhance
expression of eukaryotic proteins containing codons rarely used in E. coli. The western blot
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result shows that the recombinant his tagged PfLMQO and PfSMQO cloned in pET-15b 
plasmid were reacted with IgG anti-His antibodies This show the recombinant PfMQO 
proteins were successfully expressed in pET-15b under controlled of T7 promoter.
The solubility tests were carried out to determine the optimum conditions of the 
expressed protein by checking at various times after induction. Intracelluar protein content is 
often a balance between the amount of soluble protein in the cells, the formation of inclusion 
bodies and protein degradation. The recombinant proteins were detectable after 3 hours 
incubation and slowly degraded after 5 hours post IPTG induction in all conditions. This 
suggests the optimum temperature for PfLMQO expression is 30 °C - 37 C with 1 mM IPTG, 
Meanwhile the bacterial growth at 22 °C showed no overproduction when induced with 0.5 
mM or 1 mM IPTG. The temperature is a crucial element in the expression and the solubility 
of the recombinant protein. Growth at lower temperature will reduce expression levels but 
will lead to solubility of the protein. The overnight cultures did produce recombinant protein. 
This is in accordance with finding from study conducted by (267) which showed that the 
MQO protein is active only during exponential growth, and when the cells reach stationary 
phase, it appears to be broken down.
Molenaar et al. (1998) demonstrated that C. glutamicum MQO is identified as a 
mitochondrial membrane bound protein that can be released from the membrane by addition 
chelator. .Part of the enzyme is embedded in inner mitochondrial membrane and the other part 
is in the matrix of mitochondria. As intracellular membrane proteins, the proteins are 
frequently sequestered into insoluble inclusion bodies. As shown in Figure 5.17 both 
PfLMQO and PfSMQO were found associated with inclusion bodies. This is possibly due to 
overloading of the folding pathway during over-expression of the protein or the hydrophobic
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interactions between protein chains which increase the probability of mis-folding. The 
proteins solubility was predicted using a programme developed by Wilkinson and Harrison in 
the year 1991 (http:www.biotech.ou.edu) (282), showed that the PfLMQO and PfSMQO 
recombinant proteins had 89.3% and 86.6% chance of formation of inclusion bodies 
respectively when over expressed in E. coli. Protein solubility increases with increasing net 
charge (positive and negative). Consequently turns in the protein structure are most difficult 
to form. The high concentration of residues forming turns may be indicative of slow folding 
protein. A traditional approach to improve the solubility of recombinant protein involves 
reducing the synthesis rate of target gene product by decreasing the IPTG inducer and cell 
growth at lower temperature (227). However, the use of low temperature affects the 
transcription and translation rates therby reducing the strength of hydrophobic interactions 
that contribute to protein mis-folding (13).
From the results in this study, the PfMQO recombinant proteins were obviously 
associated with inclusion bodies. Figure 5.17 shows the protein is purifiable under 
denaturating conditions and the bands sizes ~ 60 kDa appeared on a 10% SDS-PAGE gels. By 
introducing strong denaturants such as 6 M GuHCl, 8 M urea and variety of detergents such 
as Triton™ X-100, NP-40, dodecyl p D-maltoside and octyl p D-glucoside in combination 
with reducing agents such as 20 mM DTT or p-mercaptoethanol it may greatly improve the 
solubility of the proteins. Mostly proteins purified under denaturing conditions are in the 
inactive form. Therefore, dialyzing process needs to be carried out in order to remove their 
denaturants and refold the proteins back into their active states.
The optimal conditions for solubilisation have to be determined by varying the pH and ionic 
strength of the denaturants and reducing agents in the washing buffer. The growth 
temperature is also important to minimise the formation of inclusion bodies. As mentioned
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earlier growth at lower temperature will improve the solubility but reduce the degree of 
protein expression. The optimisation will take some time due to the distinctive character of 
each protein. Due to the limitations of time, this work had to be stopped at the purification 
under denaturing conditions. Further purification trials are currently being carried out in our 
laboratory to overcome the problem of formation of inclusion bodies by using different 
growth temperatures and IPTG concentrations.
The attempt to measure the activities of the PfLMQO was performed using 
membrane preparations of E. coli Rosetta cells. The reduction of Q1 was indirectly measured 
by measuring the reduction rate of DCPIP. However, we are unable to generate the consistent 
findings due to the data irregularity using the same parameters (data not shown). The 
explanation behind this is possibly due to the protein existing in inclusion bodies. A previous 
MQO kinectics study conducted by Molenaar et al. (1998) demonstrated that the reduction of 
DCPIP was recorded using partially purified recombinant C. glutamicum. The C. glutamicum 
MQO gene of is cloned and expressed in the MQO negative C. glutamicum strain. The 
specific activity of the recombinant MQO enzyme activity was four-fold higher (5-10 pmol 
DCPIP reduced/ nmoLmin1 .mg^protein) compared to membrane preparation from wild type 
C. glutamicum. The presence of inclusion bodies is not documented. From their study it was 
also suggested that the usage of EDTA or ethylene glycol tetraacetic acid (EGTA) in the assay 
buffer strip off the enzyme thus affected the MQO activity. Mark et al. (2004) also 
demonstrated that the combination of EDTA and Mg2+ inhibited enzyme activity of Exoli 
NADH dehydrogenase. EDTA disrupts the outer membrane of E, coli cells by removing 
positive charges, causing the negatively charged heads of the phospholipids to repel each 
other (117, 163). Then, the lysozyme is able to access the peptidoglycan to cleave the Cl N-
196
acetyl muramic acid (NAM) to C4-N-acetyl glutamic (NAG) glycosidic linkage thus causing 
cell lysis.
In conclusion, the characterisation of the putative PfMQO is partially complete using 
the bioinformatic approaches and also from the direct evidence through molecular and 
biochemical data. The primary and the secondary structure of PfMQO are solely dependent on 
the bioinformatics data. However, this data must be interpreted carefully. Bear in mind that it 
is only prediction and as we understand with all predictions, accuracy can be highly variable. 
Functional characterisation such as crystallography study, NMR, mutagenesis and the 
susceptibility of the protein to proteolytic enzymes have to be carried out in order to directly 
characterise this protein. The successful expression of the PfMQO in E. coli is a good start, 
but the existence of the PfMQO in inclusion bodies is a major obstacle which has to be solved 
before the other studies can be performed.
Finally, PfMQO is a good target to study for new antimalarial drugs which target 
malarial mitochondria. The absence of this enzyme in the mammalian host is a good criterion 
as a drug target. Furthermore the gene is highly conserved among the other Plasmodium 
species as shown in Figure 5.7 and has very low similarity to the bacterial MQOs. Therefore, 
the absence of MQO in any eukaryotic organisms means that this enzyme has great potential 
for the development of a new drug target for malarial chemotherapy if shown to be essential 
during the parasite’s life cycle in the human host.
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Chapter 6: General Discussion and 
Conclusion
There were two main focuses in this study. The first was to characterise the 
atovaquone resistant parasite TM90C2B using molecular and biochemical analysis. This was 
followed by the molecular characterisation of the putative Plasmodium mitochondrial malate 
quinone oxidoreductase (PfMQO).
6.1 Molecular and Biochemical
Characterisation of the Atovaquone 
Resistant Phenotype in the Malaria Parasite 
P. falciparum
TM90C2B is an atovaquone resistant P. falciparum parasite clinically isolated from 
patients on the Thai and Cambodia border (242). The resistant parasite emerged shortly after 
atovaquone was administered as a single treatment to malaria patients. The antifolate drug 
proguanil was subsequently given in combination with atovaquone (A:P; Malarone®) to 
overcome the problem of resistance typically associated with the individual drugs (247). 
Currently, A:P is widely used for malaria chemoprophylaxis among travellers visiting malaria 
endemic areas. Atovaquone is a hydroxynaphthoquinoe and acts as a competitive inhibitor of 
ubiquinol through its binding to the ubiquinol oxidation site (Qo) the Plasmodium bc\ 
complex. The benzopyranone ring of atovaquone binds to the bcj complex via the hydroxyl 
group Glu-272 of cytochrome b and the carbonyl group His-181 of the Rieske iron sulphur 
protein (114,129).
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Plasmodium complex III is composed of two monomeric units (10 and 11) consisting 
often different polypeptides. The catalytic cores of cytochrome box are composed of three 
subunits: cytochrome b, cytochrome cj and Rieske iron-sulphur protein ([2Fe2S] ISP). These 
subunits are directly involved in electron transfer within the Plasmodium respiratory chain 
and thus coupled with vectorial translocation of protons across the inner mitochondrial 
membrane. The generation of an electrochemical gradient and thus ATP (by F0Fi ATP 
synthase (complex V) is unique to certain other eukaryotic cells and does not occur within the
Plasmodium parasite.
The Plasmodium cytfr gene is encoded by mitochondrial DNA (mtDNA) and this 
means any polymorphisms, such as substitutions or insertions, are parentally inherited (3, 41). 
The accumulation of these base substitutions or insertions through the generations introduces 
mutations to the gene sequence. The mtDNA mutation rate has been reported as 
approximately 10-fold higher than the mutation rate of nuclear DNA (36). In addition, 
mitochondrial complexes I and III have been identified as major contributors to the 
production of cellular reactive oxygen species (ROS) (186). The superoxide anion produces 
ROS in the cells and continuous exposure produces damage in various cells and causes the 
aging process in human. ROS are responsible for oxidative damage to mtDNA and the 
mitochondrial respiratory chain system (217). Mutations in mtDNA thus affect the mRNA 
and tRNA and consequently the translated protein (222).
As shown in Chapter 3, the TM90C2B strain was shown to harbour a point mutation
in the Pfcytb gene resulting in the substitution of a tyrosine to a serine at residue 268. This
mutation was shown in Chapter 4 to affect catalytic turnover and substrate affinity, as well as
atovaquone binding. Western blot analysis also indicated reduced levels of bc\ protein in the
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TM90C2B strain compared to the wild type 3D7 strain bc\. However, the results of the 
expression profiles (Chapter 3) showed the complex III genes cytb, cytci and Fes_Rieske 
expression levels were higher (~ 2 fold) in TM90C2B compared to 3D7. Two hypotheses can 
be put forward to explain these apparently inconsistent data. The first is that the described 
Y268S mutation causes bc\ instability and/or possibly protein folding problems which result 
in a reduction in bc\ protein levels. It is then possible that in order to accommodate for this, 
the TM90C2B parasite was selected through natural selection to contain an increase level of 
expression of Complex III genes, which aid to off-set the poor folding/stability issues of the 
mutated protein.
A second hypothesis is that the gene mutation giving rise to the Y268S mutation 
causes an increase in the degradation rate of the mRNA and its translated protein. The 
impairment of protein translation is apparently due to the level of translated mutant proteins 
exceeding the threshold value of the wild type proteins. This threshold is dependent on the 
instability of the mutated protein and the amount of wild type tRNA (103). The mutant 
protein phenotype only appears when the amount of mutated mRNA and tRNA reach a level 
twice that of the wild type (222). Similarly in this scenario, the TM90C2B strain’s higher 
expression levels of Complex III genes help to off-set the issues of mRNA instability.
Interestingly, Chapter 4 also showed that protein levels of PfNDH2 were lower in the
TM90C2B strain than the 3D7 strain. It is tempting to speculate therefore that the
regulation/control of protein expression/translation of both PfNDH2 and bc\ are somehow
shared or that the Y268S mutation has a deleterious effect upon PfNDH2 translation/stability.
As mentioned in Chapter 4, mitochondria from animals and plants have been shown to
possess respiratory supercomplexes, but it is not clear at this stage if Plasmodium also
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possesses a supercomplex containing PfNDH2 and Complex III, and if so how this 
phenomenon would impact on the stability/translation of both of these proteins.
6.2 Critical Assessment of the Methodology 
(Chapters 3 & 4)
In this study the expression level of selected metabolite genes were measured using 
the GeXP PCR technique. The GeXP qPCR technique is a novel, universal technique to study 
up 35 genes in one reaction compared to 5 genes for real time PCR (RT-PCR). The amplicons 
of the PCR are highly quantitative and detected using fluorescence based capillary 
electrophoresis system. The advantage of this technique is the number of genes that can be 
analysed in one reaction therefore reducing cost per sample. The GeXP technique is 
recommend to validate data from a microarray study. Nevertheless, additional techniques 
could have been used to support the GeXP technique (e.g. single RT-PCRs on key genes), or, 
additional primers could have been used for each gene to confirm the data.
The GeXP data was colected from trophozoite-stage parasites and time 
permitting it would have been interesting to perform the same experiment 
of ring-stage and schizont-stage parasites. These data would have 
confirmed that the differential expression observed between 3D7 and 
TM90C2B was present throughout the asexual life cycle.
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To our knowledge TM90C2B is the only atovaquone resistant parasite that 
has been successfully lab adapted. In future experiments it would be 
interesting to determine the gene expression from different atovaquone 
resistant isolates and determine whether similar expression/translation 
phenomena are observed.
Enzymatic activities for the dehydrogenases were measured using 
direct measurement of the quionone reductase activity at 283 nm. The 
measurement was carried out by reducing the path length to 1 mm to 
overcome the interference of hemozoin in the reaction. This is an 
improvement from many studies that use linked assays with artificial 
electron acceptors DCPIP, MTT or horse heart cytochrome c. The 
mitochondrial Percoll® fractionation was carried out to improve 
sensitivity when measuring the quinone reductase activity in 
Plasmodium strains, but perhaps the assays would have benefitted 
further from an initial purification of the mitochndria. Although very 
labour intensive this would have improved the relative activity of the 
membrane fractions and therefore improved the signal to noise ratio of 
the measurements.
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6.3 Molecular Characterisation of P. 
falciparum 3D7 malate quinone 
oxidoreductase (PfMQO)
The Plasmodium parasite consumes more energy than the host cell and is solely 
dependent on glucose fermentation for energy generation (238). Whilst the Plasmodium 
genome has been encoded for all the necessary TCA enzymes their function is still debatable 
(82). Despite not generating ATP, the Plasmodium TCA cycle is believed to be involved in 
mitochondrial redox homeostasis and de novo pyrimidine biosynthesis (262).
In the canonical TCA cycle, malate is oxidised to OAA by mitochondrial malate 
dehydrogenase (mtMDH). However in the Plasmodium parasite, mitochondrial MDH is 
replaced by MDH isoenzyme malate quinone oxidoreductase (MQO). Instead of using 
NAD(P) as a co-factor, MQO uses FADH2 and directly transfers electrons to ubiquinone 
(185, 262). This is partly a defence mechanism in the Plasmodium biology to minimise the 
effect of oxidative damage due to the generation of free radicals. The degradation of 
haemoglobin increases the production of ROS but by directly transfering the electrons to 
ubiquinone they minimise the oxidative damage (262).
The transcriptome data (PlasmoDB) showes that the intraerythrocytic parasites express 
the highest MQO level during the trophozoite and late schizont stages. Interestingly most of 
the enzymes in the Plasmodium TCA cycle also showed high expression at this stage (25). A 
recent study by Olszewski et al. (2010) demonstrate the presence of a branched a TCA cycle 
in Plasmodium. The Plasmodium TCA cycle comprises of an oxidative branch (canonical 
TCA) and a reductive branch. However only the reductive branch is functionally active and
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the oxidative branch is not involved in the cycle. The LC-MS data analysis showed malate is 
the end product from both the oxidative and reductive branch of the TCA cycle. According to 
Olzewski et al. (2010), malate is reduced to OAA in the reductive arm and also by the 
oxidation of fumarate to malate by the frimarate hydratase (fumarase) enzyme (200, 262). 
However, a study by Bulusu et al, (2011) indicates the reduction of OAA to malate is only 
catalysed by MDH. Unlike MDH, MQO is irreversible and only catalyses the oxidation of 
malate to OAA. Olszewski et al. (2010) also found the functional TCA cycle in Plasmodium 
parasite is entirely depending on the reductive arm where OAA is reduced to malate. 
Therefore the role of PfMQO in TCA cycle in Plasmodium is unclear. Previous studies 
hypothesised that MQO is replacing mitochondrial MDH in catalysing oxidation of malate to 
OAA (262, 269). But this latest finding indicates MQO is likely to be responsible only in the 
Plasmodium respiratory chain by donating electrons directly to ubiquinone pool.
The bioinformatic data analysis in Chapter 5 indicates that PfMQO is a peripheral 
mitochondrial membrane protein. Biologically as a peripheral membrane protein, the 
interaction with the membrane is not very strong. By using mild denaturing conditions with 
chelators or detergents the protein can be dissociated from the membrane. In this study 
putative PfMQO gene was successfully cloned and expressed in E. coli Rosetta cells. 
However the expression of PfMQO was in the form of an insoluble protein. We successfully 
cloned the putative PfMQO gene into the expression vector pET-15b which was equipped 
with the T7 promoter. A similar study conducted by Tripathi et al. (2004) failed to express 
PfMQO gene using the pQE30 expression system with T5 promoter.
PfMQO was expressed at high levels in E. coli Rosetta under the T7 promoter. The
overexpression of eukaryotic proteins in E. coli usually triggers the induction of heat shock
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proteins and other stress responses this causes recombinant proteins to form as inclusion 
bodies (34). However, the expressed recombinant proteins are often present in a misfolded 
form and need to refold back into their native form. As previously mentioned in Chapter 5, 
the formation of inclusion bodies can be reduced by lowering the growth temperature, by 
coexpression of the gene with molecular chaperones or by using disulfide isomerase (34). The 
solubility of the recombinant proteins can also be improved by introducing a fusion partner 
(tag) for example N-utilisation substance A (NusA), maltose binding protein (MBP), 
thioredoxin (TRX) or glutathione S-transferase (GST) (47).
6.4 Critical Assessment of the Methodology 
(Chapter 5)
(i) The methodology used for cloning and expression of recombinant PfMQO followed a 
traditional route using commercial vectors and expression strains. Within the 
constraints of these techniques a number of additional studies/approaches could have 
been made. The first is in the codon usage of the gene. An E. co//-friendly codon 
usage could have been used for the MQO gene (e.g. by synthesis of the gene) to aid 
expression. In addition, the gene could have been truncated at both the C- and N- 
terminal to improve solubility/folding. As mentioned in Chapter 5, time constraints 
ment that a number of different growth conditions and IPTG treatment regimens were 
not tested in order to minimise inclusion body formation. In addition as mentioned a 
number of further manoeuvre could have been attempted to improve the solubility of 
the recombinant proteins such as the introduction of a fusion partner (tag) for example 
N-utilisation substance A (NusA), maltose binding protein (MBP), thioredoxin (TRX)
205
or glutathione S-transferase (GST) as well as the replacement with a less aggressive 
promoter than the one used in the commercially vector.
(ii) Steady state kinetics with the recombinant protein gave inconsistent data. It would 
have been useful to have attempted to follow the MQO activity by the monitoring of 
substrate and product using LC-MS/MS, using appropriate controls.
6.5 Future Work
Based on the outputs from this thesis, a number of future studies could be designed 
towards meeting the original objectives. These include:
(i) Demonstrate the presence of supercomplexes in Plasmodium. This could be 
performed by threshold-effect studies (222) or by analyses of BLUE Native 
gel followed by a 2 dimensional SDS PAGE followed by proteomic LC- 
MS/MS analysis (88,286).
(ii) To date there is no crystal structure for the Plasmodium bc\ complex and 
most studies of atovaquone resistance rely on the S. cerevisae yeast model. 
An in silico model has been described by Kessl et al., (2003) to demonstrate 
the binding of atovaquone to the Q0 binding site of the cytochrome b. It 
would therefore be very beneficial to crystalise the parasite bc\ and 
determine its three dimensional structure. A major obstacle to this is 
obviously the insufficient amount of starting materials (i.e. the parasite cell 
free extracts). Typically 5-15 mg/ml of concentrated pure mitochondrial
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protein is required to start crystallisation of the protein (Chayen and 
Saridakis 2008). As a comparison 10 mg of pure recombinant protein can 
be harvested from 1 litre of E. coli culture (Tripathi et al.f 2004). This is 
particularly challenging as the Plasmodium parasite has only one 
mitochondrion therefore lots of parasites are required. In addition the 
mutation within the mtDNA of the TM90C2B strain slows the growth rate 
when compared to the 3D7 strain. However, with time, it should be possible 
to collect enough mitochondrial membrane for such a preparation.
Expression of PfMQO using non-bacterial expression systems, such as 
insect cell lines and the cell-free system used for many membrane 
transporters (20). This could be attempted in addition to other bacterial 
expression systems that use less aggressive promoters, e.g. using slow 
growing organisms such as Mycobacterium smegmatis.
6.6 Conclusion
Atovaquone TM90C2B was partially characterised at the genomic and biochemical 
level. The mutation at Q0 site in bc\ complex was demonstrated by automated sequencing. 
The effect of the mutation at the mRNA level was determined by GeXP PCR and showed the 
high expression of the genes in the complex. The effect of the mutation at the functional level 
was carried out by direct biochemical assays which showed the low catalytic activities of bci 
in TM90C2B compared to 3D7. The mutation in the bc\ complex also affected the activity of 
PfNDH2. The level of translated protein was quantified using western blotting and showed 
TM90C2B to have less Rieske Fe-S protein than 3D7.
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The PfMQO was partially characterised successfully using bioinformatic and 
molecular techniques. In order to complete the characterisation of the protein, biochemical 
studies must be carried out. This could be followed by studies to crystalise the protein and 
then trials with the different inhibitors. The function of PfMQO in the malaria parasite is still 
not clear. Further studies are needed to understand the properties of the protein and thus 
provide new insight into the physiology of the MQO protein assemblage within the 
Plasmodium mitochondria. Eventually data from this study would provide a system for 
identification of inhibitors for anti-MQO activity as target drug sites in the Plasmodium 
mitochondria.
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